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Colorectal cancer is one of the most common cancer types and the second 
leading cause of cancer-related deaths worldwide. Poor survival of patients 
highlights the importance of identification of novel prognostic markers. The work in 
this thesis presents Tspan6 as a potential candidate. Tspan6 is a poorly studied 
member of the tetraspanin family of proteins that has been implicated in cancer 
initiation, progression and metastasis. The expression of Tspan6 in a cohort of 
genetically profiled colorectal adenocarcinomas in this study demonstrated that 
Tspan6 expression is significantly reduced in tumours vs. adjacent non-cancerous 
tissues. To illustrate the role of Tspan6 in colorectal cancer (CRC) Tspan6 KO mice 
carrying APCmin/+ allele were generated. It was found that loss of Tspan6 gene 
accentuates APC-driven tumorigenesis in vivo. Specifically, these animals developed 
larger numbers of intestinal and colonic polyps. Interestingly, these polyps were 
significantly bigger in size and presented with a more severe neoplastic phenotype. 
The RNAseq analysis of polyps derived from APCmin/+ and APCmin/+Tspan6 KO 
showed substantial enrichment of differentially expressed genes within the MAPK 
signalling pathway. Additionally, our experiments with intestinal organoids derived 
from Tspan6 KO mice and a Caco-2 CRC cell model confirmed the important role of 
Tspan6 in EGFR-dependent signalling in colonic epithelium via a pathway involving 
autocrine production of TGF-α. Furthermore, it was demonstrated that Tspan6 
regulates the production of EVs through the involvement of an adapter protein 
syntenin-1, an established partner of Tspan6 which is known to play a critical role in 
biogenesis of multivesicular bodies (MVBs) and exosomal production. Therefore, it is 
hypothesised that the Tspan6-syntenin-1 complex plays a critical role in suppressing 




extracellular vesicles. The better understanding of the Tspan6-dependent 
mechanisms of EGFR regulation can underpin further development of EGFR-
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1.1 Colorectal cancer 
 Definition 1.1.1
Cancer is a collective term for a group of disorders that result from 
dysregulated cell growth (WHO 2015). Transformed cells proliferate in an aberrant 
manner, independent of cell control signals, leading to dysregulation in balance of 
cell proliferation and apoptosis. Newly formed, neoplastic cell populations can invade 
locally and frequently metastasise to other organs causing significant morbidity and 
ultimately death. The majority of solid tumours are highly heterogeneous and 
molecular mechanisms underlying oncogenesis differ for different types of cancer 
(Ruddon 2003). Colorectal cancer (CRC) is a malignant tumour that arises as a result 
of complex genetic or epigenetic alterations of epithelial stem cells of the colon or 
rectum. CRC is initiated within the intestinal mucosa - the lining of the luminal surface 
of the large intestine. These cells are constantly exposed to toxins from intestinal 
contents, including the colonic microbiota and digesta alongside the constant 
sloughing of the outermost cells during gastro-intestinal transit of food undergoing 
digestion. To avoid the aggregation of damaged cells in the colon, a self-renewal 
mechanism of the colonic epithelial cells takes place at a high rate (Creamer, Shorter 
et al. 1961).  
 Types of cancers in the colon and rectum 1.1.2
The most common form of CRC is adenocarcinoma, accounting for more than 
96% of all colorectal cancers. This type of cancer is initiated within the intestinal 




developing in the colorectum are carcinoid tumours that are initiated in the hormone 
producing cells of the colon; lymphomas – starting in immune cells – typically arising 
in lymph nodes, but rarely occur in colon, rectum and other organs; sarcomas – 
tumours arising in blood vessels, muscle and connective tissue (ACS 2018). This 
study is focussed on characterising adenocarcinoma of the intestine and colon. 
 Colorectal cancer incidence 1.1.3
CRC is the fourth most common type of cancer diagnosed in the United 
Kingdom, second most common cancer in Europe and third most common in the 
world and represents 12% of all diagnosed cancers in UK (SEER Research Data 
1973-2015 2018, Cancer Research UK 2015, Ferlay, Soerjomataram et al. 2015). 
The mean age of CRC diagnosis in 2015 was 85-89 years. Gender distribution of 
CRC is skewed towards the male population with a 55% in men vs. 45% in women. 
 Colorectal cancer mortality and survival 1.1.4
CRC is the second largest cause of cancer-related death in the UK, with 
approximately 16,000 lives every year (Cancer Research UK 2015). The most recent 
statistics indicate that at least 59% of men and 58% of women will survive their 
disease for 5 years after diagnosis. Remarkably, in the last 40 years the survival rate 
has more than doubled. The ten-year survival for both men and women has 
increased from 22% in 1971-1972 to 56% and 57% in 2010-2011 for men and 
women respectively. This prominent increase in the survival rate is closely linked to 
the emergence of nation-wide screening programs. The National Health Service 
(NHS) launched a screening program in England in 2006, in Wales in 2008, and in 
Northern Ireland in 2010, with the aim of detecting the disease at its earliest stage of 




five-year survival of 90%, compared to 10% diagnosed at the latest stage. This data 
exemplifies the impact the screening process has made on the diagnosis and 
detection of the disease. Additionally, major improvements have occurred due to the 
development of personalised treatments. This increases the chances of patient 
response to treatment and lowers the incidence of side effects as opposed to chemo- 
and radiotherapies.  
 The worldwide distribution of colorectal cancer 1.1.5
CRC is the third most common type of cancer worldwide with 1.36 million 
people diagnosed in 2012. CRC accounted for approximately 694,000 deaths in 
2012, comprising 8% of all cancer related deaths in the world (GLOBOCAN, 2012). 
However, the worldwide distribution of CRC incidence is not uniform. The highest 
incidence has been recorded in European countries, North America and Oceania; 
and the lowest incidence is seen in some countries of South and Central Asia and 
Africa (Brenner et al., 2014). Age-standardised incidence by region for 2008 shows a 
10-fold difference in incidence in both men and women in Central Africa compared to 
Australia and New Zealand (Figure 1-1). This pattern demonstrates that CRC is a 
disease of more developed countries. Indeed, countries of the developed world 





Figure 1-1. Age standardised incidence and mortality rates in males and females in the world in 
2012.  Numbers represent the number of colorectal cases per 100,000 individuals. In more developed 
regions incidence of colorectal cancers is up to 10-fold higher. Figure is reproduced from Ferlay J, 





 Colorectal cancer risk factors 1.1.6
Both genetic and environmental factors play a role in aetiology of colorectal 
cancer. The majority of CRCs are sporadic and account for 75%-85% of all CRC 
cases. These develop as a result of accumulation of somatic mutations, and as such 
risk of CRC development increases with age (Fredericks, Dealtry et al. 2015, Noone, 
Howlader et al. 2018). Risk further increases in individuals with one or more affected 
family members, and accounts for more than 20% of CRC cases (Valle 2014, 
Armelao, de Pretis 2014). The group of CRCs that are characterised by inherited 
germline mutations are collectively known as hereditary type of colorectal cancer and 
account for 3%-5% of CRC patients (Kuipers, Grady et al. 2015). The two most 
common hereditary syndromes that significantly increase the lifetime risk of CRC 
development are familial adenomatous polyposis (FAP) or hereditary non-polyposis 
colorectal cancer (HNPCC), also known as Lynch syndrome. Other hereditary 
colorectal cancer syndromes include MUTYH-associated with mutations in the mutY 
DNA glycosylase (MUTYH) gene, polymerase proofreading-associated polyposis 
(PPAP), juvenile polyposis (JPS), hereditary mixed polyposis (HMPS), Cowden 
syndrome (CS), Peutz Jeghers syndrome, and serrated polyposis (Talseth-Palmer 
2017, Tomlinson 2015, Church 2004). Individuals with FAP are at 100% risk of 
developing colorectal cancer, unless they undergo prophylactic colectomy, and for 
patients with HNPCC-related mutations lifetime risk of CRC is as high as 80% 
(Colussi, Brandi et al. 2013). CRC developed in patients with FAP or HNPCC is 
characterised by an early onset, at 40-50 years of age (Fredericks, Dealtry et al. 
2015, Kuipers, Grady et al. 2015). Additionally, there is an increased risk of 
developing CRC in individuals with inflammatory bowel disease (IBD), which 





1.1.6.1 Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) is an autosomal dominant inherited 
disease and is caused by mutations in adenomatous polyposis coli (APC) gene, 
which plays a central role in Wnt signalling (Vasen, Tomlinson et al. 2015) (see 
below). FAP is characterised by the appearance of hundreds to thousands of 
adenomatous polyps in the colon. Most of these patients will develop benign 
adenomas, but some will progressively accumulate additional mutations, resulting in 
the transformation of benign to malignant lesions. To date more than 300 APC 
mutations have been identified in individuals with FAP (Waller, Findeis et al. 2016). 
These mutations result in a truncated form of the protein with aberrant function. The 
vast majority of these mutations are nonsense and frameshift mutations, but 
insertions and deletions also occur. Nearly a third of germline mutations in APC 
occur at codons 1061 and 1309. As many as 5% of FAP patients carry a deletion 
mutation at codon 1061, and 10% of patients have the deletion at codon 1309. Other 
germline mutations in APC are evenly distributed between codons 200 and 1600 
(Half, Bercovich et al. 2009). Progression to malignancy requires additional genetic 
alterations in APC, and commonly FAP patients acquire a somatic mutation in the 
wild-type parental allele or loss of heterozygosity (LOH) at this locus, strongly 
supporting Knudson’s two-hit hypothesis (Knudson 1971). 
1.1.6.2 Lynch Syndrome 
Lynch syndrome or HNPCC is the most common form of hereditary colorectal 
cancer, accounting for 4-5% of CRC cases and is an autosomal dominant inherited 




numerous polyp manifestations in FAP patients, HNPCC is characterised by the 
absence or a small number of polyps with distinct histopathological features: polyps 
appear to be mucinous, poorly differentiated and often with lymphocytic infiltrate 
(Sarosiek, Stelmaszuk 2018, Seth, Ager et al. 2018). Germline mutations in HNPCC 
patients occur in genes of DNA mismatch repair machinery (MMR). Mutations in five 
genes have been identified to date: MLH1, MSH2, MSH6, PMS2 or EPCAM (Kuipers, 
Grady et al. 2015). Aberrant function of the MMR system results in sequential 
accumulation of multiple mutations in both coding and non-coding microsatellite 
sequences of DNA. This leads to high level of microsatellite instability (MSI-H) 
phenotype in HNPCC patients (Le, Ansari et al. 2017). This in turn, dramatically 
accelerates the mutation rate in other tumour-suppressor and/or oncogenes, leading 
to rapid cancer development. The most common mutations are found in MSH2 and 
MLH1, 36%-60% and 25-50% respectively (Dowty, Win et al. 2013). Mutations in 
these genes account for 95% of Lynch syndrome alterations (Colussi, Brandi et al. 
2013). 
1.1.6.3 Environmental risk factors 
Among non-modifiable risk factors, such as age, gender and family history of 
the disease, there are variety of risk factors that are greatly associated with the 
modern westernised lifestyle, including tobacco smoking, alcohol consumption, 
physical inactivity, obesity, and diet high in fat, red and processed meat and low 
consumption of dietary fibre. In the United Kingdom, 54% of colorectal cancers are 
tightly correlated to lifestyle and could be prevented (CRUK, 2015). Hence, 
environmental and lifestyle factors play an important role in the development of 




have been reported to be preventative of CRC, predominantly lifestyle factors, are 
presented in Table 1-1. It is predicted that 11% of CRC cases in UK are caused by 
the high incidence of obesity, smoking and alcohol consumption coupled with low 
levels of physical activity (Cancer Research UK 2015).  
 
Table 1-1. Overview of risk and preventive factors of colorectal cancer. Table is reproduced from 




Approximately 70% of CRC burden can be reduced by change in dietary 
habits (Haggar, Boushey 2009). A strong association of CRC development has been 
seen in individuals that consume higher than average amounts of red and processed 
meat as well as animal fat, with 13% of CRC cases in UK are believed to be caused 
by meat consumption (Cancer Research UK 2015, Haggar, Boushey 2009, Boyle, 
Langman 2000). The presence of haem iron in red meat is thought to be the 
causative agent of CRC development (Fonseca-Nunes, Jakszyn et al. 2013, Kabat, 
Miller et al. 2007). High temperatures used in production of processed meat results in 
production of heterocyclic amines and polycyclic aromatic hydrocarbons, both of 
which are believed to have carcinogenic properties. Consumption of animal fat is 
believed to cause a dysbiosis in the colon, favouring bacteria capable of degrading 
bile salts to potentially carcinogenic N-nitroso compounds (Larsson, Wolk 2006). 
Consumption of dietary fibre plays a significant role in prevention of CRC (Parkin, 
Boyd 2011, Aune, Chan et al. 2011). It is estimated that an increase in dietary fibre 
intake could reduce CRC incidence by 28% in UK (Cancer Research UK 2015). 
 Treatment of colorectal cancer 1.1.7
For patients diagnosed with colon or rectal cancer surgical removal of the 
tumour is often the main treatment. For treatment of advanced rectal tumours, a 
neoadjuvant (preoperative) radiotherapy or chemoradiotherapy with 5-fluorouracil or 
capecitabine is often used to facilitate tumour shrinking and prevent spreading to 
other tissues. It has been shown that neoadjuvant treatment is effective in reducing 
local recurrence, however it does not have a significant impact on overall survival 
(Kuipers, Grady et al. 2015, van Gijn, Marijnen et al. 2011). Adjuvant (postoperative) 




2013). Drugs used to treat CRC include 5-Fluorouracil, capecitabine, irinotecan, 
oxaliplatin, trifluridine and tipiracil. Often, two or more of these drugs are combined to 
increase the efficacy of the treatment. Sometimes, chemotherapeutic drugs are used 
in combination with targeted therapies. Three major groups of drugs for targeted 
therapies of CRC are monoclonal antibodies against EGFR (cetuximab and 
panitumumab), monoclonal antibodies and small-molecule based compound against 
VEGF-A (bevacizumab and ziv-aflibercept respectively), and small-molecule based 
multikinase inhibitor (regorafenib) targeting receptor tyrosine kinases (RTKs), such as 
EGFR, vascular endothelial growth factor receptor (VEGFR1/2/3), platelet-derived 
growth factor receptor-β (PDGF-R), fibroblast growth factor receptor (FGFR), as well 
as c-KIT, RET and BRAF (Wilhelm, Dumas et al. 2011). Anti-EGFR therapies are 
commonly used for metastatic colorectal adenocarcinomas that express high levels 
of EGFR and do not carry mutations in downstream effectors of the EGFR signalling 
pathway including KRAS, NRAS or BRAF. Anti-VEGF-A treatment is commonly used 
to prevent angiogenesis of tumours and restrict access of oxygen and nutrients 
(Willett, Boucher et al. 2004). Regorafenib is used in cases of advanced CRC when 
other drugs proved to be ineffective. It targets multiple angiogenic, stromal and 
oncogenic RTK (Ettrich, Seufferlein 2018).  
Immunotherapy has also been employed to manipulate the tumour 
microenvironment via tumour infiltrating lymphocytes. Current immunotherapies 
include immune checkpoint inhibitors directed against cytotoxic T lymphocyte 
antigen-4 (CTLA-4) and programmed cell death protein (PD-1)/PD-1 ligand (PD-L1) 
(Gong, Chehrazi-Raffle et al. 2018). A number of novel targets are currently in the 




targeting T cell immunoglobulin and mucin containing protein-3 (TIM-3), lymphocyte 
activation gene-3 (Lag-3), OX40 (CD134), glucocorticoid-induced TNF receptor 
(TNFR)-related protein (GITR, CD357), 4-1BB (CD137), CD40, and CD70 (Jager, 
Halama et al. 2016). Interestingly, only colorectal tumours with a high level of 
microsatellite instability (MSI-H) have been shown to effectively respond to current 
immunotherapies due to somatic hypermutations that lead to expression of larger 
amount of neoantigens available for immune clearing (Le, Uram et al. 2015). 
Despite the wide range of treatments available the survival of patients with 
advanced tumours has not improved in the last two decades, thus necessitating a 
deeper understanding and characterising colorectal adenocarcinoma development 
and progression. 
1.2 Molecular basis of CRC 
 The anatomical structure of the colon 1.2.1
The intestine is anatomically divided into the small intestine and the colon. The 
innermost layer of intestine, the mucosa, is lined with rapidly renewing epithelial cells. 
The proliferative cells reside in the crypts of Lieberkühn – epithelial invaginations in 
the underlying intestinal tissue. The crypts contain self-renewing stem cells and their 
progeny – transit amplifying (TA) cells. TA cells divide four to five times before 
leaving the crypt, migrating upwards, following terminal differentiation into one of the 
four differentiated types of cells – mucus-secreting goblet cells, hormone-secreting 
enteroendocrine cells, absorptive enterocytes and Paneth cells (Figure 1-2) (van der 
Flier, Clevers 2009). Paneth cells are the only differentiated type of cells that escape 
migration and participate in antibacterial defence and innate immunity (Clevers, 




anoikis with the exception of Paneth cells that are long-lived and reside at the bottom 
of the crypt between 2 and 3 months. The colonic surface lacks villi and is flat. The 
cellular organisation of the colonic epithelium is comparable to small intestine with 
the exception of Paneth cells that are absent in the colon (van der Flier, Clevers 
2009). Of note, small intestinal cancers are rare, affecting around 1,500 individuals 
compared to 41,300 cases of large bowel cancers yearly in the UK, around 30% of 
colorectal cancers occur in ascending colon, 10% in transverse, 15% in descending, 





Figure 1-2. Anatomy of the small and large intestine. (A) The architecture of mucosal layer of the 
small intestine consists of crypts (bottom) and villi (protruding into the intestinal lumen). The stem cells 
and Paneth cells reside at the bottom of the crypt, transit amplifying (TA) cells are migrating up the 
crypt and terminally differentiated cells (enterocytes, tuft cells, Goblet cells, enteroendocrine cells) are 
located at the villus compartment. (B) The surface of the colonic epithelium is flat and does not have 
villi. Crypts of the colon lack Paneth cells, but contain crypt base columnar secretory cells. The mature 
colonic epithelium contains high proportion of Goblet cells. Figure is reproduced and modified from 





 Molecular pathways of colorectal carcinogenesis 1.2.2
There are two well characterised pathways underlying tumorigenic 
transformation of colonic epithelial cells: the conventional adenoma-carcinoma 
sequence, proposed by Fearon and Vogelstein, and the serrated pathway. Adenoma-
carcinoma sequence describes molecular events that give rise to formation of 
adenomatous polyps (precursor lesions) which develop into carcinomas. The vast 
majority of sporadic colorectal cancers (up to 90%) start their development in this 
way; and are typically initiated by mutations in adenomatous polyposis coli (APC) 
gene (Fearon, Eric R. 2011, Moran, Ortega et al. 2010, Leslie, Carey et al. 2002). 
Genetic alterations at the later stages of tumorigenesis include point mutations of 
tumour-suppressor (TP53, DCC, SMAD2/4, TGF-βRII) and oncogenes (KRAS, 
PIK3CA, BRAF, CTNNB1, HER-2/ERBB2) and amplification of chromosomal 
segments (gains of chromosomes and chromosome arms 7, 8q, 13, and 20q), large 
chromosomal deletions or translocations (losses of chromosomes 4q, 8p, 17p, and 
18q) (Camps, Grade et al. 2008). The serrated neoplasia pathway has been 
identified recently and accounts for 15% to 30% of all CRCs (Kim, S. Y., Kim 2018). 
The serrated pathway is characterised by somatic mutations in BRAF or KRAS in 
early stages of polyp development and by excessive CpG island promoter 
hypermethylation resulting in epigenetic silencing of tumour-suppressor genes, e.g. 
MLH1 (Kedrin, Gala 2015). The serrated pathway is further stratified by the degree of 
microsatellite instability (MSI) into MSI-H (high) or MSI-L (low) (Yamane, 
Scapulatempo-Neto et al. 2014). Microsatellite instability is also a common feature of 




 Adenoma-Carcinoma sequence 1.2.3
In 1990, Fearon and Vogelstein proposed a model of molecular pathogenesis 
of colorectal carcinoma development – adenoma-carcinoma sequence (Fearon, 
Vogelstein 1990). The key principal of this process is the requirement of multiple 
genetic hits, caused by chromosomal instability (CIN), harbouring mutations in critical 
genes, such as APC, KRAS, TP53 and TGF-β pathway genes (Arends 2013). 
However, it is being widely recognised that it is the total accumulation of mutations 
rather than the sequence that is required for successful malignant carcinoma 
formation. An early stage of colorectal tumorigenesis is characterised by mutations in 
adenomatous polyposis coli gene (APC) and formation of dysplastic adenomas 
(Kinzler and Vogelstein, 1996). APC is a tumour suppressor gene and encodes a 
protein with multiple functions, implicated in differentiation, adhesion, polarity, 
migration, development, apoptosis, and chromosomal segregation (Leslie, Carey et 
al. 2002). The protein is located at the basolateral membrane of the colonic epithelial 
cells. Its expression levels increase as cells migrate up from the crypt base. APC 
plays a central role in the Wnt signalling pathway (see below). Disruption of APC 
abrogates its ability to negatively regulate Wnt signal transduction resulting in 
constitutive activation of the latter. Truncated APC, in the context of CRC, loses its 
binding ability to β-catenin, leading to β-catenin accumulation in the cytoplasm. 
Subsequently, β-catenin is translocated to the nucleus where the protein binds to T-
cell factor (TCF)/lymphoid enhancer (LEF) family of transcription factors and 
activates gene transcription that stimulates cell growth and inhibits apoptosis. Loss of 
function mutations in the APC gene occur in over 80% of colon adenocarcinomas 
(Fredericks, Dealtry et al. 2015). Downregulation of the APC function can be also 




promoter (Segditsas and Tomlinson, 2006).  
Although the hyperactivation of Wnt signalling results in increased cellular 
proliferation, additional molecular changes are required for cellular transformation to 
progress from adenoma to malignant type of lesion. The second step towards 
progression of CRC is activation of the KRAS gene leading to advanced 
adenomatous lesions. KRAS is a proto-oncogene that encodes a small protein with 
GTPase activity which plays an important role in controlling cell proliferation and 
differentiation (Leslie, Carey et al. 2002). Mutations in KRAS decrease its GTPase 
activity resulting in constitutive activation of downstream signalling pathways (e.g. 
Ras/Raf/MEK/ERK pathway), leading to increased proliferation and inhibition of 
apoptosis (Lemieux et al., 2015). KRAS is mutated in approximately 30% of 
colorectal adenomas and 30%-42% of colorectal cancers (Liu, Jakubowski et al. 
2011). 
The progression to late adenoma often is associated with allelic loss of 18q, 
and generally occurs due to chromosomal instability and deficiency in mismatch 
repair mechanisms. A number of tumour suppressor genes are located to this 
chromosomal region, including DCC, SMAD2, SMAD4, and Cables. SMAD2 and 
SMAD4, are key components of TGF-β signalling pathway, which in turn negatively 
regulates epithelial cell growth (Leslie, Carey et al. 2002). Genetic alterations and/or 
loss of SMAD4 or SMAD2 promote enhanced transcription of genes involved in cell 
growth and proliferation (Zhao, Mishra et al. 2018, Fleming, Jorissen et al. 2013). 
Allelic loss of 18q has been identified in 70% of colorectal cancers (Arends 2013). 




important role in tumour progression initiated by other gene alterations, such as APC 
and KRAS (Zhao, Mishra et al. 2018). 
Dysfunction of P53 plays a major role in progression of late stage adenomas 
to carcinomas. TP53 is an important tumour-suppressor gene that maintains genomic 
integrity. P53 appears to be mutated in up to 75% of colorectal cancers, typically 
through combination of missense mutations and loss of heterozygosity of 
chromosome 17p (Markowitz, Bertagnolli 2009). Recently published analysis of 
colorectal adenomas revealed the enrichment of mutations in TP53, FBXW7, 
PIK3CA, KIAA1804 and SMAD2 exclusively in cancer associated polyps (CAPs) 
compared to cancer free polyps (CFPs), highlighting the role of these genes in 
malignant transformation of benign adenomas in the colon epithelium (Druliner, 
Wang et al. 2018).  
 Serrated Pathway 1.2.4
Approximately 10% of all colorectal cancers are derived through the serrated 
pathway which is manifested by the formation of serrated group of polyps (sessile 
serrated adenomas, traditional serrated and mixed polyps) (Yamane, Scapulatempo-
Neto et al. 2014, Sweetser, Smyrk et al. 2013). Serrated polyps exhibit hyperplasia 
and lack of dysplasia on a cytological level, i.e. the crypt epithelium tends to fold in. It 
is believed to result from cell aggregation and failure of apoptosis and anoikis, 
however, the molecular basis of serration has not been fully determined (Kim, Kim 
2018, Patai, Molnar et al. 2013). Commonly observed genetic alterations in the 
serrated pathway are BRAF or KRAS mutations, hypermethylation of tumour-
suppressor gene promoters, resulting in epigenetic silencing (CIMP – CpG island 




Conventional adenoma-carcinoma and the serrated pathways are compared in 
Figure 1-3, highlighting the key molecular and histological differences. BRAF is a 
serine/threonine tyrosine kinase that functions downstream of KRAS in a signal 
transduction pathway leading to activation of MAP kinases. Mutations in either of 
these genes lead to constitutive MAPK pathway activation resulting in uncontrolled 
proliferation, cell survival, invasion and metastasis (Rustgi 2013, Chan, Zhao et al. 
2003, Heinemann, Stintzing et al. 2009). BRAF and KRAS mutations are mutually 
exclusive, and alterations in BRAF have been shown to occur at a higher frequency 
than KRAS mutations in serrated adenomas (Larki, Gharib et al. 2017, Kedrin, Gala 
2015). This emphasises BRAF to be a hallmark of serrated colorectal carcinomas. 
The most frequent mutation in BRAF is V600E and appears to be mutated in 









Figure 1-3. Schematic comparison of key events in conventional and serrated colorectal carcinogenesis.  1) Conventional, or adenoma-
carcinoma sequence, is initiated by loss of function of APC, followed by activation mutation in KRAS gene. Mutations in SMAD4 result in high grade 
dysplasia (HGD). Inactivation of tumour suppressor gene TP53 results in microsatellite stable (MSS) cancer. 2) Mismatch repair (MMR) protein 
deficiency results in MSI-high (MSI-H) cancers. 3) The serrated pathway typically is initiated by mutations in BRAF gene and CpG island methylation 
phenotype (CIMP) resulting in sessile serrated adenomas (SSA). MSI-H cancers result from methylation in MLH1 promoter; MSS cancers result from 




Hypermethylation of CpG islands flanking promoters of tumour-suppressor 
genes is often found in various cancers. CpG island methylator phenotype (CIMP) is 
found to be present in 20-30% of colorectal cancers, and in up to 80% of serrated 
colorectal carcinomas (Advani, Advani et al. 2018, Rhee, Kim et al. 2016).  
Another hallmark of CRC is microsatellite instability (MSI) (Yamane, 
Scapulatempo-Neto et al. 2014). MSI is caused by the loss of MMR genes, resulting 
in increased susceptibility to accumulating mutations within microsatellite regions 
(Markowitz, Bertagnolli 2009). Approximately 15-20% of sporadic colorectal cancers 
have a high status of microsatellite instability (MSI-H) (Colussi, Brandi et al. 2013). 
Interestingly, several studies have shown that patients with CRC associated with 
microsatellite instability have no response to chemotherapy (Testa, Pelosi et al. 
2018, Chang, Chang et al. 2017, Marmol, Sanchez-de-Diego et al. 2017). 
1.3 Signal transduction pathways in colorectal cancer  
Multiple intracellular signalling pathways tightly regulate cellular activity and 
homeostasis. Signalling cascades, such as Wnt/β-catenin, EGFR/MAPK, Notch, myc, 
TGF-β and p53 are found to be dysregulated in CRCs. Deregulation of these 
signalling pathways contributes to cellular malignancy, cancer initiation, progression 
and metastasis. Hyperactivation of Wnt and EGFR mediated signalling cascades is 
associated with initiation of colorectal carcinogenesis and are discussed below.  
 Wnt signalling  1.3.1
The Wnt signalling pathway controls a wide range of biological processes 
throughout embryonic development and adult life. It is one of the key mechanisms of 




cell fate (Wiese, Nusse et al. 2018, Katoh 2017, Fuerer, Nusse et al. 2008). Impaired 
Wnt signalling is associated with the majority of colorectal cancers, highlighting its 
importance in cancer development and progression (Krausova, Korinek 2014, 
Polakis 2012). Wnt signalling activation is determined by Wnt binding to receptors on 
the surface of the cell membrane. Wnt ligands belong to the large family of secreted 
glycoproteins that are highly conserved throughout the organisms. To date, 19 
human Wnt ligands have been identified. Although Wnt ligands are structurally 
related, they can trigger different signalling pathways (Baarsma, Konigshoff et al. 
2013, Miller 2002). Some Wnt ligands (Wnt1, Wnt3a, Wnt8) preferentially activate 
canonical, or β-catenin dependent pathway; others (Wnt4, Wnt5a and Wnt11) can 
activate non-canonical pathways (MacDonald, Tamai et al. 2009). However, the Wnt 
signalling framework is more complex and Wnt activity is context dependent.  
1.3.1.1 Canonical Wnt signalling 
The canonical Wnt pathway has been comprehensively studied and is best 
characterised. The hallmark of the canonical Wnt signalling is the accumulation of β-
catenin in the cytoplasm and its subsequent nuclear translocation. β-catenin is a 
multifunctional protein, first described as a part of cadherin-based junctions and plays 
a role in developmental and homeostatic processes. β-catenin stability in the cell is 
tightly regulated by phosphorylation events. Specifically, phosphorylation of tyrosine 
residues (Tyr831 and Tyr860) by Src kinase and serine (Ser846) by CK1α promotes 
dissociation of β-catenin from E-cadherin. Consequently, β-catenin is transferred into 
the cytoplasm where it is captured by the degradation complex consisting of Axin, 
APC, glycogen synthase kinase 3β (GSK3β), casein kinase 1 (CK1α) (Figure 1-4.A) 




residues (Ser33, Ser37, Thr41 and Ser45) targets β-catenin for ubiquitination and 
subsequent degradation by 26S proteasomes (Amit, Hatzubai et al. 2002). 
Activation of the canonical pathway is mediated by Wnt binding to the receptor 
complex that consists of one of the transmembrane Frizzled (Fz) receptors and co-
receptor low-density lipoprotein-receptor-related protein (LRP5/6). This interaction 
induces the phosphorylation of LRP5/6 by CK1α and GSK3β, which in turn facilitates 
translocation of Axin from the destruction complex to the membrane (Figure 1-4.B) 
(Nayak, Bhattacharyya et al. 2016, Komiya, Habas 2008). Additionally, cytoplasmic 
phosphoprotein Dishevelled (Dvl) is also recruited to the receptor complex, inhibiting 
the kinase activity of GSK3β. Axin recruitment to the Wnt/Fz/LRP receptor complex 
results in disruption of the destruction complex and stabilisation of β-catenin (Rao, 
Kuhl 2010, MacDonald, Tamai et al. 2009). Subsequently, β-catenin is translocated 
to the nucleus where it acts as a co-transcriptional activator by forming a complex 
with LEF/TCF family members to activate transcription of Wnt target genes (Table 
1-2). Among them are genes that play role in cell differentiation, cell signalling, 
proliferation, and adhesion (Behrens 2005).  
In addition to colorectal cancer the dysregulation of the canonical Wnt 
signalling has been implicated in a number of other malignancies, including 
melanoma, hepatocellular carcinoma, prostate, thyroid, and ovarian cancer. A range 
of mutations that lead to β-catenin stabilisation have been reported. In rare cases of 
CRC with wild-type APC, other components of Wnt signalling cascade are mutated, 
such as Axin1/2 and β-catenin (Nusse, Clevers 2017, Schneikert, Behrens 2007). In 




ligases Rnf43 and Znrf3 were identified in multiple carcinomas (Assie, Letouze et al. 
2014, Wu, Jiao et al. 2011). 
 
 
Figure 1-4. Schematic representation of canonical Wnt signal transduction pathway. (A) In the 
absence of Wnt ligands, β-catenin intracellular levels are regulated by β-catenin destruction complex, 
consisting of APC, Axin, GSK3β, and other. Axin and APC bind to β-catenin, GSK3β phosphorylates 
its N-terminal Ser/Thr residues, resulting in proteosomal degradation of β-catenin. (B) Upon binding of 
Wnts to receptor complex Frizzled/LRP5/6 (Fz/LRP), Axin from the β-catenin destruction complex is 
recruited to the membrane. Kinase activity of GSK3β is inhibited. β-catenin accumulates in the 
cytoplasm, translocates to the nucleus, where it initiates transcriptional activation of Wnt target genes 




Table 1-2 Target gene of β-catenin and their function in cancer initiation and progression. Table 
reproduced from Huang, Du 2008. 
β-catenin target genes related to cancer 
Function Target gene 
Cell proliferation C-myc; Cyclin D1 
Inhibition of apoptosis MDR1/PGP; COX-2; PPARδ 
Tumor progression MMPs; uPAR,Upa; CD44; Laminin γ2; Nr-CAM 
Growth factors c-met; VEGF; WISP-1; BMP-4 
Transcription factors c-jun, fra-1; ITF-2; Id2; AF17 
Negative feedback targets Conductin; Tcf-1; Nkd 
 
 
1.3.1.2 Non-canonical Wnt signalling pathways 
Alternative Wnt signalling pathways are mediated via β-catenin and LRP 
independent routes. A variety of non-canonical pathways have been reported, with 
the two most investigated cascades being planar cell polarity (PCP) and Wnt/Ca2+ 
pathways (Figure 1-5). Planar cell polarity is a term that describes the spatial 
organisation of cellular components in a two-dimensional plane. PCP is activated by 
Wnt4, Wnt5a or Wnt11 through various Frizzled receptors and mediated by 
Dishevelled proteins (Komiya, Habas 2008). The Fz/Dvl complex activates c-Jun-N-
terminal kinase (JNK) and Rho-associated kinase (RhoA kinase) which results in 
actin cytoskeleton reorganisation (Rao, Kuhl 2010). These phenomena are known to 
control the orientation of hairs and bristles (Yang, Mlodzik 2015). The Wnt/Ca2+ 
pathway is mediated by the interaction of Wnt5a with Frizzled-2. This interaction 
allows for the increase of intracellular levels of Ca2+ via inactivation of cGMP-
dependent kinase G (PKG), which in turn activates phospholipase C (PLC). PLC 
triggers release of intracellular levels of Ca2+, which in turn activates calcium 
dependent proteins, including protein kinase C (PKC) and Ca2+/calmodulin-




the activation of nuclear factor of activated T cells (NFAT), promoting transcription of 
genes necessary for ventral cell fate determination; and for activation of TGF-β 
activated kinase 1 (TAK 1) and Nemo-like kinase (NLK). PKC is known to regulate 
actin cytoskeleton reorganisation, resulting in tissue separation during gastrulation 
typically via activation of small GTPase Cdc42 (Komiya, Habas 2008). This pathway 
is involved in cancer, inflammation and neurodegeneration (Hapak, Rothlin et al. 
2018, Gomez-Orte, Saenz-Narciso et al. 2013). Both PCP and Ca2+ pathways were 
reported to antagonise canonical WNT signalling (Mazzotta, Neves et al. 2016, Rao, 
Kuhl 2010). 
Although the canonical signalling pathway plays a central role in CRC, the 
non-canonical Wnt-mediated pathways may also contribute to carcinogenesis. It was 
demonstrated that inactivation of RhoA results in colon cancer metastasis in mice 
(Rodrigues, Macaya et al. 2014). In addition, Wnt5a driven non-canonical Wnt 
signalling positively regulates expression of tumour suppressor 15-
hydroxyprostaglandin dehydrogenase (15-PGDH) in colon adenocarcinomas 
(Mehdawi, Prasad et al. 2016). In summary, both the canonical and non-canonical 
Wnt signalling pathways may contribute to colorectal carcinogenesis by utilising 








Figure 1-5. Schematic representation of Wnt-Ca
2+
 and planar cell polarity pathways activated 
by Wnt. (A) Wnt-Ca
2+
 pathway is initiated by Wnt binding to Frizzled (Fz). It results in activation of 
phospholipase C, which releases intracellular Ca2+ required for activation of calcium-dependent 
proteins. (B) Planar cell polarity pathway is activated by Wnt interaction with Fz/Dvl (Dishevelled) 
complex. It activates a cascade that has the small GTPases RAC1 and RHOA, and JNK kinase as 
downstream effectors that control rearrangements in the cytoskeleton and gene expression. Figure 





 EGFR signalling in colorectal cancer 1.3.2
Another important signalling pathway that is often upregulated in many 
cancers, including CRC, is the EGFR pathway. Epidermal growth factor receptor 
(EGFR) belongs to the tyrosine kinase receptor family that mediates a number of 
cellular processes, such as cell proliferation, survival, migration, and resistance to 
apoptosis (Mitchell, Luwor et al. 2018, Krasinskas 2011). Signal transduction is 
initiated by interaction between the growth factors and the receptor extracellular 
ligand-binding domain that leads to activation of various downstream effectors. 
Cascades that are activated through EGFR are presented in Figure 1-6. The 
Ras/MAPK, PI3K/Akt, and JAK/STAT pathways are the main intracellular pathways 
activated by EGFR and are involved in development of CRC. Known EGFR ligands 
include epidermal growth factor (EGF), heparin-binding (HB)-EGF, transforming 
factor alpha (TGF-α), amphiregulin (AREG), betacellulin, epiregulin (EREG) and 
epigen (Wilson, Mill et al. 2012). Different EGFR ligands bind with different affinities 
to the receptor and result in different downstream effects of EGFR signalling 
(Mitchell, Luwor et al. 2018, Ronan, Macdonald-Obermann et al. 2016). The EGFR 
ligands are detailed in Table 1-3.  
The mitogen-activated protein kinase (MAPK) pathway is crucial for cell 
proliferation and survival, and it is also important for intestinal epithelial cell 
differentiation (Tang, Liu et al. 2016). The MAPK pathway is initiated by binding of 
ligands to EGFR, which results in receptor dimerisation and auto-phosphorylation of 
EGFR cytoplasmic domain, followed by downstream phosphorylation relay to Ras 
and MAPK extracellular regulated kinases 1 and 2 (ERK1/2). Activated ERKs are 




involved in cell proliferation (Figure 1-6) (Liebmann 2001).  
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway regulates cell growth, 
apoptosis resistance, invasion, and migration and is also activated through EGFR 
(Castellano, Downward 2010, Scaltriti, Baselga 2006). PI3K can be directly recruited 
to the receptor dimer but requires EGFR dimerization with HER-3 receptor. The 
recruitment is facilitated by the docking proteins insulin receptor substrate (IRS) or 
GRB2-associated binder (GAB). The catalytic subunit of PI3K generates 
phosphatidylinositol -3, -4, -5 trisphosphate (PIP3) which is responsible for 
recruitment of serine/threonine kinase Akt. Activated Akt phosphorylates a number of 
factors responsible for cell survival, proliferation and motility (Scaltriti, Baselga 2006). 
Oncogenic activation of this pathway is known to contribute to pathogenesis and 






Figure 1-6. Schematic representation of Ras/MAPK and PI3K/Akt pathways activated by ligand 
binding to EGFR. Upon ligand binding, EGFR is dimerised and auto-phosphorylated at cytoplasmic 
domain, which provides a binding site for the adaptor proteins Grb2 and Sos either directly or through 
the association with the adaptor molecule Shc. This complex formation leads to conformational 
modification of Sos and recruitment of GTPase exchange factor (RasGEF) to the complex. This 
promotes activation of Ras (Ras-GTP) which in turn activated Raf, that through intermediate steps 
phosphorylates MAPK extracellular regulated kinases 1 and 2 (ERK1/2). Activated ERKs are then 
imported into nucleus where they phosphorylate specific transcription factors involved in cell 
proliferation. PI3K is recruited to the receptor dimer, resulting in activation of phosphatidylinositol -3, -
4, -5 triphosphate (PIP3) followed by phosphorylation of phosphoinositide-dependent kinase-1 (PDK1) 
and control activation of serine/threonine kinase Akt, which in turn can activate mTOR and NFκB 







Table 1-3. EGFR ligands, specificity to ErbB family of tyrosine kinase receptors and affinity. Table is reproduced and modified from Mitchell, 
Luwor et al. 2018. 
EGF-family ligands Receptor specificity Affinity class 
EGF EGFR High 
TGF-α EGFR High 
AREG EGFR Low 
EREG EGFR, ERBB4 Low 
HB-EGF EGFR, ERBB4 High 
BTC EGFR, ERBB4 High 
EPGN EGFR, ERBB3, ERBB4 Low 





Although EGFR mutations are uncommon in CRC, they may be acquired as a 
resistance mechanism to the anti-EGFR therapy (Zhao, Wang et al. 2017, Arena, 
Bellosillo et al. 2015). The hyperactivation of EGFR signalling in CRC is frequently 
occurring due to EGFR gene amplification and three- to fivefold increase in copy 
number is seen in approximately 50% of CRC (Krasinskas 2011). In addition, as 
mentioned earlier, EGFR downstream effectors are frequently mutated in CRC; 
KRAS is mutated in up to 40% of cases, BRAF in up to 22%, PIK3CA in 
approximately 18%, and PTEN in 13% to 19% of CRC (summarised in Table 1-4) 
(Krasinskas 2011). It has been noted that ligands, such as EREG and AREG, are 
often overexpressed in CRCs and contribute to carcinogenesis of intestinal 
epithelium (Mitchell, Luwor et al. 2018). The overexpression of EGFR ligands is also 
linked to development of metastases (Sasaki, Hiroki et al. 2013). For example, 
elevated expression of betacellulin (BTC), epigen, TGF-α, AREG and EGF was 
observed in a significant proportion of metastatic CRC and this correlated with poor 
prognosis in anti-EGFR treatment with cetuximab (Khelwatty, Essapen et al. 2017). 
Interestingly, in other studies the expression of AREG and EREG was associated 
with a better response to cetuximab and panitumumab therapy (Qu, Sandmann et al. 
2016, Zhai, Yu et al. 2017, Ronan, Macdonald-Obermann et al. 2016). Another 
recent report demonstrated a positive correlation of expression of EGFR ligands 
(TGF-α, BTC, EGF and HB-EGF) with disease-free survival (Yun, Kwak et al. 2018). 
These conflicting reports of association of EGFR ligands expression and response to 
the anti-EGFR treatment highlights the importance for further stratification of CRC 







Table 1-4. Frequency of mutations in the EGFR/MAPK pathway and their impact on clinical outcome. Table reproduced from Krasinskas 2011. 
Component 
(gene/protein) 
Protein function Defect in CRC Frequency Impact 





Protein expression 25–90% Controversial No correlation 
Mutation Rare Unknown Unknown 
Increased copy 
number 






(codons 12, 13, 61, 
146); leads to 
activation of MAPK 
pathway 
30–40% Controversial No response (if K-
Ras is mutated) 
BRAF/B-Raf Serine-threonine 
protein kinase 
downstream of KRas 
Activating mutation 
(V600E) 
5–12% Poor prognosis in 
MSS tumours 
No response (if BRAF 
is mutated) 
PIK3CA/PI3K A key signal 
transducer in the 
PI3K-AKT pathway 
Activating mutation 
(exons 9 and 20) 
14–18% Poor prognosis in K-
Ras wt tumours 
No response (if exon 
20 is mutated) 




Loss of protein 
expression; mutation; 
LOH 
13–19% Poor prognosis in K-






1.4 Mouse models of CRC 
Human CRCs are extremely heterogenous and complex. Thus, a large 
number of murine models have been developed in an attempt to recapitulate 
aetiology, pathology, and clinical progression of human disease and to address 
specific research questions. 
The most commonly used model of CRC was established in an 
ethylnitrosourea (ENU) mutagenesis screen (Moser, Pitot et al. 1990). These mice 
are predisposed to multiple intestinal neoplasia (MIN) due to a truncating mutation in 
APC gene in codon 850, hence were named APCmin (Su, Kinzler et al. 1992). 
Homozygous APCmin/min mice are embryonically lethal, confirming the crucial role of 
Wnt signalling in development. Heterozygous APCmin/+ develop up to 30 polyps, 
predominantly in the small intestine (Tong, Yang et al. 2011). The APCmin/+ has been 
used in numerous studies aimed to assess a multistep progression in colorectal 
cancer, chemoprevention, inflammation-associated tumorigenesis and anti-cancer 
host immune responses (Wang, Lu, Zhang 2015, Jackstadt, Sansom 2015, Yamada, 
Mori 2007, Kettunen, Kettunen et al. 2003). Other models with mutated APC gene 
were generated using homologous recombination of embryonic stem cells. The 
intestinal polyps that develop in these mice are histologically similar, however the 
number of polyps varies significantly between the models (summarised in Table 1-5). 
Interestingly, these polyps predominantly develop in the small intestine similarly to 







Table 1-5. Mouse models of CRC with APC truncations.  Table adapted and modified from Tong, Yang et al. 2011. 
APC mutants Mutation site Polyps/mouse Tumour 
histopathology 
Reference 
Small intestine Colon 
APCmin/+ truncating mutation at codon 850 
(ENU induced) 
~30 ~3 Benign adenomas (Moser, Pitot et 
al. 1990) 
ApcΔ716 truncating mutation at codon 716 ~300 ~3 Benign adenomas (Oshima, 
Oshima et al. 
1995) 
Apc1638N truncating mutation at codon 1638 
(neomycin insertion in exon 15) 
~3 ~0 Benign adenomas (Pretlow, 
Edelmann et al. 
2003) 
Apc1638T truncating mutation at codon 1638 
(hygromycin insertion in exon 15) 
0 0 Benign adenomas (Pretlow, 
Edelmann et al. 
2003) 
ApcΔ14 frameshift at codon 580 ~65 ~4 Benign adenomas (Colnot, Niwa-
Kawakita et al. 
2004) 
Apc1309 frameshift at codon 1309 ~35 ~3 Benign adenomas (Quesada, 
Kimata et al. 
1998) 
ApcΔ580 frameshift at codon 580 and a 
truncation at codon 605 
~120  Benign adenomas (Kuraguchi, 
Wang et al. 
2006) 
ApcΔ474 frameshift at codon 474 ~30 ~3 Benign adenomas (Sasai, Masaki 
et al. 2000) 
Apc1322T/+ truncating mutation at codon 1322 ~200 
 
  






Since APC-based mouse models predominantly result in the formation of 
intestinal adenomas in mice, researchers were prompted to generate other models 
that would recapitulate the phenotype of invasive carcinomas. As such, APC mutant 
mice were crossed with mice carrying mutations that are associated with more 
advanced stages of human adenomas or carcinomas, including KRAS, SMAD2, 
SMAD4, TP53, FBXW&7, and TGF-βR2. These experiments confirmed that a second 
mutation can accentuate the “APC-deficient” phenotype. For instance, APC-
heterozygous mice expressing constitutively active KRAS (KrasG12D) present with 
high grade dysplasia throughout the intestine (Haigis, Kendall et al. 2008). 
Heterozygous deletion of PTEN in APCmin/+ mice results in formation of invasive 
carcinomas, showing the important role of the PIK3A/Akt pathway in CRC (Shao, 
Washington et al. 2007). In addition, the expression of hypomorphic allele Egfrwa2 
and the antimorphic allele Egfrwa5 reduced the multiplicity of adenomatous polyps in 
APCmin/+ mice, demonstrating the important role of EGFR in adenoma formation 
(Dahlhoff, Horst et al. 2008, Roberts, Min et al. 2002). Other genes, known as 
modifiers of Min affect the tumour burden (Mom-1/2/3/5/7, Foxl-1, Cox-1, Cox-2, 
Mbd4, EphB2, EphB3, EphB4), location (Smad3, Smad4, EphB3, EphB4, ERα) and 
invasion (Smad4, TGF-β, Smad4, EphB2) of the APCmin/+ phenotype (Young, 
Ordonez et al. 2013). The transgenic expression of EGFR ligands also accentuates 
APCmin/+ phenotype in mice. As such, the expression of HB-EGF promotes formation 
of serrated adenomas in the caecum of APCmin/+ mice (Bongers, Muniz et al. 2012). 
The expression of BTC transgene results in increased adenoma burden in APCmin/+ 
mice (Dahlhoff, Horst et al. 2008), while TGF-α transgene enhances adenoma 




once again demonstrate that extracellular activation of EGFR plays an important role 
in colorectal carcinogenesis in APC-deficient lesions. In addition to APC models, a 
number of models with gene mutations involved in HNPCC-related carcinogenesis, 
including Msh2, Msh6, Mlh1 have been established (McIntyre, Buczacki et al. 2015, 
Tong, Yang et al. 2011). 
Apart from genetically generated models, chemically induced carcinogenesis 
is also widely used in studies with mice and is a rapid, reproducible model which 
mimics ‘Fearon and Vogelstein’ adenoma-carcinoma sequence. A variety of 
carcinogens are available including azoxymethane (AOM), methylazoxymethanol 
(MAM), 1,2-dimethylhydrazine (DMH), 2-amino-1-methyl-6-phenylimidazo [4,5-b]-
pyridine (PhIP) and 2-amino-33-methylimidazo [4,5-f] quinoline (IQ), 3,2′-dimethyl-4-
aminobiphenyl (DMAB), methylnitrosourea (MNU) and N-methyl-N′-nitro-N-
nitrosoguanidine (MNNG) (Tong, Yang et al. 2011). A selection of genetically 
modified mouse models for colorectal cancers, including rationale, strategy, 
advantages and disadvantages of each model are summarised in Table 1-6. In 
summary, a wide variety of mouse models are available to study colorectal 
carcinogenesis and careful consideration must be taken for selection of an 








Table 1-6. Genetically modified mouse models of CRC. Table adapted and modified from McIntyre, Buczacki et al. 2015. 
Mouse allele Rationale Strategy Advantages Disadvantages Reference 
APCMin/+ N/A Germline truncating 
mutation (N- terminus) 
Model of human 
familial adenomatous 
polyposis (FAP) 
syndrome and >80% 





(Moser, Pitot et al. 




Loss of heterozygosity 
occurs at wildtype 
allele in tumours 








Short life‐span means 
that adenomas do not 
acquire sufficient 





in small rather than 
large intestine 
(Halberg, Waggoner 
et al. 2009, Chen, 
X., Halberg et al. 
2008) 
 
Msh2-/- Msh2 mutations 
common in CRC 
Germline knockout Model of Hereditary 
non‐polyposis CRC 
(HNPCC) or Lynch 
Syndrome (3% of all 
CRCs) 
 
Msh2 mutation in all 
cells of body and mice 
are predisposed to 
lymphomas 










To restrict malignancy 
to intestine to prevent 
lymphoma 
Conditional 
 Cre recombinase 
expressed from 
promoter of intestinal 




No deaths from 
lymphoma 
Do not develop 
metastases 
(Kucherlapati, Lee et 
al. 2010) 
APC580S/580S To model advanced 
CRC by restricting 




Cre recombinase is 
administered through 
the anus to inactivate 
APC 
Live >1 year. 
Developed two or 
three intestinal 
adenomas 
Some mice developed 
adenocarcinomas 




APC expression in all 
cells, like APCfl/fl which 
results in development 
of life‐limiting 
hepatocellular 
carcinomas by 14 
months  




To model advanced 
CRC by restricting 
tumours to the colon 




expressed in the distal 
small intestinal and 
colonic epithelia to 
inactivate APC 
Live >1 year. 
Developed two or 
three intestinal 
adenomas 
Some mice developed 
adenocarcinomas 
Do not develop 
metastases 
(Robanus-Maandag, 
Koelink et al. 2010) 
APCMin/+ 
Trp53−/− 
To model advanced 
CRC through addition 
of cooperating gene 
mutations 
Germline mutations 
in APC and Trp53 
 Do not develop 
metastases 
(Clarke, Cummings 












To model advanced 
CRC through addition 




expressed in the distal 
small intestine/colonic 
epithelia and results in 
constitutive activation 
of K‐Ras and 
inactivation of APC 
Developed more 
adenocarcinomas 
than single mutant 
(APC or K-Ras alone) 
control mice 
Do not develop 
metastases 










To model advanced 
CRC through addition 
of cooperating gene 
mutations 
 Developed more 
adenocarcinomas 
than single mutant 
control mice. 
Do not develop 
metastases 
(Hamamoto, Beppu 
et al. 2002, Munoz, 
Upton et al. 2006, 




To model advanced 
CRC through addition 








promoter of intestinal 




Fbxw7 null control 
mice developed 
adenomas by 9‐10 
months of age 
Do not develop 
adenocarcinomas or 
metastases 











To model advanced 
CRC through addition 
of cooperating 
mutations. To restrict 
tumours to the colon 
and reduce tumour 
burden 
Adenoviral Cre solutio
n administered via the 
anus to 
simultaneously 




after five months 
Developed 
metastases to distant 
organs after six 
months e.g. liver 




required to clamp a 
section of colon to 
deliver 
Adenoviral Cre-
solution to the colon 
via the anus 















incidence. IQ, PhIP, 
DMAB, MNNG or 
MNU target multiple 
organs and exhibit a 
low tumour incidence. 
The tumours are not 
metastatic. 





1.5 Organoids as a model of colorectal cancer and normal 
intestinal epithelium 
Conventional experimental models that are utilised in cancer research extend 
from in vitro to in vivo systems. Whilst these models contributed to a significant 
progress in understanding of the disease there are a number of limitations that do not 
allow the comprehensive characterisation of individual tumours and the development 
of novel more specific and robust therapies for CRC. For example, the derivation of 
cell lines is often achieved by immortalisation using viral infections or exogenous 
expression of oncogenes, thus making them susceptible to a genetic drift. In addition, 
established cell lines are maintained out of the context of а specific tissue 
architecture and physiological properties of the tissue (Young, Madeleine, Reed 
2016). Animal models, on the other hand, provide insights into more physiological 
context of а disease, including immune responses and vasculature components. 
However, they may not be representatives of human disease and can be costly 
(Young, Madeleine, Reed 2016). The knowledge that intestinal cancers arise from 
intestinal stem cells (ISC) and not short-lived trans-amplifying cells has made the 
organoid system increasingly attractive for CRC studies and is widely applied in 
developmental studies (Barker, Ridgway et al. 2009). 
Intestinal and colonic organoids can be derived from ISCs or from isolated 
intestinal and colonic crypt structures in media containing growth factors and 
inhibitors mimicking mesenchymal signals (Sato, Vries et al. 2009, Sato, Stange et 
al. 2011). Organoids cultured in 3D ECM or Matrigel™ form three-dimensional 
structures which recapitulate tissue cellular composition and organisation ex vivo. 




be sub-cultured indefinitely. In addition, it has been shown that organoids maintain 
gene expression profile identical to freshly isolated crypts after extended propagation 
(Sato, T., Vries et al. 2009). Intestinal organoids form structures with a central lumen 
lined by villus-like epithelium and several surrounding crypt-like domains protruding 
into extracellular matrix; apoptotic cells are shed into the central lumen. Organoids 
recapitulate all epithelial cell subtypes of intestine, including stem cells, Paneth cells, 
enterocytes, enteroendocrine cells and Goblet cells (Date, Sato 2015, Middendorp, 
Schneeberger et al. 2014). Interestingly, cell organisation in organoids is identical to 
that seen in vivo with stem cells and Paneth cells residing at the bottom of crypts, 
whereas terminally differentiated enterocytes are migrating towards the lumen 






Figure 1-7. Schematic representation of intestinal organoid with crypt domains protruding into 
ECM and villus domains facing central lumen, corresponding to the intestinal architecture. 
Stem cells (Lgr5+) and Paneth cells are located at the crypt bottom, differentiated cells comprise of 
enterocytes, Goblet cells and enteroendocrine cells. Figure reproduced and modified from Roeselers, 
Ponomarenko et al. 2013. 
 
The mouse intestinal organoids are cultured in serum-free conditions in the 
presence of growth factors that facilitate stem cell renewal and differentiation, 
including R-Spondin-1, EGF, and Noggin (Sato, Stange et al. 2011, Jung, Sato et al. 
2011). Mouse colonic crypts lack Paneth cells, that are the major intrinsic source of 
Wnt3a required for ISCs, therefore for culture of mouse colon organoids additional 
Wnt3a ligands are required in the media (Clevers, Bevins 2013, Sato, Toshiro, van 
Es et al. 2010). To successfully culture human intestinal and colon organoids p38 
and TGF-β inhibitors are required (Sato, Stange et al. 2011). R-spondin-1 is an 




interaction with Rnf43/Znrf3 transmembrane E3 ubiquitin ligases, therefore inducing 
prolonged Wnt-mediated signalling in ISCs (Koo, Spit et al. 2012, Hao, Jiang et al. 
2016). Activation of EGFR is also required for the long-term culture of intestinal 
organoids to contribute to stem cell maintenance and division of TA cells (Matano, 
Date et al. 2015). Noggin is an effective antagonist of BMP signalling; the latter 
induces cell differentiation through activation of p38 and SMAD-1 and SMAD-4 
signalling cascades. It has been shown that depletion of Noggin from organoid 
cultures results in Lgr5+ stem cell loss and attenuation of organoid proliferation 
(Sato, Vries et al. 2009).  
The organoid model has been recognised as a powerful system for basic and 
translational studies. It represents an excellent genetically stable tool to study cell 
interactions, stem cell biology, as well as development of personalised therapies, 
drug screening and correction of mutations. Widely used techniques of genetic 
manipulation including lentiviral, electroporation-based transfection, gene silencing 
with shRNAs and CRISPR/Cas9 are applicable to organoids and provide further 
advantages to the model. For instance, CRISPR/Cas9 technology was used in 
human normal intestinal organoids to engineer CRC organoids by sequential 
induction of mutations in tumour driving mutations characterised in classic adenoma-
carcinoma sequence (Matano, Date et al. 2015). Organoids have also proven to be 
powerful and more reliable than 2D cell culture models in drug screening 
(Vlachogiannis, Hedayat et al. 2018, Schutte, Risch et al. 2017, Francies, Barthorpe 
et al. 2016, Longati, Jia et al. 2013). In addition, ‘CRC organoid biobanks’ have been 
formed to store organoids derived from CRC patients, which would greatly benefit 




and personalised therapy (van de Wetering, Francies et al. 2015).  
In summary, intestinal and colonic organoids represent a robust, reproducible, 
genetically stable model that is suitable for basic research and has many applications 
in translational research. The utilisation of organoids will allow reduction in animal 
models used and benefit the understanding of tumour development prospectively 
leading to personalised medicine. 
1.6 Tetraspanins 
 Overview 1.6.1
Tetraspanins are a large family of small transmembrane glycoproteins that are 
evolutionarily conserved among protozoan and metazoan organisms (Boavida, Qin et 
al. 2013, Huang, Yuan et al. 2005). Tetraspanins are expressed in nearly all cells of 
the human body and multiple members of the tetraspanin superfamily are expressed 
in each cell (Levy, Shoham 2005). The human genome has 33 genes encoding 
tetraspanin proteins. Tetraspanins have been implicated in a wide array of 
physiological functions including immune, reproductive, and urogenital systems 
(Yeung, Hickey et al. 2018, Yang, Sari et al. 2016, Schroder, Lullmann-Rauch et al. 
2009, Wright, Geary et al. 2004, Le Naour, Rubinstein et al. 2000). 
 Tetraspanin structure 1.6.2
Four transmembrane domains of tetraspanins link together two extracellular 
loops – a large extracellular loop (LEL) and a small extracellular loop (SEL) 
(demonstrated in Figure 1-10). Tetraspanins have a number of characteristic 
structural features that distinguish them from other classes of four transmembrane 




domain and polar residues in the transmembrane region. Highly polar residues – 
Asn, Gln and Glu – in transmembrane domains 1, 3 and 4 are 70%-90% conserved 
among all tetraspanins (Hemler 2005, Stipp, Kolesnikova et al. 2003). These 
residues are crucial for the formation of strong hydrogen bonds between each other 
or other residues contributing to the stabilisation of the transmembrane domain 
tertiary structure. There is also evidence that transmembrane region 1 of the 
tetraspanin CD82  is crucial for the biosynthesis and delivery of the protein to the cell 
surface through interaction with calnexin, an endoplasmic reticulum (ER) molecular 
chaperone (Cannon, Cresswell 2001). 
 Extracellular domains of tetraspanins present with a higher variation in size 
and sequence. It is thought that the large extracellular loop (LEL) is structurally 
similar among all tetraspanins: comprising of three helices and a variable region 
which determines the functional characteristic of each tetraspanin and contains 
nearly all known tetraspanin protein-protein interaction sites (Seigneuret, 
Delaguillaumie et al. 2001). Specifically, residues crucial for Hepatitis C Virus (HCV) 
E2 glycoprotein binding to tetraspanin CD81 were mapped to the hypervariable 
region of the LEL of CD81 (Kitadokoro, Bordo et al. 2001, Drummer, Wilson et al. 
2002). The variable region of LEL is stabilised by two to four disulphide bonds and 
involves a conserved cysteine-cysteine-glycine (CCG) motif – another hallmark of the 
tetraspanin structure. The SEL of the tetraspanins has not been studied in great 
detail and little is known of its contribution to the function of tetraspanins. It is 
predicted that ~70% of tetraspanins share similar features of SEL – it is enriched in 
hydrophobic residues, predicted to form a β-strand region that interacts with the LEL 




uroplakins (UPIa and UPIb) (Seigneuret 2006, Seigneuret, Delaguillaumie et al. 
2001, Min, Wang et al. 2006, Kitadokoro, Bordo et al. 2001). All tetraspanins are 
characterised by the presence of a variable number of cysteine residues at the 
predicted cytoplasmic portions, and where investigated these cysteines are found to 
be palmitoylated (Berditchevski, Odintsova et al. 2002, Charrin, Manie et al. 2002, 
Yang, Claas et al. 2002). Palmitoylation is required for the efficient tetraspanin-
tetraspanin interaction as well as association with other proteins that are organised 
into the tetraspanin enriched microdomain (TEM/TERM) (Levy, Shoham 2005, 
Hemler 2005). In 2016, the first crystal structure of full-length tetraspanin CD81 was 
resolved (Zimmerman, Kelly et al. 2016). This work revealed that transmembrane 
domains are organised in the ‘cone-like’ structure, where transmembrane domains 1 
and 2 are separated from transmembranes 3 and 4 at the membrane, and a 
cholesterol molecule can bind the interface of the formed cavity resulting in the 
conformational change of the LEL (Figure 1-8). It is suggested that such a 
conformational shift determines binding ability of CD81 to its partner proteins, 
membrane localisation and has consequent effects on the regulation of cellular 
function of tetraspanins (Matthews, Szyroka et al. 2017). However, it remains unclear 






Figure 1-8. Crystal structure of tetraspanin CD81. Four transmembrane domains of CD81 (TM1-
TM4) form a cone-like structure in the membrane. Molecular dynamic simulation suggests binding of 
cholesterol molecule (yellow) to the intramembrane cavity resulting in a conformation change of the 
LEL. Figure is reproduced from Zimmerman, Kelly et al. 2016. 
 
 
 Tetraspanin function 1.6.3
Functionally tetraspanins are implicated in the modulation of signalling 
pathways underlying cell adhesion, proliferation, motility, host-parasite interactions, 
and cell fusion (van Deventer, Dunlock et al. 2017). Specific functions of tetraspanins 
are determined by multiple cis- interactions with partner proteins, resulting in 
modulation of their signal transduction potential (e.g. integrins, receptor tyrosine 
kinases), intracellular trafficking (integrins, ADAM10) and clustering at the cell 




facilitators (Hemler 2014, Charrin, Jouannet et al. 2014, Charrin, Manie et al. 2003). 
In addition to their function in cis-, several tetraspanin proteins were shown to 
function as receptors (in trans-) for a number of soluble ligands. Specifically, CD9 
was reported as a receptor for pregnancy-specific glycoproteins (PSGs), CD63 – for 
tissue inhibitor of metalloproteinase 1 (TIMP-1), Tspan12 – for Norrin, and CD82 - for 
a transmembrane protein DARC (Moore, Dveksler 2014, Aaberg-Jessen, Sorensen 
et al. 2018, Lai, Zhang et al. 2017, Hur, Choi et al. 2016).  
Tetraspanins and their partner proteins are organised into microdomains and 
specific clustering is crucial for molecular function of membrane proteins. The 
generally accepted model of TEMs/TERMs proposes heterotypic associations 
between multiple tetraspanins and their partners (Hopf, Colwell et al. 2012, Charrin, 
le Naour et al. 2009, Levy, Shoham 2005). However, recently it was demonstrated by 
super-resolution microscopy that tetraspanins form nanoclusters of ~10 homotypic 
tetraspanin molecules that overlap with nanoclusters of partner proteins and rarely 
overlap with clusters formed by other tetraspanins (Zuidscherwoude, Gottfert et al. 
2015).  
One of the best studied examples of how tetraspanins affect function of the 
associated receptors is tetraspanin-dependent regulation of laminin-binding integrins 
(α3β1, α6β1, α6β4 and α7β1)  by CD151 (Kazarov, Yang et al. 2002, Sterk, Geuijen 
et al. 2002, Sawada, Yoshimoto et al. 2003, Berditchevski 2001, Yang, Claas et al. 
2002). The CD151-integrin interaction is mediated by the LEL of CD151 and results 
in the conformational change of integrins from an inactive to an active state (Figure 




impair integrin-mediated cell adhesion, thus supporting a role for CD151 in the 
regulation of integrin-mediated adhesion strengthening (Nishiuchi, Sanzen et al. 
2005). The functional importance of CD151 is further demonstrated in individuals with 
a CD151 nonsense mutation that results in hereditary nephritic syndrome (leading to 
kidney failure) and epidermolysis bullosa (fragile skin) (Karamatic Crew, Burton et al. 
2004). This phenotype was associated with the deficient assembly of the basement 
membrane in these organs. Importantly, certain variants of epidermolysis bullosa 
were associated with deficiencies in α6 and βintegrin subunits (Ashton, Sorelli et 
al. 2001). Accordingly, CD151-KO in FVB/N mice has also caused significant renal 
defects, strengthening the role of CD151 in regulation of integrin function (Sachs, 
Kreft et al. 2006, Baleato, Guthrie et al. 2008). Furthermore, histologically similar 
kidney and skin abnormalities were observed in α3-, α6-, and β4-KO mice (Belkin, 






Figure 1-9. Schematic representation of CD151-integrin interaction on the cell surface. The 
association of integrins with CD151 results in a conformational change of integrins into an active state 
and adhesion to extracellular laminins. Figure is adapted and modified from Haeuw, Goetsch et al. 
2011. 
 
The role of tetraspanins in the intracellular trafficking of the associated 
proteins is best exemplified by studies focussed on CD81 and its partner CD19 
(Cherukuri, Shoham et al. 2004, Levy 2014, Vences-Catalan, Rajapaksa et al. 2012). 
The interaction of CD81 and CD19, a B cell specific immunoglobulin domain 
containing protein, occurs through the LEL of CD81 during biosynthesis in the ER 
(Shoham, Rajapaksa et al. 2006). It has been shown that CD81 deficient mice have 
approximately a 50% reduction of CD19 expression on the surface of B cells 
(Miyazaki, Muller et al. 1997, Tsitsikov, Gutierrez-Ramos et al. 1997, Maecker, Levy 




due to deficient trafficking of the protein from the ER to the Golgi (van Zelm, Smet et 
al. 2010). Loss of CD19 expression on B cells results in immunodeficiency, 
characterised by impaired antibody responses (Shoham, Rajapaksa et al. 2003). 
Similarly, tetraspanins of the TspanC8 group have been shown to regulate 
intracellular trafficking and the maturation of matrix metalloprotease ADAM10 (Saint-
Pol, Eschenbrenner et al. 2017, Matthews, Koo et al. 2018). The subgroup of 
TspanC8s consists of six tetraspanins (Tspan5, Tspan10, Tspan14, Tspan15, 
Tspan17 and Tspan33), characterised by eight cysteine residues in their LEL. It has 
been shown that TspanC8s specifically interact with ADAM10 via their LEL, and 
facilitate trafficking of ADAM10 from the ER to the plasma membrane and the 
removal of its inhibitory pro-domain (Noy, Yang et al. 2016, Haining, Yang et al. 
2012, Prox, Willenbrock et al. 2012). Expression of ADAM10 was significantly 
reduced in erythrocytes in the Tspan33-KO mouse model (Haining, Yang et al. 
2012). In addition to their role in endocytic trafficking of ADAM10, different 
TspanC8s, which appear to bind to different regions of ADAM10, determine the 
specificity of ADAM10 towards different substrates. For example, complex of 
Tspan15/ADAM10 promotes cleavage of N-cadherin, whereas Tspan14/ADAM10 
and Tspan5/ADAM10 promote cleavage of Notch (Matthews, Szyroka et al. 2017, 
Jouannet, Saint-Pol et al. 2016, Haining, Yang et al. 2012, Zhou, Fujiwara et al. 
2014, Ruiz-Garcia, Lopez-Lopez et al. 2016). 
Tspan12 regulates multimerization of Frizzled-4/Lrp5 complex at the 
membrane facilitating β-catenin stabilisation and enhanced Norrin-induced Wnt 




Frizzled-4 forms a complex with its co-receptors Lrp5 or Lrp6 and activates the 
canonical Wnt signalling pathway in response to Wnt ligands or Norrin (structurally 
unrelated to Wnt cysteine-knot like growth factor) (Bang, Kim et al. 2018). The mouse 
KO model for Tspan12 exhibited impaired vascular development in the retina, a 
phenotype that was also demonstrated in mice deficient for Frizzled-4, Lrp5 and 
Norrin (Junge, Yang et al. 2009). Interestingly, Tspan12 mutations result in familial 
exudative vitreoretinopathy (blindness disorder) due to impaired retinal vasculature 
development (Nikopoulos, Venselaar et al. 2010, Poulter, Ali et al. 2010). 
Tetraspanins have been shown to associate with multiple signalling 
molecules, including G-protein coupled receptors (GPCRs), EGFR, c-MET, C-Kit, 
ADAM10 and ADAM17, protein kinase C (PKC), and phosphatidylinositol 4-kinase 
(PI4K) (Termini, Gillette 2017). For instance, in the context of EGFR signalling CD82 
has been shown to negatively regulate ligand-induced receptor dimerization and 
endocytosis (Odintsova, Voortman et al. 2003, Berditchevski, Odintsova 2016, 
Danglot, Chaineau et al. 2010). In addition, CD9 was reported to mediate EGFR 
signalling and was shown to inhibit proteolytic cleavage of TGF-α (Murayama, 
Shinomura et al. 2008, Shi, Fan et al. 2000). Another study demonstrated that CD9 
promotes trafficking of pro-TGF-α to the cell surface from the Golgi (Imhof, Gasper et 
al. 2008). Furthermore, it has been shown that tetraspanin CD82 expression results 
in Wnt signalling inhibition through decreased phosphorylation of β-catenin and its 
intracellular re-distribution to E-cadherin complexes (Abe, Sugiura et al. 2008, 
Chigita, Sugiura et al. 2012). Another study has also demonstrated the role of CD63 
in regulating β-catenin stabilisation via Akt-dependent GSK3β inhibition (Seubert, Cui 




 Tetraspanins and colorectal cancer 1.6.4
Tetraspanins are associated with the development and progression of various 
cancers including CRC (Hemler 2014, Wang, Li et al. 2011, Romanska, Berditchevski 
2011). Specifically, Tspan8 (C0-029), Tspan12, CD151 and Tspan1 have been 
shown to be upregulated in colorectal carcinomas and this is associated with a poor 
prognosis (Richardson, Jennings et al. 2011, Hashida, Takabayashi et al. 2003, Liu, 
Chen et al. 2017, Greco, Bralet et al. 2010, Chen, Zhu et al. 2009). However, 
expression of CD9, CD82, and uroplakin UPKIa are positively regulated with patient 
survival (Hashida, Takabayashi et al. 2003, He, Kong et al. 2014). Interestingly, 
Tspan8 has been proposed as a potential target for radio-immunotherapy in CRC 
using mouse monoclonal antibodies which are proven to effectively inhibit tumour 
growth in preclinical mouse models (Maisonial-Besset, Witkowski et al. 2017). The 
molecular functions of these tetraspanins in the context of colorectal cancer have not 
been well investigated in detail. Tspan8 and CD151 were shown to regulate cell 
motility through integrin and E-cadherin modulation thus linking their functions to 
metastasis of CRC cells (Malla, Pandrangi et al. 2018, Kohno, Hasegawa et al. 2002, 
Zhu, Ailane et al. 2017, Guo, Xia et al. 2012). Tspan12 was shown to promote β-
catenin signalling through the association with LRP5 and Fzd4 and stabilisation of 
the complex (Knoblich, Wang et al. 2014, Junge, Yang et al. 2009). Therefore, it is 
important to investigate molecular functions of tetraspanins associated with CRC to 
fully unravel their potential implications not only in diagnostics but also in treatment 
and disease management. 
 Tetraspanin 6 1.6.5




Maeda et al. in 1998 (Maeda et al., 1998). Tspan6 comprises of 245 amino acids and 
displays all key features of the tetraspanin proteins. In the LEL Tspan6 has a 
predicted N-linked glycosylation site at residue Asn134 (Figure 1-10). EST database 
analysis suggested that Tspan6 is expressed at high levels in brain and at lower 






Figure 1-10. Schematic representation of Tspan6.  The transmembrane domains form a cone-
shaped structure, large extracellular loop (LEL) contains conserved CCG motif, where cysteines (C) 
form di-sulphide bonds, and Asn134 (N) glycosylation site. The N-terminus of Tspan-6 contains PDZ-
binding motif.  
 
Tspan6 is a poorly studied tetraspanin and little is known about its contribution 
to cellular processes. Early studies have shown that Tspan6 is localised to 
adherence junctions (Yamazaki, Okawa et al. 2008). In 2012, Tspan6 was 
demonstrated to play a role in retinoic acid-inducible gene I-like receptor- (RLR-) 
inducible immune response to Sendai virus (SeV) infection through association with 
mitochondrial antiviral signalosome (MAVS) resulting in negative regulation of IFN-
stimulated response element, NF-κB, and IFN-β signalling (Wang, Tong et al. 2012). 
More recently Tspan6 expression was shown to negatively correlate with the onset of 




Tspan6 was implicated in the biogenesis of multivesicular bodies (MVBs) and can 
stimulate exosome production through the recruitment of an adaptor protein, 
syntenin-1 (Guix, Sannerud et al. 2017). Tspan6 was also reported as a potential 
stimulator of autophagy identified in a high-throughput short hairpin RNA (shRNA) 
screen (Strohecker, Joshi et al. 2015). Moreover, Tspan6 was found to be expressed 
on exosomes isolated from the LIM1863 colon carcinoma cell line (Tauro, Greening 
et al. 2012).  
Tspan6 expression was studied in CRC patients. The authors reported that 
higher expression of Tspan6 in tumours associated with better survival, although not 
significantly (n=30, p=0.60), suggesting that Tspan6 may be considered as a 
potential colon cancer biomarker (Chiang Sum-Fu, Tsai Ming-Hung, Tang Reiping, et 
al. 2014). More recently, analysis of mRNA expression in 597 CRC cases has 
demonstrated positive correlation of high Tspan6 expression and patient survival 
(p=0.0356) (Figure 1-11) (Uhlen, Zhang et al. 2017). In addition, Tspan6 expression 
was reported to associate with complete response to neoadjuvant therapy in locally 
advanced rectal cancers (Chauvin, Wang et al. 2018). Growing evidence implicating 
Tspan6 in the development of CRC encouraged us to study in more detail how 





Figure 1-11. CRC patient survival with Tspan6-high (purple) and Tspan6-low (blue) expression 
of mRNA transcript in CRC tumours. High expression of Tspan6 favours overall 5-year survival of 
CRC patients (63% vs 59% in Tspan6-high and Tspan6-low expressing tumours respectively, 






 Tetraspanins, extracellular vesicles and exosomes 1.6.6
It has been proposed that tetraspanins can also regulate carcinogenesis via 
exosomes – nanovesicles that function as a powerful tool of communication between 
various cell types in the tumour microenvironment (Malla, Pandrangi et al. 2018, Lu, 
Li et al. 2017). Exosomes are small bi-lipid membrane vesicles, 30nm to 100nm in 
diameter, and are enriched in cholesterol, sphingomyelin, ceramide, tetraspanin 
proteins, plasma membrane proteins, signalling molecules and genetic material 
including mRNAs, miRNAs, and lncRNAs (Bastos, Ruivo et al. 2018, Toh, Lai et al. 
2018). The content of exosomes varies greatly depending on the cell of origin and it 
is becoming more evident that the biogenesis and cargo sorting into exosomes is a 
tightly regulated process.  
Exosomes are derived from the endocytic pathway through the formation of 
multivesicular bodies (MVBs) (Alenquer, Amorim 2015). The endocytic pathway is 
considered as a mechanism of protein recycling and degradation, and exosomes 
were believed to be means of disposing of redundant cellular waste; however it is 
becoming more evident that exosomes have important biological function in 
mediating cellular communication (Nagarajah 2016).  
The maturation of endosomes is associated with acidification of the 
intraluminal compartment and formation of multiple intraluminal vesicles (ILVs), 
resulting in a late endosome or MVB. Furthermore, late endocytic organelles are 
directed into one of the two pathways: 1) fusion with lysosomes for protein 
degradation or 2) fusion with plasma membrane for exosomal release (Figure 1-12). 
Rab GTPases have been shown to mediate endosome and MVB fate, for example 




promotes maturation of early endosomes to late endosomes and MVB formation, and 
Rab11, Rab27a/b, Rab35 target MVBs to the plasma membrane, followed by fusion 
and exosome release (McGough, Vincent 2016, Alenquer, Amorim 2015). The 
content of exosomes is variable and the sorting of proteins into exosomes is not fully 
understood. One of the best studied mechanisms requires Endosomal Sorting 
Complex Required for Transport (ESCRT) complex and is implicated in ILV formation 
and maturation of early endosomes. ESCRT machinery contains up to 30 different 
proteins and is subclassified into five complexes (Juan, Furthauer 2018, Colombo, 
Moita et al. 2013). It is unclear which ESCRT machineries are involved in exosomal 
production, however the components of ESCRT-I and -III, including Alix and Tsg101, 
have been reportedly identified as exosomal markers (Juan, Furthauer 2018). ALIX 
has been reported to recruit PDZ-domain-binding cargo proteins, such as syndecans, 
tetraspanin CD63 and Frizzled receptors into MVBs through association with 
syntenin-1 (McGough, Vincent 2016, Baietti, Zhang et al. 2012, Latysheva, Muratov 
et al. 2006). Syntenin-1 is an adaptor protein that interacts with partner proteins via 
one of its PDZ (PSD95/Dlg/ZO-1) domains (Sarkar, Boukerche et al. 2004). The 
Alix/Syntenin/Syndecan complex plays a crucial role in exosome cargo sorting and 
ILV formation (Juan, Furthauer 2018). Syntenin-1 binds to the cytoplasmic tail of the 
transmembrane heparan sulfate proteoglycan (HSPG) syndecan via its PDZ domain, 
the endoglycosidase heparanase cleaves heparan sulfate side chains of syndecan, 
resulting in syndecan clustering and recruitment of alix-ESCRT complex to the N-
terminal domain of syntenin to facilitate budding and cleavage (Baietti, Zhang et al. 
2012, Ghossoub, Lembo et al. 2014). The Alix/Syntenin-1 complex was also shown 




association with syntenin-1 and with the aid of the phospholipase D2 (PLD2) 
regulates ILV production in endosomes (Ghossoub, Lembo et al. 2014). Interestingly, 
syntenin-1 has been reported to be upregulated in several cancers, including 
melanoma, glioma, breast cancer, urothelial cell carcinoma, and small cell lung 
carcinoma; its elevated expression in breast cancer and melanoma is negatively 
regulated with patient survival (Kegelman, Das et al. 2015). Moreover, syntenin-1 is 
speculated to affect HSPG aggregation, which in turn has been reported to be crucial 
for cancer-derived exosomes (Fares, Kashyap et al. 2016, Christianson, Svensson et 
al. 2013). The role of tetraspanins in ESCRT-dependent EV biogenesis is not fully 
understood. It is believed that tetraspanins may regulate an alternative, ESCRT-
independent exosome biogenesis. As such, upon depletion of ESCRT complex 
proteins, human epithelial cells Hep2, HeLa and melanocytic MNT-1 cells, were able 
to generate CD63 enriched extracellular vesicles (EVs) (Colombo, Moita et al. 2013, 







Figure 1-12. Schematic representation of exosome biogenesis. Exosome biogenesis starts with 
plasma membrane invaginations, formation of early endosomes, followed by formation of intraluminal 
vesicles (ILVs) within the endosome, maturation to late endosome/multivesicular body (MVB) that can 
be targeted for lysosomal degradation or fusion with plasma membrane for exosome release. Figure 
reproduced from Zhang, B., Yin et al. 2014. 
 
The enrichment of tetraspanin proteins on exosomes suggests that individual 
tetraspanins and, perhaps, TEMs/TERMs as a whole play an important role in 
functionality of exosomes. Cytoplasmic portions of several tetraspanins have 
endocytic trafficking signals which may be responsible for their recruitment to late 
endocytic organelles and, subsequently, to exosomes (Berditchevski, Odintsova 
2007). For example, it has been shown that the C-terminus of CD63 contains 
tyrosine-based sorting motif YEVM that binds to adaptor proteins AP-2 and AP-3, 
facilitating clathrin-dependent internalisation of CD63 enriched TEMs/TERMs 
(Berditchevski, Odintsova 2007, Rous, Reaves et al. 2002). The putative tyrosine-
based C-terminal motif YXXØ (Tyr-Xaa-Xaa-Ø, where Ø represents of an amino acid 
with a bulky hydrophobic side chain) is a common feature of 13 human tetraspanins 




to internalise into endosomes with their partner proteins, thus, suggesting their 
involvement in the recruitment of the partners to exosomal membranes. As such, 
tetraspanin CD82 internalises in a complex with EGFR and immunoglobulin protein 
EWI-2 (Zhang, Lane et al. 2003). Similarly, tetraspanins CD82 and CD9 facilitate 
endocytosis of E-cadherin and β-catenin (Chairoungdua, Smith et al. 2010). Other 
examples include CD81-dependent recruitment of Wnt11 into EVs in murine cancer-
associated fibroblasts (Luga, Zhang et al. 2012); the role of tetraspanin CD9 in 
sorting of CD10 metalloproteinase cargo recruitment to EVs in B-cells (Mazurov, 
Barbashova et al. 2013); the involvement of Tspan8 in selective recruitment of 
vascular cell adhesion molecule 1 (VCAM-1) and integrin α4 in pancreatic 
adenocarcinoma cells (Nazarenko, Rana et al. 2010); and the role of CD81 in sorting 
of MHC class molecules, B cell receptor, intercellular adhesion molecule 1 (ICAM-1) 
and Rac into EVs (Perez-Hernandez, Gutierrez-Vazquez et al. 2013). 
Exosomes are currently accepted as important messengers for cellular 
communication and regulation of biological processes associated with tumour 
initiation, progression and metastasis (Bastos, Ruivo et al. 2018). For instance, 
melanoma-derived exosomes were reported to contain high levels of vascular 
endothelial growth factor (VEGF) and IL-8 resulting in enhanced angiogenesis and 
immunosuppression in tumours (Ekstrom, Bergenfelz et al. 2014). Additionally, 
exosomes derived from cancer were shown to promote tumour metastasis by 
conditioning a pre-metastatic niche in distal organs for pancreatic cancer (liver 
metastasis) and melanoma (lung and liver metastasis) (Hoshino, Costa-Silva et al. 
2015, Costa-Silva, Aiello et al. 2015). Furthermore, cancer-derived exosomes have 




formation and progression (Mincheva-Nilsson, Baranov 2014). In colorectal cancers, 
exosomes were reported to contain multiple miRNAs (let-7a, miR-1229, miR-1246, 
miR-150, miR-21, miR-223, and miR-23a), that are elevated in CRC patients and 
considered as biomarkers of CRC (Ogata-Kawata, Izumiya et al. 2014). Furthermore, 
exosomes containing miRNA miR-4772-3p were shown to positively correlate with a 
better outcome of adjuvant therapy and decreased risk of tumour recurrence in stage 
II and stage III CRCs (Liu, Eng et al. 2016). MicroRNA-210-containing exosomes 
showed the ability to promote epithelial-mesenchymal transition (EMT) and tumour 
invasion (Bigagli, Luceri et al. 2016). Interestingly, tetraspanins have been implicated 
in sorting RNAs into EVs. As such, Tspan8 expressing cells were shown to enrich 
secreted exosomes in 285 mRNA and miRNA transcripts (Nazarenko, Rana et al. 
2010). Exosomes have also been implicated to play a role in chemo- and drug 
resistance. For instance, tumour-derived exosomes were shown to be enriched in 
ΔNp73 mRNA, a transcript of which inhibits the tumour suppressor function of TP53, 
promoting chemoresistance to oxaliplatin in the colon cancer cell line HCT116 
(Soldevilla, Rodriguez et al. 2014). A more recent study demonstrated that exosomes 
derived from KRAS mutant cells can induce drug resistance to anti-EGFR treatment 
with cetuximab in cetuximab-sensitive, namely Caco-2 cells (Zhang, Zhang et al. 
2017).  
In summary, exosomes play an important role in tumour development, 
progression and metastasis, and investigating how individual tetraspanins modulate 
their composition and function may lead to better understanding a better 




1.7 Research Objectives 
Tetraspanin 6 (Tspan6) is a poorly studied protein of the tetraspanin family of 
transmembrane proteins with no defined cellular function. While changes in 
expression of Tspan6 in CRC have been reported, the contribution of the protein in 
development of the disease has not been investigated. The aim of this project was to 
examine the role of Tspan6 in normal epithelium and in the progression to CRC. In 
this study, the biological effects of Tspan6 expression on tissue homeostasis and its 
role in the early stages of carcinogenesis and underlying mechanisms were 
addressed. The hypothesis of this project proposes that Tspan6 expression in CRC 
negatively regulates tumorigenesis by modulating EGFR-dependent signalling 
through interaction with syntenin-1 and limiting production of exosomes containing 
EGFR ligands.  
 Aims 1.7.1
The specific aims of this study were as follows:  
1) To examine Tspan6 expression and distribution in CRC; 
2) To determine the involvement of Tspan6 in colorectal carcinogenesis 
using Tspan6 KO mouse model; 
3) To examine cellular functions of Tspan6 in intestinal epithelial cells. 
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2 MATERIALS AND METHODS 
2.1 Cell culture methods 
 Mammalian cell lines 2.1.1
Mammalian cell lines used in this project are listed in the Table 2-1. All cells 
were obtained from American Type Culture Collection (ATCC) unless stated 
otherwise.  
Table 2-1. Mammalian cells used in the project 
Cell Line Source Tissue Cell type 
HEK293T ATCC® Human Embryonic Kidney Epithelial 
Caco-2 gifted Human Colorectal adenocarcinoma Epithelial 
L cells ATCC® Murine Subcutaneous Connective 
Tissue 
Fibroblast 





Amsbio Human Embryonic Kidney Epithelial 




 Cell line authentication 2.1.2
Caco-2 cells were kindly provided by Dr Chris Tselepis (University of 
Birmingham). Caco-2 cells were authenticated by multiplex PCR and short tandem 
repeat (STR) DNA profiling analysis using GenePrint® 10 System (Promega). The 
DNA was isolated from Caco-2 cells and ten loci were amplified using multiplex PCR 
according to the manufacturer’s instructions. The resulted STR profile was matched 
to Caco-2 STR profile published on the ATCC website and 87.5% match was 
identified against the cells used in these studies (Figure 2-1). The obtained STR 
MATERIALS AND METHODS 
67 
  
profile did not match other cell lines in the database (ATCC), confirming the 
authenticity and purity of the Caco-2 cell line. 
 
Figure 2-1. Authentication of the Caco-2 cell line.  (A) The expected STR profile of Caco-2 cell line 
with alleles of nine DNA loci. (B) The STR profile of Caco-2 experimental cells with identified alleles for 
nine DNA loci shows 87.5% match to the expected profile. (C) The example of allele amplification 
profile in Caco-2 experimental cells for locus D7S820, D16S539 and CSF1PO. Black arrows indicate 
amplified alleles of named loci with annotations below. 
 
 Mammalian cell line culture 2.1.3
All cells were cultured in high glucose (4500 mg/l) Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco), supplemented with 10% (v/v) Foetal Calf Serum (FCS) 
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(Gibco) and 50 U/ml Penicillin / 50 μg/ml Streptomycin (Gibco). Stably transfected 
Caco-2 cells were maintained in the presence of 2 μg/ml puromycin (Sigma-Aldrich), 
L-Wnt3a cells were grown in 0.4 mg/mL Geneticin® (G418), HA-R-Spondin-1-Fc 
293T cells - in 300 µg/ml Zeocin, and L-WNR cells - in 0.5 mg/ml Hygromycin B and 
0.5 mg/ml Geneticin® (G418). All cell lines were cultured at 37°C, in a humidified 
incubator (Galaxy R CO2 Incubators, RS Biotech) in 5% CO2 atmosphere. Cells 
were passaged when they reached 80% confluency. For passaging, growth medium 
was removed, and cells were washed with sterile phosphate buffered saline (PBS) to 
remove all traces of serum. To detach cells from a plastic surface of the flask/plate, 
they were incubated with 0.05% Trypsin-EDTA (Gibco) for 5 min at 37°C. 
Subsequently dislodged cells were resuspended in fresh growth medium and 
pelleted by centrifuging at 190 x g for 3 min in Heraeus Megafuge 40 (ThermoFisher 
Scientific). After resuspension cells were plated at required density (1:5 for Caco-2 or 
1:10 for HEK293T, L Cells, L-Wnt3a cells, Noggin-secreting 293 cells, and HA-R-
Spondin-1-Fc 293 cells, L-WNR cells). Growth media was changed every three days.  
 Cryopreservation of cell lines  2.1.4
For cryopreservation, cells (collected as described above) were resuspended 
in freezing solution (10% (v/v) dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and 90% 
(v/v) FCS). The suspension of 1x106 cells/ml was subsequently frozen in 1 ml 
CryoTube™ vials (Nunc) at -80°C for at least 24h before transferring to liquid 
nitrogen for long term storage. Cells were recovered by thawing in a water bath for 2 
min at 37°C. Thawed cell suspension was transferred to a tube with 9 ml of pre-
warmed complete growth medium and pelleted by centrifugation at 190 x g for 3 min. 
Cells were resuspended in fresh medium and seeded in T25 tissue culture flask. 
MATERIALS AND METHODS 
69 
  
Cells were incubated at 37°C, in humidified 5% CO2 atmosphere for at least 48h 
before further manipulation. 
 Caco-2 3D culture 2.1.5
Caco-2 3D colonies were plated on polymerised growth factor 
reducedMatrigel™ (BD Bioscience) supplemented with 0.4 mg/ml Matrigel™ in 
complete growth medium or in DMEM supplemented with 10% FCS in 8-well 
chamber LabTek (Thermo Fisher Scientific). Each well was pre-coated with 45 µl of 
100% Matrigel™ and incubated for 15 min in the incubator at 37°C for Matrigel™ to 
solidify. Subsequently, 6x103 cells were mixed with 0.4 mg/ml Matrigel™ in DMEM 
and added to each Matrigel™ coated well. Cells were incubated at 37°C, in 
humidified incubator (Galaxy R CO2 Incubators, RS Biotech) in 5% CO2 atmosphere.  
For the experiments involving EGF and cetuximab cells were plated on 
Matrigel™-coated LabTek in 0.4 mg/ml Matrigel™ in complete growth medium. After 
24 hours 10 ng/ml of EGF or 25 µg/ml cetuximab were added and cells were 
incubated in cell incubator at 37°C for 5 days. Fresh media containing EGF or 
cetuximab was added every two days. The growth of colonies was examined using 
phase-contrast microscopy (Nikon) and images of 25 fields were taken for 
subsequent analysis. The diameter of colonies and lumens were measured using 
ImageJ Software. Approximately 150 colonies per condition were analysed.  
2.2 Organoid culture  
 Organoid derivation 2.2.1
Mouse intestine and colon were collected into ice-cold PBS. The intestine was 
cut into 3cm pieces and villi were scraped using a coverslip. Then tissue was cut into 
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2-3 mm sections and placed in a Falcon tube with modified ice-cold PBS (PBS-0) 
(Sigma-Aldrich) and vigorously shaken for 3 min to remove contaminating villi. This 
process was repeated until the supernatant was clear. Subsequently, intestinal tissue 
was incubated in 25ml of gentle cell dissociation reagent (StemCell Technologies) for 
15 min on a rocker at room temperature to separate the crypts and villi from the 
intestinal basal surface. The crypts were then isolated from villi by centrifugation at 
300 x g 5 min. The supernatant was discarded and pellets resuspended in 10 ml of 
ice-cold PBS and centrifuged for 2 min at 150xg to remove single cells. Crypts were 
then counted and resuspended in Matrigel™ (~200 crypts/50µl of Matrigel™). Crypt-
Matrigel™ suspension was then pipetted into the centre of the pre-warmed 24-well in 
the dome-shaped droplet. Subsequently, the plate was incubated for 15 min to allow 
Matrigel to solidify. Then, 500 µl of Intesticult™ organoid growth medium (StemCell 
Technologies) was added to each well. Organoids were incubated in a CO2- 
incubator for 7-8 days and media was changed every 3 days. To evaluate EGFR-
dependent organoid growth, organoids were cultured in mouse intestinal organoid 
media: Advanced DMEM/F-12 (Gibco) supplemented with 20% (v/v) R-Spondin-1 
conditioned medium, 100 ng/ml Noggin (Peprotech), 1xB27 (ThermoFisher 
Scientific), 1xN2 (ThermoFisher Scientific), 1.25 mM N-Acetyl Cysteine (Sigma-
Aldrich), 10mM Nicotinamide (Sigma-Aldrich), 100µg/ml Primocin (Vivogen) and in 
the presence (control) or absence of 50 ng/ml EGF (Peprotech). Organoids were 
cultured for 7 days and the growth was examined using phase-contrast microscopy 
(Nikon) every three days of culture.  
 Mouse intestinal organoid passaging and maintenance 2.2.2
For passaging, organoids were collected into a 15ml tube and gently washed 
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by pipetting with 10ml ice-cold PBS-0. Organoids were pelleted by centrifugation at 
300 x g for 5 min. The supernatant and excess Matrigel™ were removed and 
discarded. Organoids were then resuspended in 1ml of ice-cold PBS-0 and 
mechanically disrupted by pipetting. Once the suspension appeared cloudy and no 
large structures were detected, the suspension was checked under microscope to 
identify crypt-like structures. Subsequently, cells were further washed twice with ice-
cold PBS-0, resuspended in the required amount of Matrigel and plated on pre-
warmed 24-well plate as described above and overlaid with 750 µl of growth medium. 
Each well, containing approximately 50-100 organoids was split into three wells.  
 Organoid embedding into paraffin blocks 2.2.3
Organoids were fixed with 4% paraformaldehyde/3% sucrose/PBS (PFA) 
supplemented with 1mM CaCl2 and 0.5 mM MgCl2 for 30 minutes at room 
temperature. PFA fixed samples were then washed with PBS three times for 5 
minutes. Organoids were resuspended in 3% low-melting-point agarose (Sigma-
Aldrich). After agarose polymerisation, the pellets were fixed in 10% formalin buffered 
saline (Sigma-Aldrich) for 4 hours followed by two 30-minute wash in PBS. Samples 
were dehydrated in graded alcohol (75% - 1hr, 95% - 1hr, 100% - 1hr) and alcohol 
was replaced with xylene for 1hr, followed by 2hr incubation in paraffin bath at 60°C. 
Samples were then embedded into fresh paraffin using HistoStar™ (ThermoFisher 
Scientific) and stored at room temperature.  
 Organoid size measure 2.2.4
Organoids derived from C57Bl/6J wild-type, Tspan6 KO, APCmin/+, and 
APCmin/+Tspan6-/y mice were imaged using phase-contrast microscopy after five days 
in culture. Approximately 10 fields were taken for analysis. Images were analysed 
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using ImageJ software as shown in Figure 2-2. The Fast Fourier Transform (FFT) 
algorithm was first used to filter out large structures (down to 200 pixels) and 
smoothen small particles. Following this, the threshold level was corrected for each 
image to highlight organoids structures. The algorithm of particle analysis was used 
to measure organoid area (pixel2), filtering out particles smaller than 1000 pixel2. The 
area of organoids was measured and presented as average area (pixel2) of organoid 
per genotype. More than 100 organoids per genotype were measured. 




Figure 2-2. ImageJ algorithm for organoid size measure.  (A) The FFT Bandpass filter was 
corrected to reduce the image complexity and smoothen small objects in the field. (B) Threshold for 
each image was corrected to isolate organoids from the background. (C) The particle analysis was run 
to detect structures >1000 pixel
2
. (D) Analysed structured were overlaid with masks and area of 
organoid and other statistical values shown in result window. 
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2.3 Cell transfection 
 Stable gene expression cell line establishment 2.3.1
Stable expression of FLAG-Tspan6 in Caco-2 cells was established using 
lentiviral transduction. The vectors psPAX2 and pMD2.G were provided by D. Trono 
(Geneva, Switzerland); the pLVx-Flag-Tspan6 (puro) plasmid was provided by Dr. 
Berditchevski. Lentiviral particles were produced using PEI-based (polyethyleimine) 
transfection protocol on 70% confluent HEK293T (Yang, S., Zhou et al. 2017). The 
HEK293T cells were plated on 6cm plate and incubated at 37°C until 70% confluency 
was reached. Immediately prior to transfection, 3.2ml of fresh media was added to 
the cells. To transfect cells, 8 µg total DNA (3.6 µg psPAX; 1.8 µg pMD2.G; 2.6 µg 
pLVx-puro/ pLVx-Flag-Tspan6) was mixed with 800 µl of serum free, antibiotic free 
DMEM. The mix was vortexed, and 12 µg of PEI was added to the mixture, vortexed 
and incubated for 10min at room temperature. Subsequently, the DNA/PEI mix was 
added to the HEK293T cells, the total volume of media was 4 ml. Following 16-hour 
incubation, media was exchanged for the fresh complete growth medium and 
incubated for 24 hours to produce viral particles. Virus containing supernatant was 
harvested and supplemented with polybrene (1 µg/ml). The supernatant was filtered 
using 0.22 µm filter (Millipore) and added to Caco-2 cells following 24 hours 
incubation. To increase the efficiency of lentiviral gene transduction, infection of 
target cells was repeated. For stable gene transduction, selection with 2 μg/ml 
puromycin started 48 hours after the last infection cycle. Transfection efficiency was 
determined by Western blot analysis using polyclonal anti-TSPAN6 antibody (Thermo 
Fisher Scientific) and monoclonal anti-FLAG antibody (Sigma-Aldrich). 
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 siRNA gene silencing  2.3.2
Transfection of Caco-2 cells was carried out using Lipofectamine™ RNAiMAX 
Reagent (Invitrogen) as per manufactures instructions in a 24-well format. The 
reverse transfection procedure was utilised. Predesigned small interfering RNA 
directed against syntenin-1 (Eurofins MWG Operon) and a non-targeting siRNA 
control (Qiagen) were used to knockdown gene expression at 10 nM final 
concentration. For each well to be transfected 6pmol siRNA was diluted into 50 µl of 
Opti-MEM® (Thermo Fischer Scientific) and mixed by pipetting. Separately, 3 µl of 
Lipofectamine™ RNAiMAX was diluted in 50 µl of Opti-MEM®. Diluted siRNA mix 
and diluted Lipofectamine RNAiMAX were mixed and incubated for 5min at room 
temperature. Subsequently, siRNA-Lipofectamine complexes were added to each 
well containing 3x105 Caco-2 cells in 500 µl antibiotic free media. Following 24-hour 
incubation at 37°C in a CO2 incubator cells were detached using TrypLE Express 
enzyme (Gibco) for 5 min at 37°C and plated in 0.2 mg/ml Matrigel™ on pre-coated 
with 100% Matrigel 48-well plates. Growth of colonies was examined using phase-
contrast microscopy and protein expression knockdown was examined by Western 
Blot.  
2.4 Conditioned media production 
 Wnt3a and WNR conditioned media 2.4.1
Mouse fibroblast L cells expressing Wnt3a (or co-expressing Wnt3a, R-
Spondin-3 and Noggin) were passaged at 1:10 dilution once a week at 90% 
confluency. Wnt3A conditioned medium was prepared according to the 
manufacturers protocol. Briefly, cells were cultured in DMEM/FCS media in five 15 
cm tissue culture dishes for 4 days after subculture (1:10). Subsequently, the media 
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was collected, filtered through 0.2 µm filter and stored at 4°C (marked as the “batch 
1). Cells were cultured in fresh growth medium for further 3 days, collected and 
sterile filtered as described above (batch 2). Media from batch 1 and batch 2 were 
mixed at 1:1 ratio, filtered through 0.2 µm filter system and stored at 4°C for up to 4 
weeks.  
 R-Spondin-1 conditioned media 2.4.2
The 293T cells expressing HA-R-Spondin-1-Fc were passaged at 1:10 dilution 
once a week at 80% confluency. For conditioned medium, cells were expanded in 
complete growth medium in T-225 (225 cm2 area) tissue culture flask. Once cells 
reached 80% confluence, the media was changed to Advanced DMEM/F-12 
containing GlutaMAX and cultured for further 7-10 days. Subsequently, the 
supernatant was collected, and cells and debris were removed by centrifuging at 
3,000 x g for 15 min at 4°C. The supernatant was sterile filtered through a 0.2 µm 
filtering system and stored at 4°C for up to 4 weeks. The activity of conditioned 
medium was determined by performing Luciferase TopFlash assay.  
2.5 Protein analysis 
 Extraction of whole-protein lysates from cells 2.5.1
For Western blot analysis whole cell lysates were prepared. Cells (1x106) were 
lysed in 100 µl 1x Laemmli (63mM Tris-HCl pH 6.8 2.1 ml, 10% v/v glycerol, 2% w/v 
SDS) supplemented with 1x Protease/Phosphatase Inhibitor Cocktail (Cell Signalling 
Technologies). Subsequently lysates were heated at 95°C for 5min, sonicated and 
centrifuged for 10min at 16000 x g at 4°C in MicroCL 17 Microcentrifuge 
(ThermoFisher Scientific).  
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 Extraction of whole-protein lysates from organoids 2.5.2
Organoids were collected into Eppendorf tubes in ice-cold PBS-0 containing 
1x protease/phosphatase inhibitor cocktail (Cell Signalling Technologies) and 
centrifuged at max speed for 20 seconds at 4°C. The supernatant and separated 
Matrigel™ were removed and organoids were washed in 1ml of PBS-0/ 
protease/phosphatase inhibitor cocktail. The pellet was lysed in 1x Laemmli (63mM 
Tris-HCl pH 6.8 2.1 ml, 10% v/v glycerol, 2% w/v SDS) supplemented with 1x 
protease/phosphatase inhibitor Cocktail. Subsequently lysates were heated at 95°C 
for 5min, sonicated and centrifuged for 10min at 16000 x g at 4°C.  
 SDS-PAGE and Western Blot analysis 2.5.3
Equal amounts of whole cell lysates (~40 µg of total protein) were resolved in 
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gels. For 
signalling experiments samples were reduced by adding 5% v/v β-mercaptoethanol 
(SigmaAldrich). Samples were loaded on 10% SDS-PAGE and resolved at 13 mAmp 
using Bio-Rad electrophoretic equipment and 1x SDS/Tris/Glycine running buffer 
(GeneFlow). The resolved proteins were then transferred onto nitrocellulose 
membrane at 40V at 4°C overnight using 1x Tris/Glycine transfer buffer (Geneflow). 
The membrane was briefly washed in TBST and blocked using 5% w/v skimmed milk 
powder in TBST by incubation for 1 hour at room temperature. Subsequently, 
membranes were probed with appropriate primary antibodies (Table 2-2) overnight at 
4°C diluted in 3% w/v BSA-TBST-3mM NaN2. After washing with TBST (3x 5 min), 
membranes were incubated with secondary antibody conjugated with fluorescent dye 
(i.e. goat anti-mouse Ab IRDye 680LT, or goat anti-rabbit Ab IRDye 800CW (LI-
COR)) for 1 hour at room temperature. Then, membranes were washed with TBST 
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2x 5min and dH2O 1x 5 min proteins were visualized and the signal was quantified 
using Odyssey®CLx Infrared Imaging System (LI-COR). The protein expression was 
normalised to expression of housekeeping proteins (β-actin, β-tubulin, or GAPDH). 
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Table 2-2. Primary antibodies used in the project 
Primary antibodies Host Source Dilution 
Tspan6  Rabbit Thermo Scientific (cat #AP9224)   1:500  
p-EGFR-Y1045  Rabbit Cell Signalling Technologies (Cat# 2237S)   1:500  
p-EGFR-Y1068  Rabbit Cell Signalling Technologies (Cat# 2234)   1:700  
EGFR  Mouse Thermo Scientific (Cat# MS-665-P0)   1:700  
p-β-catenin T41/S45  Rabbit  Cell Signalling Technologies (Cat# 9565)   1:500  
p-β-catenin S552  Rabbit  Cell Signalling Technologies (Cat# 5651)   1:1000  
β-catenin  Mouse  BD Laboratories (Cat# 610153)   1:2000  
p-ERK T202/Y204  Rabbit Cell Signalling Technologies (Cat# 9101)   1:1000  
ERK1/2  Rabbit Cell Signalling Technologies (Cat# 9102)   1:1000  
p-Src family Y527 Rabbit Cell Signalling Technologies (Cat# 2105)   1:1000  
Src  Rabbit Cell Signalling Technologies (Cat# 2108)   1:1000  
p-p38 T180/Y182 Rabbit Cell Signalling Technologies (Cat# 4511)   1:1000  
p38 MAPK  Rabbit Cell Signalling Technologies (Cat# 8690)   1:1000  
p-cCbl (Tyr774) Rabbit Cell Signalling Technologies (Cat# 3555)   1:700 
c-Cbl Rabbit Cell Signalling Technologies (Cat# 2747)   1:700 
GAPDH Mouse Abcam (Cat #ab8245)   1:3000 
β-actin  Mouse Sigma-Aldrich (Cat# A5316)   1:40000  
β-tubulin  Mouse Sigma-Aldrich (Cat# A5317)   1:3000  
 
 
 Co-immunoprecipitation (co-IP) assay 2.5.4
For co-immunoprecipitation studies, 3x106 cells were cultured in 10 cm tissue 
culture dish (Corning) until they reach 90% confluency. Subsequently, cells were 
washed with sterile PBS and proteins were solubilised in 500 µl of protein extraction 
solution (0.5% Brij98-0.5% Triton-X-100-PBS or 0.8% Brij98-0.2% Triton-X-100-PBS) 
for 4hr on tube rotator at 2 x g at 4°C. Insoluble material was pelleted by 
centrifugation at 16000 x g at 4°C and supernatants were incubated with 20 µl of 
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ANTI-FLAG M2 agarose beads (Sigma-Aldrich) for 4hr on tube rotator at 2 x g at 
4°C. Then, beads were washed 3x with ice-cold lysis buffer and precipitated proteins 
were eluted by 30 μl of 2x concentrated Laemmli buffer after incubation at 60°C for 
10’. For normalized co-IP blots, proteins were extracted from equal number of cells 
for each cell line. 
2.6 Cellular activity assays 
 Luciferase TopFlash assay 2.6.1
The experiment was set in a 96-well format using HEK293T cells. Each tested 
condition was tested in triplicate which served as the technical repeat. Cells were 
transfected using polyethyleimine (PEI) (Sigma-Aldrich). For each transfected well, a 
total of 15ng of plasmid DNA was used (Luciferase TopFlash (or FopFlash):Renilla at 
ration 9:1) and diluted in 7.5µl of DMEM without serum and antibiotics. Separately, 
0.75 µg of PEI was diluted in 7.5 µl of FCS. Subsequently, plasmid DNA and PEI 
solutions were mixed together and incubated for 20 min at room temperature. 
Meanwhile, cell suspension was prepared in DMEM/10%FCS. For a 96-well plate, 
2.5x104 cells/well was required for transfection. Then, cells and plasmid DNA/PEI 
were mixed together seeded onto the plate. After 24 hours of incubation at 37°C in 
the CO2 incubator, medium was replaced with Wnt3a CM/complete growth medium 
(DMEM/10% FCS) (50:50), or Wnt3a CM/R-Spondin-1 CM/complete growth medium 
(50:10:40). After 24 hours of treatment, cells were washed twice with PBS and lysed 
using Passive Lysis Buffer (Promega) for 15min at room temperature on a rocking 
platform. 20 µl/sample was transferred to a new 96-well opaque plate with clear flat 
bottom. Firefly (Photinus pyralis) and Renilla (Renilla reniformis) luminescence 
signals were measured sequentially from the same sample, using the Dual-Glo 
MATERIALS AND METHODS 
81 
  
luciferase assay system (Promega). Briefly, the luminescence signal of the firefly 
luciferase expressed from TopFlash or FopFlash plasmid was quantitatively 
measured first by the addition of Luciferase Assay Reagent II (LARII). After, the firefly 
signal was quenched by addition of Stop & Glo® reagent to the same sample, and 
Renilla luciferase signal was measured and quantified. Luminescence signal was 
measured using PHERAstar FS microplate reader (BMG Labtech). Firefly 
luminescence signal values were normalized according to their corresponding Renilla 
signal values. TOP-flash signal was standardized to the background signal 
(FOPflash).  
 Proliferation assay 2.6.2
To evaluate proliferation of Caco-2 in monolayer an Alamar Blue assay was 
carried out. Caco-2 cells were plated in 96-well plate at concentrations 5000 
cells/well, 10000 cells/well, 20000 cells/well and 40000 cells/well. Following 72 hours 
of incubation in CO2-incubator 10µl of Alamar Blue (Thermo Scientific) was added to 
each well and incubated for 4 hours at 37°C. The fluorescence was read using 
Fluoroskan Ascent™ Microplate Fluorometer. Zero time point was measure after 3 
hours of incubation at 37°C in CO2-incubator to allow cells to attached to the plate 
prior to addition of Alamar blue to the cells.  
 Proliferation of Caco-2 in 3D ECM 2.6.3
Caco-2 3D colonies were grown on 100% growth factor reduced BD 
Matrigel™ (BD Bioscience) supplemented with 2% (v/v) Matrigel™ in complete 
growth medium or in DMEM supplemented with 10% FCS in 96-well clear bottom 
black opaque plates (Corning). Each experimental well was coated with 15µl of 100% 
Matrigel™ and incubated for 15 min in cell incubator at 37°C. Subsequently, 8x103 
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cells were resuspended in 2% (v/v) Matrigel™/growth media and dispensed into the 
wells. Cells were incubated at 37°C for 72 hours in humidified incubator in 5% CO2 
atmosphere and cell growth was assayed using CellTiter-Glo (Promega) according to 
manufacturer’s recommendations. The growth rate was expressed as ratio of 
fluorescence signal on day 3 to fluorescence signal on day of plating. 
 Growth Inhibition Assay 2.6.4
Inhibitory effects of cetuximab was measured using Alamar Blue assay. Caco-
2 cells were plated in 96-well plate at a concentration 3,000 cells/100µl per well. After 
24 hours cells were treated with cetuximab antibody (Merck Biopharma) at 
concentrations 0.1 µg/ml, 0.5 µg/ml, 1 µg/ml, 5 µg/ml, 10 µg/ml, 25µg/ml, and 
50µg/ml in complete growth medium or DMEM supplemented with 3% FCS. 
Following 72 hours of incubation in CO2-incubator 10µl of Alamar Blue was added to 
each well and incubated for 4 hours at 37°C. The fluorescence was read using 
Fluoroskan Ascent™ Microplate Fluorometer. A separate plate was set for each 
experiment with cell numbers varying from 5000 to 40000 cells/well to allow for 
accurate control of operating within the linear range of fluorescence/cell density 
relation in each experiment. Three independent experiments were carried out for 
each cell line and condition.  
 Organoid Growth Inhibition Assay 2.6.5
Inhibitory effects of Lapatinib were measured using CellTiter-Glo® 3D Cell 
Viability Assay (Promega) in a 96-well format. An opaque 96-well plate with clear flat 
bottom was pre-coated with 15 µl of 100% Matrigel and placed in the incubator. 
Mouse intestinal organoids from C57Bl/6J-WT and C57Bl/6J-Tspan6 KO mice were 
mechanically disrupted as described in section 2.2.2. Following the last wash with 
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PBS-0, a total number of crypts was estimated by counting. Crypts (~25/well) were 
resuspended in 4% Matrigel/Growth medium and 100 µl of suspension was plated 
per each well. The plate was incubated for 24 hours at 37°C in CO2 incubator. After 
this time period, serial dilutions of an inhibitor (20nM, 50nM, 100nM, 200nM and 
400nM) were prepared in complete growth media, and 100µl was added to the test 
plate. The final concentrations of Lapatinib were: 10nM, 25nM, 100nM, and 200nM. 
The organoids were cultured for 6 days and the cell viability was measured using 
CellTiter-Glo® 3D Cell Viability Assay according to the manufacturer’s protocol. 
Briefly, an equal amount of CellTiter-Glo® reagent was added to each well and 
incubated for 1hr at room temperature. The luminescence was measured using 
PHERAstar FS microplate reader.  
 Organoid co-culture assay 2.6.6
For co-culturing C57Bl/6J wild-type or Tspan6 KO organoids, cells were plated 
together in the same well in two Matrigel™ domes in a 6-well plate and cultured for 7 
days in mouse intestinal organoid media without EGF. Two controls were used in this 
experiment when each type of organoid was plated with Matrigel™ dome (empty) in 
mouse intestinal organoid media containing 50 ng/ml of EGF (Figure 2-3.A) or in 
mouse intestinal media without EGF (Figure 2-3.B).  




Figure 2-3. Experimental design for organoid co-culture. (A) Viability control of organoid: C57Bl/6J 
WT or Tspan6 KO organoids were cultured in mouse intestinal organoid media. (B) Experimental 
control of organoids: C57Bl/6J WT or Tspan6 KO organoids were cultured in mouse intestinal 
organoid media without EGF ligand. (C) C57Bl/6J WT and Tspan6 KO organoids were cultured in the 
same experimental well in mouse intestinal organoid media free of EGF. 
 
 EGFR stimulation assay 2.6.7
To evaluate the role of Tspan6 in EGFR-mediated signalling, 3x105 cells were 
plated into 35mm tissue culture dish in complete growth medium overnight. 
Subsequently the cells were serum starved for further 24 hours followed by EGF 
stimulation at 10 ng/ml for fixed periods of time. Cells were subsequently lysed as 
described in section 2.5.1 and signalling events were assayed using Western blot.  
 Extracellular vesicle depletion assay 2.6.8
C57Bl/6J Tspan6 KO organoids were cultured in mouse intestinal organoid 
media without EGF. After three days, conditioned media was collected and divided 
into two fractions. Extracellular vesicles (EVs) were depleted from one fraction by 
multi-step centrifugation (Figure 2-4). First, conditioned media was centrifuged at 
2000 x g for 10 minutes at 4°C, followed by ultracentrifugation at 10000 x g for 45 
minutes at 4°C, and 70000 x g for 2 hours at 4°C to pellet EVs. The supernatant and 
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fraction II of conditioned medium were supplemented with 20% (v/v) R-Spondin-1 
conditioned medium, 100 ng/ml Noggin (Peprotech), 1x B27 (ThermoFisher 
Scientific), 1x N2 (ThermoFisher Scientific), 1.25 mM N-Acetyl Cysteine (Sigma-
Aldrich), 10 mM Nicotinamide (Sigma-Aldrich) and used to culture C57Bl/6J wild-type 
or Tspan6 KO organoids. Fresh conditioned media and EVs depleted conditioned 
medium were prepared for media change each three days of culture. The organoids 
were cultured in EVs depleted medium for 7 days. 
 
 
Figure 2-4. Extracellular vesicle depletion by differential centrifugation for functional analysis 
on organoids. Media conditioned by C57Bl/6J Tspan6 KO organoids in EGF-free conditions was 
collected after three days of growth. Media was depleted of extracellular vesicles by differential 
centrifugation in three steps followed by supplementing with essential organoid media components 
and used to culture C57Bl/6J WT organoids. Non-processed conditioned media was also 
supplemented with essential organoid media components and used to culture C57Bl/6J WT organoids 
as control. 
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 Anti-mouse TGF-α ELISA assay 2.6.9
To detect mouse TGF-α in media conditioned by C57Bl/6J wild-type or Tspan6 
KO organoids, a sandwich-type ELISA was employed. Organoids were cultured for 3 
days in mouse intestinal organoid medium with 16.7 ng/ml of EGF or in the absence 
of EGF. The conditioned medium was collected and centrifuged at 1000 x g for 10 
minutes and analysed according to manufacturers’ instructions. Briefly, samples and 
standards were dispensed into ELISA plate wells pre-coated with mouse TGF- α 
antibody (MyBioSource). Following this, biotinylated detection antibody specific to 
mouse TGF-α and Avidin-Horseradish-Peroxidase (HRP) conjugates were added 
consecutively, followed by incubation with substrate solution. The enzyme-substrate 
reaction was terminated using stop solution and the optical density (OD) was 
measured spectrophotometrically at a wavelength of 450 nm using PHERAstar plate 
reader. The concentration of TGF-α was calculated using standard curve. Samples 
were run in duplicates.  
 Extracellular vesicle quantification 2.6.10
To identify extracellular vesicles secreted by C57Bl/6J APCmin/+ and 
APCmin/+Tspan6-/y organoids were cultured for 6 days in mouse intestinal organoids 
media Intesticult (STEMCell Technologies), in mouse intestinal organoid media 
without EGF ligands. The conditioned media was collected and filtered using 0.45 µm 
sterile filters and analysed using Nanosight LM10 v3.3.104 (Malvern Technologies). 
The experiment principle is depicted in Figure 2-5. Nanoparticle Tracking Analysis 
(NTA) allows rapid analysis of concentration and size of particles ranging from 10 nm 
to 1000 nm.  
  




Figure 2-5. Principle of nanoparticle tracking analysis (NTA). Particles or extracellular vesicles in 
suspension are dispersed into microscope cell. A laser beam is passed through the sample and light 
scattered from particles can be visualised and recorded in high resolution by camera mounted onto 
the lens. Vesicles moving under Brownian motion are recorded and video is analysed by NTA 
software. The software allows tracking of individual particles and calculates their hydrodynamic 
diameters using the Stokes Einstein equation. The output is presented as histogram representing 
particle size and concentration distribution. 
 
 
2.7 Animal studies 
 Study approval 2.7.1
All animals were treated in accordance with local ethical committee guidelines 
and the UK Animals (Scientific Procedures) Act 1986, and all procedures were 
carried out in accordance with Home Office guidelines (United Kingdom) under the 
project number: 70/8494. All mice were housed with their littermates and maintained 
on a 12-hour light/dark cycle, with access to food and water ad libitum. 
 Genotyping of Tspan6 KO mice 2.7.2
A constitutive global Tspan6 KO mouse model was generated on C57Bl/6 
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background by the Deltagen, Inc pharmaceutical company (NY) by the insertion of a 
Neomycin cassette in exon 2 of the Tspan6 gene. To validate the KO model the DNA 
purified from ear samples of the 21 days old mice was genotyped in house using 
KAPA Mouse Genotyping Kit (KAPABiosystems) according to manufacturer’s 
protocol. Briefly, DNA was extracted using KAPA Express Extract enzyme for 10 min 
at 75°C, and enzymatic activity was terminated at 95°C for 5min. The extracted 
samples were then amplified by PCR using KAPA2G Fast Genotyping Mix and gene 
specific primers against exon 2 (forward and reverse) and additional forward primer 
against the Neomycin cassette (Figure 2-6.A). To detect both wild-type and mutated 
alleles the multiplex reaction using three primers was performed (Supplementary 
Table 8-1). PCR conditions for Tspan6 were 7 min at 95°C (initial denaturation) 
followed by 35 cycles of 10 seconds at 96°C (denaturation), 30 seconds at 60°C 
(annealing) and 1.5 min at 68°C (elongation). The resulted PCR products were 
resolved on 1.4% (w/v) agarose gel (Invivogen). The expected PCR product size was 
260bp for wild-type and 405bp for Tspan6 KO (targeted) allele (Figure 2-6.B). 
  




Figure 2-6. The schematic presentation of Tspan-6 KO mouse model generation. (A) The Tspan-
6 KO mouse was generated by insertion of Neomycin cassette into exon 2 of Tspan-6 gene. Arrows 
indicate the set of three primers was used to identify the genotype of mice. Two gene specific (GS) 
and one neomycin cassette (Neo) primers were used to ensure the correct neomycin cassette 
insertion and amplify endogenous (E) and targeted (T) alleles. (B) A representative agarose gel 
electrophoresis with the PCR products amplified with specific primers GS-F1, GS-R1, Neo-R2. The 
PCR product of 260bp corresponds to wild-type (WT) and 405bp corresponds to Tspan-6 knockout 
(KO) allele; a double band represents a heterozygous (HET) allele. 
 
 
 Mouse models for colorectal carcinogenesis 2.7.3
For in vivo tumorigenesis studies an APCmin/+ C57BL/6 mouse line (Jackson 
Laboratory) was utilised. To create APCmin/+Tspan6-/- animals, Tspan6 -/+ female mice 
were crossed with APCmin/+ male mice. Genotyping for Tspan6 mutation was carried 
out as described in Genotyping of Tspan6 KO mice and genotyping of mice for APC 
mutation was carried out by TransnetYX Inc. All mice were weighed twice a week 
post weaning and examined for symptoms of disease development, which included 
weight loss (up to 20%), hunched posture, pale feet, blood in stool, limping. Mice 
showing these features were culled by cervical dislocation and organs were 
harvested. The intestine and colon were flushed with ice-cold PBS, opened 
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longitudinally and fixed in methacarn (6:3:1 methanol absolute : chloroform : acetic 
acid glacial) for 4 hours at room temperature. The tissue was subsequently rolled and 
fixed in 10% neutral buffered formalin solution (Sigma-Aldrich) overnight. The rolled 
intestines were embedded into paraffin blocks in Royal Orthopaedic Hospital NHS 
Foundation.  
 Polyp imaging and scoring 2.7.4
To examine polyp burden of C57Bl/6J APCmin/+ and APCmin/+Tspan6-/y mice, 
intestines were imaged using Brunel BMSF stereomicroscope (Brunel Microscopes 
Ltd) equipped with 5mpx camera after fixation in methacarn. Polyp counts and size 
were assessed using ImageJ software. Polyp size was presented as area (mm2). 
 Pathological examination 2.7.5
Pathological examination of histological sections (both mouse and human) 
was performed with the aid of Dr Maha Ibrahim and Dr Rahul Hejmadi. 
Haematoxylin-eosin stained slides of mouse intestines were assessed for intestinal 
adenomas. The exclusion criteria were applied during examination. 
Table 2-3. Criteria for histopathological examination of mouse intestinal tissue. 
Inclusion Criteria Exclusion Criteria 
Intact muscularis mucosae Epithelium misfolding (due to processing)  
Viable mucosa Degenerated/autolysed 
GIT viscera present  Reactive lymphoid follicle underlying the 
epithelium 
 Tangential sectioning 
 Fixation artefact 
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 RNA sequencing 2.7.6
RNA samples were extracted from intestinal polyps of C57Bl/6J APCmin/+ (n=3) 
and APCmin/+Tspan6-/y (n=5) mice using RNeasy RNA extraction kit (Quiagen). RNA 
concentrations were determined using Qubit fluorometer (ThermoFisher). The quality 
of RNAs were checked using Agilent 2200 TapeStation (Agilent Technologies) and 
RNA 5-100ng RNA in total for each sample with RNA Integrity Number (RIN) of >7.0 
was used for library preparation (Supplementary Table 8-3). Poly-adenylated RNA 
libraries were prepared using the automated Neoprep Library System (Illumina) 
according to manufacturer’s protocol. The libraries were sequenced on an Illumina 
NextSeq 500/550 (Illumina) using a High out-put flow cell 150 cycle (cat. No. FC-404-
2002) using a paired end 75 cycle program. The aim was to achieve approximately 
25 million reads per library. The RNAseq reads were aligned to the mouse genome 
(Mus musculus mm10 Refseq) using the STAR Aligner v.2.5. Library preparation and 
sequencing was done by Celina Whalley (University of Birmingham). The RNA 
sequencing data was analysed by Dr Andrew Beggs (University of Birmingham). 
2.8 Staining and imaging methods 
 Human Samples  2.8.1
Human FFPE tissue samples were obtained from Human Biomaterials 
Resource Centre (HBRC), University of Birmingham under local ethics committee 
approval (Ref no.16-250). Samples from SCORT and COIN colorectal cancer clinical 
trials were utilised in this study.  
 Tissue sectioning 2.8.2
For histopathological analysis and immunohistochemical assay tissue was 
sectioned to 4µm thickness and mounted on positively charged adhesive-coated 
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slides (Surgipath™). Slides were kept at 4°C for long term storage. 
 Immunohistochemistry 2.8.3
To visualise antigens of interest ImmPRESS™ peroxidase detection system 
(Vector® labs) was used according to manufacturers’ recommendations. Briefly, 
tissue slides were deparaffinised with Xylene (Fisher) and rehydrated with graded 
ethanol (100%, 95% and 75%); each incubation being 5 minutes in duration. 
Endogenous peroxidase activity was blocked by incubation of slides in 0.3% 
hydrogen peroxide solution for 15 minutes. Antigen retrieval in 0.01M citrate buffer 
(pH 6.0) was performed for detection of Tspan6, p-ERK, Ki67 and β-Catenin in 
microwave at high power for 20 minutes. For detection of p-EGFR heat mediated 
EDTA (pH 9.0) antigen retrieval at 65°C overnight (12-16 hours) was used. The 
sections were blocked with 1x Casein Solution (Vector Labs) for 10min at room 
temperature following overnight incubation with primary antibody at 4°C. 
ImmPRESS™ HRP Universal Antibody Polymer Detection Kit (Vector® labs) was 
then applied for 30 min at room temperature, followed by treatment with 
substrate/chromogen solution ImmPACT™ Dab (Vector Labs) for 2 min at room 
temperature. Slides were counterstained with haematoxylin, dehydraded in graded 
alcohol and mounted with coverslips using DPX resin (Sigma Aldrich). Washes with 
1x TBST were performed between each step, three times for 5 minutes.  
 Tspan6 antibody optimisation 2.8.4
Prior to carrying out immunohistochemical analysis of human tissue samples, 
Tspan6 antibody (Atlas Antibodies) was validated for specificity and optimised for 
optimum dilution. Formalin fixed paraffin embedded (FFPE) xenografts of human 
breast cancer cells MDA-MB-468 pLVx and MDA-MB-468 Tspan6 were stained with 
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Tspan6 antibody using citrate buffer (pH 6.0) antigen retrieval at concentrations of 
1:50, 1:100 and 1:200. A strong membranous staining was detected at concentration 
1:100 in cells exogenously expressing Tspan6 (MDA-MB-468 Tspan6), whereas 
weak staining was detected in cells expressing endogenous Tspan6.  
2.9 Immunofluorescence 
Mouse intestinal organoids and Caco-2 cells were cultured in 2% Matrigel™ 
on pre-coated with 100% Matrigel 8-well Nunc® Lab-Tek® Chamber Slide™ system 
for 5 days. Cells were fixed with 4% paraformaldehyde/3% sucrose/PBS (PFA) 
supplemented with 1mM CaCl2 and 0.5 mM MgCl2 for 30 min at room temperature 
and permeabilized with 0.1% (v/v) Triton X-100 for 2 minutes. Organoids were 
incubated with blocking buffer (10% heat inactivated goat serum/PBS) for 1 hour at 
room temperature. Subsequently, cells were incubated with primary antibodies 
overnight at 4°C. On the following day, organoids were incubated with fluorophore-
conjugated secondary antibodies and/or Phalloidin Alexa Fluor 568 (Molecular 
Probes) (diluted 1:40 in 1%BSA/PBS) for 1 hour at room temperature. Cells were 
then counterstained with Hoechst33342 (1μg/ml in PBS) for 5 min at room 
temperature. Washes between each step were performed with 1%BSA/PBS (3x 10 
min). The images were captured using Zeiss LSM780 confocal system with 40X oil 
immersion objective. 
2.10  Scoring  
Scoring of Tspan6 immunohistochemical staining on human colorectal 
adenocarcinomas and adjacent normal tissues was carried out by histopathologists 
Dr Maha Ibrahim and Dr Rahul Hejmadi independently and in a blinded fashion. To 
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evaluate the expression of Tspan6 in human tissues the intensity and percentage 
(0%-100%) of cells with membranous staining was recorded: 1 - weak or trace; 2 - 
moderate; 3 – intense. The final H-score was determined by adding the results of 
multiplication of the percentage of cells with staining intensity ordinal value. In event 
of any disagreement on scoring an opinion of a third histopathologist was requested.  
2.11  Statistical analyses 
Statistical analysis of data from all studies was performed using Graph Pad 
Prism v7.04 (Graphpad Software Inc.) and presented as the mean with standard 
error mean (SEM) or standard deviation and indicated in figure legends. For box-and-
whisker plots, data presented as the median with highest and lowest values. To 
analyse normally distributed data from two unpaired groups a Student t-test was 
utilised, for analysis of unpaired non-parametric data a Mann-Whitney U test was 
used. To compare multiple unmatched groups one-way ANOVA test was used. P 
value p< 0.05 was considered statistically significant. Asterisks indicate levels of 
significance (* – p < 0.05; ** – p < 0.01; *** – p < 0.001). 
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3 RESULTS CHAPTER I: EXPRESSION OF TSPAN6 IS 
DECREASED IN COLORECTAL CANCER 
3.1 Introduction 
It has been suggested that Tspan6 is a potential diagnostic and prognostic marker for 
CRC (Sum-Fu, Ming-Hung, Reiping, et al. 2014). The expression of Tspan6 in this 
study was investigated on a small sample size of Taiwanese population (n=30), and 
no data of Tspan6 protein expression is available for European populations. Recent 
data indicated that Tspan6 expression correlates with better survival of CRC patients 
and is positively associated with response to neoadjuvant therapy in locally advanced 
rectal cancers (Uhlen, Zhang et al. 2017). The aim of this chapter was to extend 
these initial observations by examining the expression of Tspan6 in the cohort of 
genetically profiled CRC tumours and the adjacent normal tissue, and to evaluate if 
the expression of Tspan6 is associated with clinicopathological characteristics and 
mutational profile of CRC tumours. The TCGA data was also interrogated for the 
methylation status of the Tspan6 gene.  
3.2 The expression of Tspan6 in colorectal adenocarcinoma is 
greatly reduced compared to adjacent non-cancerous colon 
epithelium 
To examine the expression of Tspan6 in tumours of patients diagnosed with 
CRC in the UK paired adenocarcinoma and adjacent non-cancerous colon 
specimens were analysed by IHC. A total of 46 samples were selected in random 
unbiased fashion from the SCORT clinical trial cohort under local ethics committee 
approval (Supplementary Table 8-4).  Specificity of the antibodies was confirmed by 
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performing IHC on Tspan6-positive and Tspan6-negative breast cancer xenografts 
(Figure 3-1).  
 
Figure 3-1. Anti-Tspan6 antibody used in immunohistochemical assay is specific to Tspan6 
protein. Anti-Tspan6 antibody was tested on paraffin embedded sections of MDA-MB-468 human 
breast cancer cell line xenografts grown in mouse breast fat pads. Cells expressing endogenous 
levels of Tspan6 have weak to negative staining (MDA-MB-468 pLVx); cells with exogenously 
expressed Tspan6 (MDA-MB-468 Tspan6) show intense membranous staining. 
 
In normal tissues Tspan6 was expressed in epithelial cells, and little if any 
expression was detected in the stromal component of the colonic tissue. A semi-
quantitative approach was used to score each sample. In non-cancerous colonic 
epithelium Tspan6 was predominantly present at the plasma membrane. CRC 
tumours were highly heterogeneous for Tspan6 expression, and it was noted that 
intensity of Tspan6 staining at the deeper advancing areas of tumour was higher 
when compared to the centre of the tumour (data not shown). Furthermore, a 
significant proportion of tumour cells had decreased or lost the membranous staining 
of Tspan6, with many tumour cells displaying cytoplasmic distribution (Figure 3-2.A). 
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Detailed analysis demonstrated that Tspan6 expression was significantly reduced in 
colorectal adenocarcinomas with a median H-score in normal tissue of 180 vs H-
score of 130 in tumours (p=0.0026) (Figure 3-2.B). Interestingly, interrogation of 
TCGA and methylation data using the MEXPRESS tool revealed negative correlation 
of Tspan6 expression with methylation (probe cg01473187, Xq22.1, chrX:99891163-
99891163) of Tspan6 in colon adenocarcinomas (n=299, p<0.001, r=-0.437) (Figure 
3-3). This methylation site is located in the intron 1 of Tspan6 gene, in the DNase I 
hypersensitivity cluster, suggesting that this region is a regulatory region of Tspan6 
gene transcription.  




Figure 3-2. Expression of Tspan6 is decreased in colorectal adenocarcinomas. (A) Paraffin 
embedded sections of tumour and adjacent non-tumour tissue analysed for expression of Tspan6 
show strong membranous expression of Tspan6 in normal colon epithelium and weak diffused 
cytoplasmic staining in tumour tissue. (B) Tspan6 expression is significantly decreased in colorectal 
adenocarcinomas (CRC) compared to adjacent normal (AN) tissues, error bars show mean  SEM, 









Figure 3-3. Expression of Tspan6 is regulated by DNA methylation. Visualisation of TCGA data for Tspan6 mRNA expression in colon 
adenocarcinomas using MEXPRESS. Tspan6 expression (yellow) is negatively correlated with increased methylation (cg01473187 probe, blue) 
in intron 1 at CpG island (green), n=299, p<0.001, Pearson correlation coefficient r=-0.437. Figure is reproduced from (Koch, De Meyer et al. 
2015).
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3.3 Tspan6 expression is not correlated with clinicopathological 
characteristics of CRC 
Next, it was evaluated whether Tspan6 expression is correlated with 
clinicopathological characteristics of the CRC patients. Specifically, protein 
expression was analysed in CRC subclassified by various factors such as patient 
age, gender, tumour stage, extramural vascular invasion (EMVI) status, and tumour 
site. This analysis demonstrated that Tspan6 expression does not correlate with 
patient age (r2=0.0052) (Figure 3-4). In this study, the cohort consisted of 24 males 
and 13 females (for the rest of the cohort the gender was not recorded). The median 
Tspan6 H-score in normal tissues was 190 and 175, and in tumours 125 and 120, in 
males and females respectively. The Tspan6 expression in tumours of the male 
patients was significantly decreased (p=0.0029), whereas the reduction of the 
expression in tumours of female patients was not statistically significant (p=0.1406) 
(Figure 3-5). Of note, there was no difference observed in normal tissue expression 
(p=0.3462) or tumour (p=0.7352) between the male and female population.  
The expression of Tspan6 was compared between CRC tumours at different 
anatomical sites of the colon: caecum (n=10), sigmoid colon (n=12), rectum (n=7), 
transverse colon (n=3), ascending (n=4) and descending colon (n=3). It was found 
that expression of Tspan6 does not differ greatly in normal colon epithelium 
(p=0.7296) or in CRC tumours (p=0.3952) in different areas of the colon (Figure 3-6). 
 From the analysed tumours, 12 were positive for EMVI, which is correlated 
with the poorer prognosis of CRC patients. It was found that median expression of 
Tspan6 in EMVI+ tumours was non-significantly elevated compared to EMVI- 
tumours, with median Tspan6 H-score of 135 and 125 correspondingly (Figure 3-7). 
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 In addition, the expression of Tspan6 was analysed in tumours of different 
stages. In this study, 3 tumours were stage II, 22 stage III and 14 stage IV. It was 
found that in tumours of stage II and stage III the expression of Tspan6 is decreased 
(p=0.25, n=3 and p=0.0011, n=22 respectively) (Figure 3-8). However, no difference 
in Tspan6 expression between normal tissue and tumour was observed for 
metastasised CRC of stage IV (p=0.7993, n=14), suggesting that Tspan6 expression 
is downregulated in earlier stages of CRC development and is not affected in 
advanced adenocarcinomas of stage IV. 
In summary, Tspan6 expression does not correlate with age, and tumour site 
and is likely to play a role in early steps of tumour development as its expression is 
downregulated in stage II and stage III CRCs. 
 
Figure 3-4. Expression of Tspan6 is not correlated with patient age, r
2 
represents coefficient of 
determination (Pearson correlation, n=46, r2=0.0052). 




Figure 3-5. Expression of Tspan6 is not correlated with gender of CRC patients. The expression 
of Tspan6 in adjacent normal and tumour tissues of male (n=24, blue) and female (n=13, red) CRC 
patients. Tspan6 protein expression is decreased in tumours, **p=0.0029 (males) and p=0.1406 
(females). No difference in Tspan6 expression between genders was found in normal (p=0.3462) or 
tumour (p=0.7352) tissues. Error bars represent mean ±SEM, paired Wilcoxon signed-rank test was 
used for statistical analysis of Tspan6 expression in normal vs. tumour tissues, and non-parametric 
Mann-Whitney U test was used for statistical analysis of Tspan6 expression in males and females. 
  




Figure 3-6. Expression of Tspan6 is not linked to tumour site in the colon.  Tspan6 expression in 
adjacent normal colon epithelium (A) and colorectal CRC (B) at anatomically different sites of the 
colon. No significant difference in expression of Tspan6 in normal tissues (p=0.7296) or tumour 
(p=0.3952) was found, error bars represent mean ±SEM, a one-way ANOVA test was used for 
statistical analysis. 
 
Figure 3-7. Expression of Tspan6 is not correlated with extramural vascular invasion (EMVI) 
status of CRC. Tspan6 expression in CRC with EMVI+ (green) and EMVI- (orange). No significant 
difference in protein expression of Tspan6 was found in CRC depending on EMVI status (p=0.6138). 
Error bars represent mean ±SEM, non-parametric Mann-Whitney U test was used for statistical 
analysis. 




Figure 3-8. Tspan6 is downregulated in stage II and stage III, but not stage IV CRC. The 
expression of Tspan6 in adjacent normal (green) and tumour tissues (orange) in stage II (n=3), stage 
III (n=22) and stage IV (n=14) CRC. Tspan6 protein expression is decreased in stage II (p=0.25) and 
stage III (**p=0.0011) tumours, no significant difference in Tspan6 protein expression was found in 
stage IV CRC (p=0.7993). Error bars represent mean SEM, paired Wilcoxon signed-rank test was 
used for statistical analysis of Tspan6 expression in normal vs. tumour tissues. 
 
3.4 Tspan6 expression does not correlate with tumour driving 
mutations 
In this study tissues from 46 patients were analysed, of which 36 tumours 
have been fully sequenced by next generation sequencing (NGS). The expression of 
Tspan6 in these tumours was analysed in relation to mutations in KRAS, BRAF, 
PIK3CA, TP53, APC and CTNNB1 genes. The data shows that Tspan6 expression 
does not correlate with mutations in any of these CRC tumour driver genes (Figure 
3-9). In addition, copy number of BRAF, PIK3CA, PTEN, and CTNNB1 genes were 
increased in some of the analysed tumours. It was found that Tspan6 expression 
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does not correlate with copy number variation of named genes in these tumours 
(Figure 3-10). Thus, it was concluded that common cancer driver genes do not 
regulate expression of Tspan6; however, the results are inconclusive due to the small 









Figure 3-9. Expression of Tspan6 does not correlate with mutations in APC, KRAS, BRAF, PIK3CA, TP53, PTEN and CTNNB1 genes.  Tspan6 
expression in CRC with wild-type (WT, orange) or mutated (mut, green) genes: APC (A), KRAS (B), BRAF (C), PIK3CA (D), TP53 (E), PTEN (F) and 
CTNNB1 (G). No correlation of Tspan6 expression and mutations in any of the listed genes were found. Error bars represent mean SEM, Mann-
Whitney U test was used for statistical analysis. 




Figure 3-10. Expression of Tspan6 does not correlate with copy number variations of BRAF, 
PIK3CA, PTEN and CTNNB1 genes.  Tspan6 expression in CRC with 1 copy (n=1, orange) or copy 
number variation (n>1, green) of BRAF (A), CTNNB1 (B), PIK3CA (C), and PTEN (D). No correlation 
of Tspan6 expression and mutations in any of the listed genes were found. Error bars represent mean 
SEM, Mann-Whitney U test was used for statistical analysis. 
  




In this chapter the expression of Tspan6 was analysed in the cohort of CRC 
patients. It was found that Tspan6 protein expression level is decreased in CRC 
tumours. This data is consistent with mRNA expression data, supporting the 
hypothesis that Tspan6 is differentially expressed in colorectal cancer (Hlubek, 
Brabletz et al. 2007, Uhlen, Zhang et al. 2017). However, this result is in contrast with 
an earlier report describing the upregulation of Tspan6 in CRC in the Taiwanese 
population (Sum-Fu, Ming-Hung, Reiping, et al. 2014). There are several factors 
which may account for the discrepancy between these studies. Firstly, there may be 
age and ethnicity-based differences between two patient cohorts. Secondly, the 
differences may arise from the variation in the use of immunological reagents: the 
antibody used for IHC of Tspan6 in Sum-Fu publications was not specified. Finally, 
relatively small sizes of both cohorts may also account for the observed differences.  
Although it was found that Tspan6 protein expression level is decreased in 
stage II and stage III CRC, but not in stage IV carcinoma, there was no correlation 
between Tspan6 expression in tumours and clinicopathological parameters, such as 
age, anatomical site of tumour, or EMVI status. Interestingly, the differences in 
Tspan6 expression between the tumour and adjacent non-cancerous tissues were 
more prominent in males than in females. Given that Tspan6 gene is localised on 
chromosome X, silencing of the gene during tumour initiation may reflect more 
dramatically on the male population due to only one copy of the gene. Hence the 
second copy of functional gene of Tspan6 in females may partially compensate for 
the loss of one functional allele of the gene. One cannot exclude the possibility of 
genetic rearrangements due to chromosomal loss of heterozygosity (LOH) in tumours 
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resulting in downregulation of Tspan6 in CRC. It has been shown that LOH of X-
linked genes is frequent in CRCs and associated with sporadic colon 
adenocarcinomas (Liu, Kain et al. 2012, Ali, Marafie et al. 2014, Bottarelli, Azzoni et 
al. 2007). Genes FLNA, TBX22, KIAA2022, IRS4, PCDH11X, GPR112 and F8 are 
proposed X-linked CRC related genes (Liu, Kain et al. 2012). Another study 
demonstrated downregulation of another X-linked gene, RPS6KA6, in 90% of colon 
carcinomas, 86% of colon adenomas, and 80% of renal cell carcinomas (Lopez-
Vicente, Armengol et al. 2009). Tspan6 is located at Xq22.1 in the human genome, 
and loci including Xq22.1–q22.2, Xq21.1, Xq22.1, Xq22.3, Xq22.2 and Xq23 were 
reported to be susceptible to copy number variation in human CRCs (Ali, Marafie et 
al. 2014). In males, X-linked genes may be silenced by a mutation, gene deletion, or 
aberrant methylation; in females an additional “skewed” X-inactivation (inactivation of 
X chromosome with wild-type allele of the gene) is required (Liu, Kain et al. 2012). 
There were no mutations in Tspan6 gene found to be associated with CRC (Forbes, 
Beare et al. 2017). However, the evidence from methylation and clinical TCGA data 
suggests that Tspan6 expression is likely to be regulated by epigenetic mechanisms.  
There was no correlation identified between the Tspan6 expression and 
mutations in CRC driver genes, including KRAS, BRAF, PIK3CA, TP53, APC and 
CTNNB1 genes, indicating that the Tspan6 expression is not regulated by aberrant 
signalling of key signalling pathways implicated in CRC development. Hence, Tspan6 
might present a novel tumour-associated gene and downregulation of Tspan6 
expression is likely to be an early event in CRC progression. Indeed, the analysis of 
Tspan6 expression in a cohort of CRC patients suggests that Tspan6 may be 
considered as a biomarker of non-metastatic (stages I-III) CRC. 
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4 RESULTS CHAPTER II: TSPAN6 DEFICIENCY 
ACCENTUATES APC
MIN/+ 
PHENOTYPE IN VIVO 
4.1 Introduction 
The data on Tspan6 expression in patient samples indicated that the 
expression of Tspan6 is decreased in colorectal cancer. In addition, recent reports 
linked Tspan6 expression with patient survival as well as response to neoadjuvant 
therapy in CRCs (Uhlen, Zhang et al. 2017, Chauvin, Wang et al. 2018). It was, 
therefore, important to investigate the biological role of Tspan6 in colon epithelium 
and its possible role in CRC development and progression. The aim of this chapter 
was to characterise the effects of Tspan6 loss in a mouse model, examine its role in 
CRC using the APCmin/+ mouse model and identify the molecular pathways affected 
by the loss of Tspan6.  
4.2 The loss of Tspan6 does not result in spontaneous tumour 
formation in C57Bl/6J mice 
A constitutive global Tspan6 KO mouse model was generated by the 
Deltagen, Inc pharmaceutical company by the insertion of a Neomycin cassette in 
exon 2 of the Tspan6 gene. The Tspan6 mice were validated using a PCR 
genotyping method from the DNA purified from ear samples of the 21 days old 
littermates and amplified by PCR using gene specific primers. Overall, 23 animals 
were analysed: eight wild-type, three heterozygous, and 12 knockout mice 
(Supplementary Table 8-5).  
Wild-type and Tspan6 KO mice were culled at 52 weeks of age by cervical 
dislocation. These mice did not exhibit any obvious symptoms of illness, discomfort 
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or social anxiety. This was in agreement with previous reports showing that Tspan6 
deletion does not affect behaviour patterns in mice (Salas, Callaerts-Vegh et al. 
2017). Interestingly, Tspan6 KO mice were bigger in size (Figure 4-1.A), which is 
reflected both in the length of the body and the larger amount of visceral adipose 
tissue in the abdomen cavity (Figure 4-1.B-C). The data from heterozygote mice were 
not considered in this study to account for compensation effect from the functional 
copy of Tspan6 in this model. Although the intestinal epithelium of Tspan6 KO mice 
appeared normal, it was found that 10 out of 12 Tspan6 KO mice displayed mild to 
moderate submucosal oedema (Supplementary Table 8-6). In contrast, only two of 
the wild-type animals presented mild interstitial oedema. Together, these indicate 
that the loss of Tspan6 results in phenotypic changes of the intestines. 
 
 
Figure 4-1. The loss of Tspan6 results in enlarged body size of C57Bl/6J mice. (A) The 
representative image of body size of wild-type (WT) and Tspan6 knockout (KO) mice, n=8 and n=12 
respectively. (B) The average mouse weight and (C) the average body length. The weight of animals 
was not affected by the expression of Tspan6 and the body length was significantly enlarged 
(p=0.0081) in Tspan6 KO mice. Mice were weighed immediately after cervical dislocation and the 
body length was measured from the tip of the nose to the base of the tail of mice. The Student t-test 
was performed for statistical analysis. 
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4.3 Tspan6 knockout results in higher polyp burden in intestine 
and colon of APCmin/+ mice 
To study the role of Tspan6 in colorectal tumorigenesis, Tspan6 KO mice were 
crossed with APCmin/+ mice on the C57Bl/6J background. The heterozygous females 
Tspan6-/+ were mated with APCmin/+ male mice to generate double mutant 
APCmin/+Tspan6-/y male mice. The mice were born in expected Mendelian ratios, 
viable and fertile. In total 7 wild type, 16 Tspan6 KO, 16 APCmin/+ and 36 
APCmin/+Tspan6-/y mice were analysed in this study. Interestingly, double mutant mice 
developed symptoms of illness (anaemia, hunched posture, bloody stool and rapid 
loss of weight) earlier than APCmin/+ animals, with median 14 weeks postpartum and 
16 weeks respectively (Figure 4-2). 
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Once animals were euthanized, the animal weight and the body length 
measurements were taken. In accordance to findings with aged animals, Tspan6 KO 
mice had significantly enlarged body length compared to wild-type (p=0.0033) (Table 
4-1). A similar trend was observed in APCmin/+Tspan6-/y double mutant mice 
(p=0.1154). Additionally, the average animal weight was considerably increased with 
deletion of functional Tspan6 in both normal (WT vs. Tspan6 KO) and colon cancer 
(APCmin/+ vs. APCmin/+Tspan6-/y) models (p=0.0448 and p=0.0491 respectively). 
The intestine of animals was cut longitudinally, and polyp number and size 
were evaluated. A total of 14 APCmin/+ and 20 APCmin/+Tspan6-/y mice were 
compared. As expected, the intestines of the wild type and Tspan6 KO did not show 
any visible polyps. The mean number and size of visible polyps was significantly 
increased in APCmin/+Tspan6-/y double mutant mice compared to mice carrying 
APCmin/+ mutation alone. The number of polyps among analysed mice doubled upon 
loss of Tspan6 (p<0.0001), with a mean of 46 and 90 polyps per mouse in APCmin/+ 
and APCmin/+Tspan6-/y mice respectively (Figure 4-3). The average size of intestinal 
polyps in APCmin/+Tspan6-/y mice increased two-fold compared to APCmin/+ mice 
(p=0.0031), 1.96 mm2 and 0.82 mm2 respectively. The median size of polyps in 
APCmin/+ mice was 0.75 mm2 and in APCmin/+Tspan6-/y mice 1.7 mm2. These data 
indicate that the loss of functional Tspan6 increases the incidence of polyp formation 
in APCmin/+ mice. 
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WT (n=7) 30.885 9.671 
Tspan6 KO (n=16) 34.481 10.187 
p-value (t-test WT vs. KO) 0.045 0.003 
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min/+
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Figure 4-3. Tspan6-deficiency results in increased polyposis in small intestine and colon in 
C57Bl/6J APC
min/+ 







mice. Tspan6 KO mice showed normal mucosa on macroscopic 
examination. Tspan6 deficient mice showed an increase in tumour numbers and size throughout the 
intestine compared to APC
min/+ 



















significantly larger number of polyps, p<0.0001. The size of polyps was determined by measuring the 
diameter and presented as area (mm
2
). Tspan6 deficiency results in polyps of bigger size, p=0.0031. 
Mann-Whitney non-parametric test was used for statistical analyses. 
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Interestingly, the incidence of colonic adenoma formation in colon of APCmin/+ 
mice has been previously reported to be 35% of the APCmin/+ population (Moser, Pitot 
et al. 1990, Luongo, Moser et al. 1994, Boivin, Washington et al. 2003, Xiao, Yin et 
al. 2010, Grill, Neumann et al. 2014). In agreement with these studies, it was found 
that 5 out of 14 APCmin/+ mice (35.7%) have developed colonic adenomas. 
Remarkably, the loss of Tspan6 on the APCmin/+ background enhanced development 
of colonic polyps to 95.2% with 20 out of 21 of APCmin/+Tspan6-/y animals presenting 
with neoplastic lesions in the colon (Figure 4-4). The three-fold difference (p=0.0002) 
indicates the important role of Tspan6 in modulating tumorigenesis in the colon. 
 
 
Figure 4-4. The loss of Tspan6 facilitates adenoma formation in colon of C57Bl/6J APC
min/+ 






mice that developed 




mice is significantly higher than in APC
min/+
 mice (p=0.0002). A Fisher’s exact test was used for 
statistical analysis. 
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4.4 Loss of Tspan6 results in intestinal adenomas with a more 
severe phenotype 
The intestinal ‘swiss rolls’ from wild-type, Tspan6 KO, APCmin/+ and double 
mutant APCmin/+Tspan6-/y mice were analysed for the presence of macroscopic and 
microscopic lesions. The detailed histological analysis of normal intestinal mucosa 
revealed no foci of cellular transformation or increased proliferation between the 
APCmin/+ and double mutant APCmin/+Tspan6-/y mice, and complete absence of 
hyperplastic regions in wild-type and Tspan6 KO (Figure 4-5). The morphology of 
mucosa in duodenum, jejunum, ileum and colon were comparable: no variations of 
crypt-to-villi ratio in the small intestine were found. The colonic tissue was also 
normal. These results indicate that the loss of Tspan6 does not result in 
morphological changes of mouse normal intestinal mucosa in C57Bl/6J mice. 
However, in agreement with findings at the macroscopic level, the polyp burden was 
significantly increased in APCmin/+Tspan6-/y mice when compared to APCmin/+ 
(p=0.0172), with median number of 29 and 17 polyps per histology slide per animal 











Figure 4-5. The loss of functional Tspan6 does not affect the morphology of normal mucosa in small intestine and colon epithelium in 







mice. The H&E staining revealed that loss of Tspan6 does not result in cellular atypia in intestinal epithelium and with normal villous-to-crypt ratio. 




Figure 4-6. The loss of Tspan6 promotes intestinal polyp formation in C57Bl/6J APC
min/+
 mice. 







 mice. Black arrows indicate intestinal adenomas. (B) A number of polyps per 






 mice. A significantly higher number of 




 mice, p=0.0172. Horizontal bars represent median with range. 
Mann-Whitney nonparametric test was used for statistical analysis. 
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To evaluate if the loss of Tspan6 influences morphology of intestinal polyps in 
APCmin/+ mice, further histopathological analysis was performed by trained 
histopathologists in a blinded fashion. Polyps were classified as 1) non-dysplastic, 2) 
with low-grade dysplasia, and 3) with high grade dysplasia. Low grade dysplastic 
polyps show elongated crypts with decreased inter-glandular stroma, elongated cell 
nuclei, decreased number of mucin-producing goblet cells (Figure 4-7.B) (Boivin, 
Washington et al. 2003). High-grade dysplasia was assigned to polyps that had 
severe disorganization of the glandular architecture, absent stroma between glands, 
often appearing as cribriform structures usually with intraluminal necrosis and loss of 
cellular polarity, abnormal nuclear changes such as hyper-chromatism, increased 
nuclear-cytoplasmic ratio, irregular and pseudostratified nuclei (Figure 4-7.C). In total 
19 APCmin/+ and 23 APCmin/+Tspan6-/y mice were analysed. The majority of polyps 
among both strains appeared to have low grade dysplasia, 95% and 87% of animals 
respectively. Interestingly, as many as 10 out of 23 APCmin/+Tspan6-/y mice (43%) 
appeared to have low grade dysplastic polyps with foci of high-grade dysplasia, 
compared to 1 out of 19 in APCmin/+ mice (5%), indicating that these polyps are 
progressing to malignant type (Figure 4-7 and Table 4-2). These data suggest that 
loss of functional Tspan6 accentuates neoplastic features of APCmin/+ polyps, and, 
therefore, may contribute to future progression of non-malignant polyps to a more 
severe phenotype.  




Figure 4-7. The loss of Tspan6 results in more severe histological abnormalities in C57Bl/J6 







 mice. (A) Genetic deletion Tspan6 alone does not affect intestinal or colonic 
epithelia of C57/Bl/J6 mice. (B) Polyps of APC
min/+
 present with low grade dysplastic adenomas 
throughout the small bowel. (C) Loss of Tspan6 in APC
min/+
 mice results in the formation of lesions with 
high incidence of focal high-grade malignant changes of intestinal mucosa. 
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4.5 Tspan6 deficiency contributes to upregulation of key signalling 
pathways in mouse intestinal adenomas  
To examine changes in gene expression associated with a loss of Tspan6 in 
the intestinal epithelium of APCmin/+ mice, RNA sequencing was performed. 
Polyadenylated mRNA from intestinal polyps of three APCmin/+ mice (control) and five 
APCmin/+Tspan6-/y double mutant mice was extracted and sequenced using the 
Illumina sequencing platform. The whole transcriptome sequencing showed 1238 
differentially expressed genes (adjusted p value < 0.05) between the two types of 
adenomas (Figure 4-8). KEGG analysis revealed a significant enrichment of multiple 
pathways that are known to enhance tumour progression (Table 4-3). Cell 
proliferation and growth (MAPK signalling pathway, Wnt signalling pathway, ErbB 
signalling), focal adhesion, and DNA repair pathways (mismatch repair, nucleotide 
excision repair) appeared to be upregulated in adenomas of APCmin/+Tspan6-/y mice 
when compared to APCmin/+ mice.  




Figure 4-8. The loss of Tspan6 results in differential gene expression in intestinal polyps of 
APC
min/+ 
mice. The principal component analysis plot (PCA) illustrating the differential gene 
expression between intestinal polyps of APC
min/+ 




 (green, n=5) mice.  
 
Table 4-3. Summary table of pathway enrichment analysis of RNAseq data  
Pathway p-Value 
MAPK signalling pathway 0.003212 
Ubiquitin mediated proteolysis 7.81E-07 
Endocytosis 0.011859 
Focal adhesion 0.019936 
Chemokine signalling pathway 0.019289 
Wnt signalling pathway 0.016458 
Neurotrophin signalling pathway 0.02865 
Insulin signalling pathway 0.042612 
T cell receptor signalling pathway 0.033175 
Phosphatidylinositol signalling system 0.011894 
ErbB signalling pathway 0.028932 
Nucleotide excision repair 0.019021 
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Intestinal tumorigenesis is a multistep event commonly described by 
alterations in Wnt signalling pathways followed by dysregulation of the KRAS-
mediated pathway (Fearon, Eric R. 2011). The finding that these pathways appeared 
to be upregulated in adenomas of APCmin/+Tspan6-/y mice are of interest as these 
imply that the loss of Tspan6 accelerates progression of adenomas to more 
malignant lesions according to a pattern previously described by Fearon and 
Vogelstein (Vogelstein, Fearon et al. 1988). To confirm if these pathways are indeed 
hyperactivated in APCmin/+ and APCmin/+Tspan6-/y double mutant mice, the FFPE 
samples were stained using IHC for p-ERK, p-EGFR and β-catenin. These 
experiments demonstrated that both MAPK and Wnt pathways are upregulated in 
polyps of APCmin/+Tspan6-/y mice when compared to APCmin/+ mice (Figure 4-9). In 
both cases β-catenin staining was predominantly cytoplasmic with a considerable 
proportion of cells presenting with nuclear staining (Figure 4-9.A). Of note, some 
membranous staining of β-catenin was observed in polyps of APCmin/+ mice, and 
more intensive nuclear staining was seen in polyps of APCmin/+Tspan6-/y double 
mutant mice, indicating the more effective translocation of β-catenin to the nucleus 
and transcriptional activation of downstream genes. Accordingly, some of the Wnt 
target genes (i.e. SFRP1 and AXIN2) were upregulated in intestinal polyps of 
APCmin/+Tspan6-/y double mutant mice. The abundance of p-ERK in adenomatous 
polyps of APCmin/+Tspan6-/y mice appeared to be markedly increased, supporting the 
data obtained from RNAseq analysis (Figure 4-9.B). Similarly, stronger staining of p-
EGFR (Y1068) was observed in adenomas of APCmin/+Tspan6-/y mice when 
compared to APCmin/+ mice (Figure 4-9.C). The enhanced activation of EGFR 
appeared to be particularly interesting, indicating that the dysregulation of MAPK 
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signalling is not linked to hyperactivation of Ras. In spite of enhanced activation of 
Wnt and MAPK signalling pathways staining of mouse tissues with anti-Ki-67 
demonstrated no difference between APCmin/+ and APCmin/+Tspan6-/y animals (Figure 
4-9.D). In addition, the β-catenin, p-ERK and p-EGFR abundance and distribution 
were analysed in normal mucosa of APCmin/+ and APCmin/+Tspan6-/y mice. As 
expected, there were no changes in levels of expression of β-catenin, p-ERK, and p-
EGFR in normal mucosa (Figure 4-10). Here, the expression of p-EGFR and p-ERK 
were limited to intestinal crypts and transit amplifying cells and were comparable 
between the two models. Expression of β-catenin appeared strongly membranous 
across crypt-villous length with some cytoplasmic and nuclear staining localised to 
the crypt. These data indicate that Tspan6 is a modifier gene in colorectal 
carcinogenesis that augments the effect of tumour driving mutations, such as APC.  
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Figure 4-9. The effect of Tspan6-deficiency on expression of β-Catenin, p-ERK, p-EGFR and 
Ki67 in intestinal polyps of APC
min/+ 





































Figure 4-10. The loss of Tspan6 does not affect expression of β-Catenin, p-ERK, and p-EGFR in 
normal intestinal mucosa intestinal of APC
min/+ 







normal mucosa. (B) A representation of the area of p-







Horizontal bars represent median with range. Nonparametric Mann-Whitney statistical test was used 
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4.6 Discussion  
The role of Tspan6 in CRC initiation and progression in vivo has been 
described in this chapter. The results show that Tspan6 KO mice are viable and 
fertile with no obvious developmental or pathological defects. Tspan6 deletion did not 
induce any gross morphological or histopathological abnormalities in adult mice, 
implying that Tspan6 is largely dispensable for somatic cellular homeostasis. As 
there are 33 tetraspanins expressed in mammals, there exists a possibility for 
functional compensation for the loss of Tspan6 by other tetraspanins. For example, a 
double knockout of tetraspanins CD9 and CD81 resulted in complete infertility in 
mice due to impaired egg-sperm fusion and spontaneously developed pulmonary 
emphysema (Rubinstein, Ziyyat et al. 2006, Takeda, He et al. 2008). The most 
closely phylogenetically related tetraspanins to Tspan6 are Tspan3 and Tspan7 
(Charrin, le Naour et al. 2009). While knockout of Tspan7 has not been reported, the 
phenotype of the animals lacking Tspan3 also appears to be normal (Kwon, Bajaj et 
al. 2015). Interestingly, Tspan3 has been proposed to have a functional relevance in 
colorectal carcinogenesis through in silico analysis of promoter regions in Caco-2 
colorectal cell line (Moss, Doran et al. 2007). Furthermore, it has been recently 
demonstrated that Tspan3 is expressed in the endocytic compartment of mammalian 
cells (Seipold, Damme et al. 2017). Therefore, Tspan3 might partly (or fully) 
compensate for the loss of Tspan6 in regulation of extracellular vesicles secretion, an 
important functional feature of Tspan6 (see below). Generation of double knockout 
Tspan6-Tspan3 mice could shed a light on functional redundancy and specificities of 
these tetraspanins.  
It was also found that body length, weight and fat deposition in KO mice is 
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increased, which could be linked to altered hormone production. Indeed, a significant 
decrease in thyroid gland weight was noticed in Tspan6 KO animals when compared 
to wild-type (Supplementary Table 8-7). Moreover, other processes that result in 
body mass and size changes include insulin-regulated glucose uptake (Rosen, 
MacDougald 2006) and signalling cascades, including Wnt (Arango, Szotek et al. 
2005, Kennell, MacDougald 2005), Bone Morphogenic Proteins (BMPs) (Hino, 
Miyazawa et al. 2012, Tseng, He 2007) and Fibroblast Growth Factors (FGFs) 
(Gesta, Tseng et al. 2007, Yamasaki, Emoto et al. 1999). In addition to interstitial 
oedema, it was found that the lungs of Tspan6 KO mice were heavier and often 
appeared discoloured (darkened) upon post-mortem examination. Further 
investigation will be necessary to identify molecular mechanisms/pathways 
responsible for these subtle anatomical changes in Tspan6 knockout animals. 
Tspan6 KO mice did not show spontaneous tumour formation at 52 weeks of 
age, indicating that Tspan6 does not function as a tumour suppressor as such. 
However, our results demonstrate that lack of Tspan6 can accentuate a neoplastic 
phenotype of APCmin/+ mouse model. Due to spontaneous loss of heterozygosity 
(LOH) APCmin/+ mice develop on average 30 intestinal polyps by 90 days of age 
(Daniel, L., Liyuan et al. 2004, Rene, Sansom Owen 2016). Obstruction caused by 
polyps, internal bleeding from larger polyps and anaemia results in animal death by 
150 days of age (Nalbantoglu, Blanc et al. 2016). On average, APCmin/+ mice in our 
study presented with severe illness symptoms at 16 weeks of age and 
APCmin/+Tspan6-/y mice at 14 weeks of age, with some animals showing symptoms as 
early as 11 weeks of age. The loss of Tspan6 significantly increased polyp burden 
and promoted tumorigenesis, resulting in a substantial increase of focal high-grade 
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dysplastic adenomas with potential to develop into invasive carcinomas. Similarly to 
Tspan6, deletion of neural precursor cell expressed developmentally down-regulated 
protein 4 (Nedd4) and cyclin-dependent kinase 8 (CDK8) exacerbated adenoma 
formation in APCmin/+ mice (Lu, Thoeni et al. 2016, McCleland, Soukup et al. 2015). 
Thus, Tspan6 can be added to the list of genetic modifiers of APC-driven 
tumorigenesis in vivo. 
In the classic adenoma-carcinoma sequence the inactivation of APC was 
described as the first molecular change in pre-neoplastic colonic tissues (Leslie, 
Carey et al. 2002, Rubinfeld, Albert et al. 1997). The RNAseq analysis of intestinal 
polyps from APCmin/+ and APCmin/+Tspan6-/y mice showed an enrichment of genes 
associated with Wnt signalling, including Wnt target genes AXIN2 and SFRP1, 
indicating the hyperactivation of Wnt signalling upon the loss of Tspan6. EGFR 
signalling pathway dysregulation is associated with progression of tumorigenesis. It 
was found that MAPK signalling pathway is upregulated in intestinal adenomatous 
polyps of APCmin/+Tspan6-/y when compared to APCmin/+. EGFR is a known oncogene 
and is often activated or overexpressed in colorectal cancers (Heinemann, Stintzing 
et al. 2009). Although, due to technical reasons (lack of suitable antibodies), we 
could not reliably assess the total expression levels of EGFR protein in mice, 
activation of EGFR was clearly increased in APCmin/+Tspan6-/y mice, thus providing 
an explanation for increased MAPK signalling in these animals. Importantly, the 
enhancement of Wnt and MAPK signalling in normal mucosa of APCmin/+Tspan6-/y 
mice was not observed, thus indicating that loss of Tspan6 is involved in neoplastic 
progression only in the context of complete inactivation of the APC gene. It has been 
previously reported that constitutive activation of MAPK signalling pathway results in 
RESULTS CHAPTER II 
133 
  
polyps with high grade dysplasia in APCmin/+KrasG12D mice (Haigis, Kendall et al. 
2008). These results are consistent with adenoma-carcinoma sequence of colon 
tumorigenesis. Therefore, one can speculate that Tspan6 plays a regulatory role in 
EGFR/MAPK signalling in intestinal tissue and its loss contributes to progression of 
benign adenomas to dysplastic pre-malignant type of lesions. 
EGFR hyperactivation occurs in less than 5% of CRC patients due to somatic 
mutations or gene amplification (Leary, Lin et al. 2008, Wood, Parsons et al. 2007, 
Heinemann, Stintzing et al. 2009). The mRNA analysis did not allow the evaluation of 
gene copy number variation or mutations in regulatory regions of DNA. Therefore, 
possible involvement of genetic mechanisms responsible for excessive EGFR 
activation in APCmin/+Tspan6-/y animals remains unclear.  
Interestingly, it was found that Ki67 labelling did not show increase in polyps of 
double mutant mice, suggesting that the loss of Tspan6 does not affect the cell cycle 
and proliferation. Thus, it is possible that the EGFR/MAPK activation results in 
activation of cell survival mechanisms rather than proliferation. It has been previously 
shown that loss of Ras association domain-containing protein 1 (Rassf1a) in APCmin/+ 
mice results in increased intestinal adenoma formation and results in enhanced Wnt 
signalling during early tumorigenesis. Moreover, proliferation and apoptosis were not 
affected in Rassf1a-deficient mice (van der Weyden, Arends et al. 2008). 
Alternatively, dysregulation of Tspan6 and APC inactivation may rely on a novel 
pathway which is important for tumour initiation and early growth of intestinal 
adenomas. The increased activation of additional signalling pathways in polyps of 
APCmin/+Tspan6-/y mice, such as DNA mismatch repair and focal adhesion, illustrate 
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later stages of progression to carcinoma and may indicate clonal selection of cancer 
cells (Fearon, Eric R. 2011). 
In this study the incidence of adenoma formation in the colon of Tspan6-
deficient APCmin/+ mice was shown to be significantly higher than in the control group. 
The anatomy and biology of colon is distinct from small intestine in mice: colon crypts 
lack the secretory lineage of Paneth cells and the surface of mucosa is flat (Yasuhiro, 
Hideki 2007). Therefore, tumorigenesis and underlying pathways in the colon is 
different to that in small intestine (Chen, Hao et al. 2004). The mechanisms of 
adenoma formation and progression have been linked to KRAS activation (Byun, 
Hung et al. 2014), increased expression of cyclooxygenase-2 (COX-2) (Jacoby, 
Seibert et al. 2000, Sonoshita, Takaku et al. 2002), and DNA methylation (Hatano, 
Semi et al. 2015, Scarpa, Scarpa et al. 2016). In this study the mechanisms of 
mouse colon tumorigenesis were not explored, however, it became apparent that 
Tspan6 may regulate a novel uncharacterised pathway of polyp formation in colon of 
APCmin/+ mice. 
Altogether, results described in this chapter suggest that Tspan6 deficiency 
facilitates tumorigenesis in synergistic fashion with APC-mutation in vivo. The 
mechanisms of regulation are further discussed in subsequent chapters of this thesis.
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5 RESULTS CHAPTER III: TSPAN6 REGULATES 
AUTOCRINE SECRETION OF EGFR LIGANDS IN MOUSE 
INTESTINAL ORGANOID MODEL  
5.1 Introduction  
The consequences of Tspan6 KO in vivo indicated that Tspan6 is involved in 
regulation of several signalling pathways associated with cancer development and 
progression, including Wnt and MAPK transduction pathways. To address the 
functional implication of Tspan6 within the intestinal epithelium an ex vivo organoid 
model derived from mouse intestinal tissue was utilised. The aim of this chapter was 
to characterise mouse intestinal organoids derived from wild-type and Tspan6 KO 
intestinal tissues and investigate how Tspan6 affects organoid growth.  
5.2 Tspan6 does not affect organoid morphology  
To determine the molecular function of Tspan6 in the intestinal and colonic 
tissues an ex vivo organoid model was utilised. Organoids were derived from small 
intestinal tissue of C57Bl/6J WT, Tspan6 KO, APCmin/+, and APCmin/+Tspan6-/y mice. 
The knockout of Tspan6 in organoid lines was assessed using the PCR genotyping 
method (Figure 5-1). All types of organoids were cultured using a well-established 
protocol in media containing EGF, Noggin and R-spondin-1 (Sato, Stange et al. 
2011). Initially it was evaluated whether the expression of Tspan6 affects the general 
morphology and size of organoids. Intestinal organoids form structures with the 
central lumen lined by villus-like epithelium and several surrounding crypt-like 
domains protruding into the extracellular matrix; apoptotic cells are shed into the 
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central lumen (Sato, Vries et al. 2009). Both wild-type and Tspan6 KO organoids 
appeared to have a normal phenotype as described above. This phenotype was 
maintained over 40 passages. In addition, no difference in the plating efficiency 
between wild-type and Tspan6 KO organoids during their routine passaging was 
noticed. The populations of APCmin/+ and APCmin/+Tspan6-/y organoids appeared to be 
heterogeneous: consisting of budded (normal) and spheroid structures. It has been 
previously reported that due to APC mutation and hyperactivation of Wnt signalling 
pathway organoids lose the gradient of Wnt signalling from highest at the base of the 
crypt and lowest at the villous compartment of differentiated cells resulting in 
symmetrical spheroid structures (Sato, Toshiro, van Es et al. 2010). The ratio of 
budded to spheroid structures did not differ between the APCmin/+ and 
APCmin/+Tspan6-/y organoids (p=0.874) representing approximately half of formed 
organoids (Figure 5-2.C). Additionally, staining of organoid cultures with phalloidin 
(marking F-actin) demonstrated that deletion of Tspan6 does not affect polarisation of 
intestinal organoids. The formation of the F-actin ring on the apical surface of both 
organoids indicates the appropriate organisation of cytoskeleton and organoid 
integrity (Figure 5-3). The size of organoids derived from different strains of mice was 
comparable (Figure 5-2.A, B). These data indicate that the loss of functional Tspan6 
does not alter formation and has no obvious effect on the phenotype of intestinal 
organoids. 
  




Figure 5-1. A representative agarose gel electrophoresis with the PCR products amplified 
with specific primers against endogenous and mutated alleles of Tspan6  in wild-type and 






(B) organoids. The PCR product of 260bp 
corresponds to wild-type (WT) and 405bp corresponds to Tspan6 KO allele.  
 
  




Figure 5-2. Expression of Tspan6 does not affect mouse intestinal organoid morphology. 






mice and cultured in mouse intestinal organoid media for 5 days. (A) The morphology of 
organoids was comparable between all four types independent of Tspan6 expression; organoids 
presented with central lumen lined with villous-like epithelial layer of cells and protruding crypt-like 









were formed due to enhanced Wnt signalling but not the level of Tspan6 expression. (B) The size of 







The size of organoids was determined using ImageJ analysis by measuring the area of organoids in 
the field. For statistical analysis more than 100 organoids were analysed and Student t-test showed 
non-significant size difference between all types of organoids relative to wild-type. (C) Distribution of 








(green) organoid cultures. The 
appearance of cystic structures in both cultures was at similar frequency (p=0.874). The organoids 
were imaged on day 5 of culture (analysis of organoid size at later time points proved to be inaccurate 
due to accumulation of apoptotic cells around organoids) and 10 fields were analysed for each 
genotype (n=3). Student t-test was used for statistical analysis. 




Figure 5-3. Expression of Tspan6 does not affect polarisation of mouse intestinal organoid 
phenotype. The immunofluorescent image of organoid mid-section shows that cellular polarisation 
and apical F-actin ring (red) formation are preserved in organoids lacking Tspan6 after five days of 
culture, Hoechst 33342 was utilised as a nuclear stain (blue). 
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5.3 Loss of Tspan6 results in increased Wnt and MAPK signalling 
To validate the RNAseq data generated using mouse polyps, the expression 
of β-catenin, pEGFR and pERK was analysed using immunohistochemistry in 
organoids derived from intestine of WT, Tspan6 KO, APCmin/+, and APCmin/+Tspan6-/y 
mice. These experiments confirmed that both Wnt and MAPK signalling pathways 
are hyperactivated in lines lacking Tspan6. In WT organoids a strong nuclear β-
catenin expression was localised only in the areas of crypt domains, where the Wnt-
mediated signalling is at the highest level (Figure 5-4). In APCmin/+ organoids, Wnt 
signalling is moderately enhanced when compared to the WT line. However, in 
Tspan6 KO and APCmin/+Tspan6-/y organoids the level of β-catenin expression 
appeared to be uniformly high throughout the whole structure of the organoid, 
including crypt-like structure and villus-like structure, in both membranous and 
nuclear compartments (Figure 5-4). Likewise, pERK expression in WT and APCmin/+ 
organoids was lower than in Tspan6 KO and APCmin/+Tspan6-/y organoids, indicating 
higher levels of MAPK signalling pathway activation in organoids lacking Tspan6 
(Figure 5-4). Similar differences were observed when organoids were stained with 
anti-pEGFR antibody (Figure 5-4). In agreement with the analysis of mouse tissues, 
there was no apparent difference in Ki67 labelling between WT and Tspan6 KO, and 
APCmin/+ and APCmin/+Tspan6-/y organoids, indicating that Tspan6 has little if any 
effect on cellular proliferation under standard culturing conditions. Taken together, 
these data indicate upregulation of Wnt- and MAPK-signalling pathways represents 
an intrinsic property of Tspan6-deficient intestinal epithelium.  











intestinal organoids.  Brightfield images of FFPE sections stained with β-catenin, p-ERK, p-EGFR 
and Ki67. Sections were counterstained with haematoxylin (blue). 
 
 
5.4 Tspan6 deficiency results in EGF-independent growth of mouse 
intestinal organoids 
A combination of niche factors, including EGF, is essential for establishment 
and growth of murine intestinal stem cells (Sato, Stange et al. 2011), and as such, a 
withdrawal of any of these factors results in failure to form organoids and cell death. 
To further probe functional links of Tspan6 with EGFR mediated signalling, mouse 
organoids were cultured in EGF-free media. In agreement with previous reports, in 
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the absence of EGF WT organoids failed to form typically budding structures and 
underwent cell death (Hisha, Tanaka et al. 2013). However, organoids derived from 
the Tspan6 deficient mice were able to grow, forming budded structures with defined 
villus- and crypt-like domains (Figure 5-5). 
 
 
Figure 5-5. Loss of Tspan6 results in EGF-independent growth of mouse intestinal organoids. 
Wild-type (WT) and Tspan6 KO organoids were cultured in complete organoid growth media 
containing EGF, Noggin and R-spondin-1 (ENR) and in media lacking EGF (-EGF). In the absence of 
EGF wild-type organoids undergo cellular death, yet Tspan6 KO organoids grow and differentiate. The 
organoids were imaged on day 5 of culture and 10 fields were analysed for each genotype (n=4). 
Student t-test was used for statistical analysis. 
 
 
To understand the molecular mechanisms underlying this phenomenon, the 
expression and activation of EGFR as well as changes occurring upon withdrawal of 
EGF in organoids were examined. As illustrated in Figure 5-6.A, the total levels of 
EGFR and activation of the receptor were very low when WT and Tspan6 KO 
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organoids were cultured in standard, EGF-containing media. However, upon EGF 
withdrawal from the media, the protein level has increased in both organoid lines. 
Furthermore, the level of activated EGFR (measured using anti-pEGFR Tyr1068 
antibodies) was ~3-fold higher in Tspan6 KO organoids when compared to WT 
organoids (Figure 5-6.B). Accordingly, an increase in ERK phosphorylation was 
observed in Tspan6 KO organoids when compared to organoids derived from the WT 
animals. By contrast, there were no differences in the levels of β-catenin 
phosphorylation on Ser552, a hallmark of in β-catenin activation and translocation to 
the nucleus. Interestingly, there was a subtle decrease in phosphorylation of β-
catenin at Thr41/Ser45 in Tspan6 KO organoids observed in cultures after EGF 
withdrawal. The increase in Src family activation, Akt phosphorylation and decrease 
in p38 activation were also noted in Tspan6 KO organoids compared to organoids 
established from the control animals. These results suggest that Tspan6 KO 
organoids retain capacity for cellular growth and differentiation through EGFR-
mediated MAPK signalling regardless of exogenous extracellular stimuli, namely 
EGF. In addition, our data suggest that Tspan6 is likely to regulate other signalling 
pathways which contribute to cell survival and proliferation. 
5.5 Tspan6-mediated MAPK activation is EGFR-dependent 
The activation of MAPK signalling pathway in Tspan6 KO organoids in the 
absence of EGF can be mediated by the autocrine secretion of EGFR ligands or by 
activation of MAPK pathway downstream of the EGFR. To distinguish between these 
possibilities organoids were grown in the presence of pan-EGFR inhibitor lapatinib. 
Inhibition of EGFR using lapatinib resulted in growth inhibition of both lines of 
organoids with no difference in sensitivity to increasing concentration of the inhibitor 
RESULTS CHAPTER III 
144 
  
(Figure 5-7.A, C). Similarly, both WT and Tspan6 KO organoids were highly sensitive 
to the MEK inhibitor (Figure 5-7.B). These data strongly suggested that Tspan6 
regulates EGF-independent growth of organoid cultures at the level of the receptor 
activation. 
  




Figure 5-6. The loss of Tspan6 results in differential expression of key signalling molecules in 
mouse intestinal organoids.  (A) Western blot analysis of p-EGFR, p-ERK, p-β-catenin, p-Src family, 
p-Akt, and p-p38 in WT or Tspan6 KO organoids cultured in complete growth media (control) or in 
media lacking EGF (-EGF). (B) Quantification analysis of phosphorylation level of signalling molecules 
relative to the total expression of the molecule. Data was normalised to β-actin expression (n=1). 




Figure 5-7. Tspan6-mediated MAPK activation is EGFR-dependent.  (A) Phase-contrast images of 
WT and Tspan6 KO organoids in response to increasing concentrations of pan-EGFR inhibitor 
lapatinib (LPT) after 6 days of culture. (B) Phase-contrast images of WT and Tspan6 KO organoids in 
response to increasing concentrations of MEK inhibitor (MEKi) after 6 days of culture. (C) A dose-
response curve of WT and Tspan6 KO mouse intestinal organoids treated with lapatinib. Cell viability 
was measured by CellTiter-Glo3.0 ATP-based assay after 6 days of treatment (n=2). Plots were 
normalised to DMSO (control) treated organoids. 
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5.6 Tspan6 regulates secretion of EGFR-ligands 
The fact that Tspan6 KO organoids can grow in media without EGF and yet be 
dependent on signalling via EGF receptor suggests that Tspan6 may regulate 
autocrine production of EGF ligands. To test this hypothesis the WT and the Tspan6 
KO organoids were co-cultured in EGF-free conditions. Remarkably, only when co-
cultured with Tspan6 KO organoids did WT organoids form viable structures. 
Additionally, these organoids were stimulated to proliferate and differentiate, although 
at a slower rate than in normal conditions, resulting in normal budding structures with 
formation of crypt-villi substructures (Figure 5-8). These data strongly suggest that 
growth of Tspan6 KO organoids (and WT organoids in co-culture experiments) in 
EGF-depleted media is supported by an EGFR-activating autocrine factor. 
  





Figure 5-8. Tspan6 regulates secretion of an EGFR-ligand in mouse intestinal organoids.  
Phase-contrast images of WT and Tspan6 KO intestinal organoids cultured separately in complete 
growth media containing EGF, Noggin and R-spondin-1 (ENR), and in media lacking EGF (-EGF); and 
co-cultured together in media lacking EGF (-EGF co-culture). Images were taken on day 7 of culture. 
Co-culturing with Tspan6 KO organoids rescued WT organoids in –EGF conditions. 
 
5.7 EGFR-ligand is secreted in extracellular vesicles by Tspan6 KO 
organoids 
Tspan6 has been shown to have a role in the formation of multivesicular 
bodies (MVBs) and secretion of extracellular vehicles (EVs) (Guix, Sannerud et al. 
2017), which may potentially carry membrane bound EGFR ligands, such as pro-
TGFα (transforming growth factor α) and pro-AREG (amphiregulin) (Singh, Carpenter 
et al. 2016). Thus, it was further examined whether a “trans-stimulating proliferative 
effect” of Tspan6 KO organoids in EGF-free media involves EVs. As expected, media 
conditioned by the Tspan6 KO organoids grown under the EGF-free conditions 
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allowed proliferation and differentiation of both Tspan6 KO and WT organoids. 
Interestingly, after 5 days in culture Tspan6 KO organoids were larger when 
compared to WT, indicating the knock-in effect of EGFR ligands delivered by EVs to 
the vesicles secreted in an autocrine fashion (Figure 5-9). Strikingly, when 
conditioned media was depleted of EVs, WT organoids failed to form viable 
structures and rapidly underwent cell death (Figure 5-9). Tspan6 KO organoids 
remained unaffected although of a smaller size when compared to Tspan6 KO 
organoids grown in the presence of EVs. These data indicate that Tspan6 plays an 










Figure 5-9. Tspan6 regulates secretion of an EGFR-ligand in extracellular vesicles. Phase-contrast images of WT and Tspan6 KO intestinal 
organoids cultured in the presence (+EVs) or absence (-EVs) of Tspan6 KO-derived extracellular vesicles. The conditioned media from Tspan6 KO 
organoids cultured for three days in EGF-free media was collected. Half of the conditioned media was depleted from the extracellular vesicles by ultra-
centrifugation. Both parts (non-depleted and depleted of EVs) of the condition media were supplemented with essential media components excluding 
EGF and fed to WT and Tspan6 organoids. Images were taken after 7 days of culture. Tspan6 KO-derived extracellular vesicles facilitated formation 
and growth of WT organoids in –EGF conditions. 
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5.8 Tspan6 plays a role in secretion of extracellular vesicles 
Extracellular vesicles are a heterogenous group of cell-derived vesicles that 
range from 30nm to 1µm in size and can be classified into exosomes (30-100 nm) 
derived from intracellular multivesicular bodies (MVBs) and ectosomes or micro-
vesicles (>100nm) that are derived through shedding of the plasma membrane. To 
evaluate the quantity and the size of secreted vesicles conditioned media from 
organoids cultured in complete growth media and in media without EGF was 
analysed using nanoparticle tracking analysis (NTA) that accurately assesses the 
size and concentration using light-scattering characteristics of the particles. The 
analysis of the vesicles generated by WT grown under the control conditions 
revealed six peaks corresponding to 60 nm, 174 nm, 221 nm, 324 nm, 380 nm, and 
469 nm, with the mean concentration of 1.27x108 +/- 9.68x106 particles/ml (Figure 
5-10. A, C). The size range of vesicles produced by Tspan6 KO organoids was 39 
nm, 86 nm, 177 nm, 321 nm, and 456 nm, with the mean concentration of 2.36x108 
+/- 2.64x107 particles/ml (Figure 5-10. B, D). The concentration of macro-vesicles 
(i.e. 320 nm and 450 nm) did not differ between the samples. By contrast, 
concentration of vesicles of ~175 nm in the media conditioned by Tspan6 KO 
organoids was ~2-fold higher compared to media conditioned by organoids 
established from the WT animals (with 2.0x106 and 1.1x106 vesicles/ml respectively) 
(Figure 5-10. C, D). Moreover, this difference was even more pronounced when 
vesicles of 50-100 nm (vesicles corresponding to size of exosomes) were analysed: 
media conditioned by Tspan6 KO organoids contained 1.07x105 +/- 6.9x103 
vesicles/ml versus 0.12x105 +/- 2.6x103 vesicles/ml in media conditioned by the WT 
organoids (Figure 5-10. E, F). Vesicles generated by WT and Tspan6 KO organoids 
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in EGF-free conditions were analysed in parallel. The distribution of vesicle size was 
different when compared to that seen for organoids grown under the control 
conditions, with three major peaks detected corresponding to the vesicles of ~220 
nm, 540 nm, and 720 nm. An additional peak was recorded for WT organoids 
vesicles of 329 nm that was not seen in Tspan6 KO vesicle profile (Figure 5-10. G, 
J). The mean concentration of vesicles did not differ greatly between the samples, 
with 1.49x109 +/- 3.23x107 vesicles/ml and 1.13x109 +/- 5.58x107 vesicles/ml found in 
the media conditioned by WT and Tspan6 KO organoids respectively. Notably, 
examination of exosome-size vesicles (50 nm-100 nm) revealed that Tspan6 KO 
organoids produced ~900-fold more vesicles than the WT organoids (554.7 +/- 198 
vesicles/ml vs. 4.5x104 +/- 9.2 103 vesicles/ml) (Figure 5-10. K, L). These data 
indicate that Tspan6 participates in vesicle production and negatively regulates 
production of vesicles up to 100 nm size, namely exosomes, ex vivo in control and 
EGF-free conditions. 
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Figure 5-10.  Loss of Tspan6 results in higher production of extracellular vesicles. (A-B) NTA 
video screenshot of EVs derived from wild-type (WT) and Tspan6 KO organoids respectively cultured 
in complete organoid growth media. (C-D) Representative NTA profiles of total EVs derived from WT 
and Tspan6 KO organoids respectively cultured in complete organoid growth media. Total 
concentration of exosomes and SEM (red) are also indicated on the graph. (E-F) Exosomal fraction 
of EVs derived from WT and Tspan6 KO organoids respectively cultured in complete organoid growth 
media. Total concentration of exosomes and SEM (red) are also indicated on the graph. (G-H) NTA 
video screenshot of EVs derived from WT and Tspan6 KO organoids respectively cultured for 5 days 
in media lacking EGF. Total concentration of exosomes and SEM (red) are also indicated on the 
graph. (I-J) Representative NTA profiles of total EVs derived from WT and Tspan6 KO organoids 
respectively cultured for 5 days in media lacking EGF, presented as concentration vs. size histogram. 
Total concentration of exosomes and SEM (red) are also indicated on the graph. (K-L) Exosomal 
fraction of EVs derived from WT and Tspan6 KO organoids respectively cultured in complete organoid 
growth media. Total concentration of exosomes and SEM (red) are also indicated on the graph (n=1).  
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5.9 Tspan6 facilitates production of TGF-α 
Extracellular vesicles and exosomes released by cells carry molecules and 
genetic material that are utilised for autocrine-dependent growth and for paracrine 
intercellular communications in normal and cancerous tissues (Abak, Abhari et al. 
2018, Rashed, Bayraktar et al. 2017, Bobrie, Colombo et al. 2011). In this study 
Tspan6 has been shown to regulate the release of EGFR ligands in the form of 
extracellular vesicles that contribute to integrity and survival of intestinal organoids 
under EGF-free culturing conditions. It has been shown that TGF-α is secreted by the 
intestinal epithelium and an increase in its expression directly associates with 
development of sporadic colorectal neoplasms (Tu, Ahearn et al. 2015). Thus, it was 
examined whether TGF-α secretion is affected by Tspan6 expression by intestinal 
organoids. Specifically, ELISA was carried out on media conditioned by wild-type and 
Tspan6 KO organoids cultured in complete growth media or in media free of EGF. 
The analysis revealed that in both conditions WT organoids release approximately 
6.55-fold less TGF-α than Tspan6 KO organoids, 47.1 +/- 5.91 pg/ml and 308.7 +/- 
5.4 pg/ml respectively (Figure 5-11). These data indicate that extracellular vesicles 
released by Tspan6 KO organoids carry EGFR ligand, namely TGF-α. 




Figure 5-11. Loss of Tspan6 results in higher production of TGF-α. WT and Tspan6 KO intestinal 
organoids were cultured in complete growth media (control) and in the absence of EGF (-EGF) for 3 
days and conditioned media was analysed by ELISA. The results were normalised to β-actin level 
measured by Western blot (n=1). 
 
5.10 Loss of Tspan6 results in an increased number of Paneth cells 
in mouse intestinal organoids  
In the intestinal stem cell crypt niche, Paneth cells produce EGF and TGF-α 
and are playing a major role in maintaining stem cells in the intestinal crypts (Clevers, 
Bevins 2013). To evaluate the role of Tspan6 on Paneth cell population the WT and 
Tspan6 KO organoids were stained for the Paneth cell marker Lysozyme using an 
immunofluorescence technique. Strikingly, the increased population of Paneth cells 
in the crypt domain of Tspan6 KO organoids was observed when compared to wild-
type, with the mean of 2.7 +/- 0.28 and 4.6 +/- 0.54 Paneth cells per crypt (Figure 
5-12). These data demonstrate that Tspan6 is involved in promoting the commitment 
to Paneth cell lineage in ex vivo organoid model. 
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5.11 Tspan6 deficiency results in Wnt-independent growth of 
mouse colon organoids 
In mice, colon crypts lack Paneth cells; therefore, stem cells can regulate Wnt, 
MAPK and Notch pathways in autocrine fashion or with assistance of other cells, 
namely fibroblasts (Date, Sato 2015, Kabiri, Greicius et al. 2014). For the 
maintenance of the colonic organoid cultures, the addition of Wnt ligands are 
required, and Wnt3a – a potent canonical β-catenin dependent Wnt signalling 
pathway activator. To evaluate if the lack of Paneth cells in colonic crypts affects the 
ability of Tspan6 KO organoids to maintain their population and expansion, the 
organoids were derived from the colon of wild-type and Tspan6 KO mice and 
cultured in the media lacking Wnt3a and EGF. In agreement with previous reports, 
upon withdrawal of Wnt3a from the media, the wild-type organoids underwent cell-
death after three days of culture. By contrast, Tspan6 KO colonic organoids were 
able to expand in this media and formed a heterogenous population of cystic and 
differentiated structures (Figure 5-13). In additional experiments both growth factors, 
Wnt3a and EGF, were withdrawn from the culture media. As predicted, wild-type 
colonic organoids failed to form viable structures resulting in cell death (Figure 5-13). 
However, colonic organoids lacking the functional Tspan6 were able to grow, 
proliferate and differentiate. Furthermore, the ability to modulate Wnt signalling was 
observed by both intestinal and colon organoids lacking functional Tspan6 (Figure 
5-14). These data indicate that Tspan6 regulates MAPK and Wnt signalling pathways 
in organoids derived from intestinal and colonic tissue.  
  




Figure 5-12. Loss of Tspan6 promotes Paneth cell expansion in mouse intestinal organoids. (A) 
A whole-mount immunostaining of WT and Tspan6 KO organoids after 5 days of culture. β-catenin 
(green) staining is more intense, and number of Paneth cells marked with lysozyme (red) is increased 
in Tspan6 KO organoids. Nuclei (blue) were counterstained with Hoechst 33342. (B) Maximum 
projection image showing distribution of Paneth cell is the intestinal organoid crypt. (C) Quantification 
of number of Paneth cells per organoid crypt in WT (n=15) and Tspan6 KO (n=14) organoids. Student 
t-test was performed for statistical analysis. 




Figure 5-13. Loss of Tspan6 results in EGF- and Wnt-independent growth of mouse colonic 
organoids. Wild-type and Tspan6 KO colonic organoids were cultured in commercially available 
mouse intestinal organoid media (Intesticult), complete colon organoid growth media containing 
Wnt3a, EGF, Noggin and R-spondin-1 (WENR), organoid growth media lacking Wnt3a (ENR)and in 
media lacking both Wnt3a and EGF (-Wnt -EGF). In the absence of Wnt3a and both growth factors 
(Wnt3a and EGF) wild-type organoids undergo cellular death, and Tspan6 KO colon organoids 
preserve ability to grow and differentiate (n=3). 




Figure 5-14. The loss of Tspan6 results in enhanced Wnt activity in mouse intestinal and colon 
organoids. The TOP/FOP analysis of HEK293 T cells stimulated with DMEM/F-12 media (control), or 
media conditioned by WT and Tspan6 KO intestinal (SI) and colonic (COL) organoids for 24 hours 
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5.12  Discussion 
The results described in this chapter demonstrate that loss of functional 
Tspan6 results in EGF-independent growth of mouse intestinal organoids. Further, 
the upregulation in activation of EGFR and ERK was observed by IHC. EGF and 
EGFR dependent signalling play an important role in intestinal cell homeostasis and 
regulate cell migration and proliferation (Date, Sato 2015, Suzuki, Sekiya et al. 2010). 
Accordingly, EGF withdrawal results in attenuation of intestinal organoid growth and 
decreased survival (Drost, van Jaarsveld et al. 2015, Matano, Date et al. 2015). 
Further support for the essential role of EGFR-dependent signalling in maintaining 
growth of intestinal organoids was provided by Sato and colleagues who 
demonstrated that organoid cultures with mutations in KRAS or PI3KCA, downstream 
effectors of the EGFR signalling cascade, can grow in EGF-free media (Sato, Stange 
et al. 2011, Matano, Date et al. 2015). Interestingly, the total level of EGFR in EGF-
free conditions was elevated, suggesting upregulation of receptor in response to 
limiting ligand availability.  
It was noticed that activation of p38 is induced in Tspan6 KO organoids in 
response to EGF withdrawal from the culture. While the biological significance of this 
observation in the context of Tspan6 KO animals requires further investigation, 
recent study demonstrated that p38 activation is associated with crypt formation and 
differentiation of intestinal organoids (Rodriguez-Colman, Schewe et al. 2017). 
Moreover, conditional deletion of p38α was also shown to affect differentiation of the 
secretory lineage of cells of the mouse intestinal epithelium (Otsuka, Kang et al. 
2010). It is therefore possible that EGF-dependent regulation of p38 contributes to 
the phenotypic changes associated with deletion of Tspan6 in APCmin+/- animals.  
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The growth inhibition by lapatinib, a highly specific EGFR inhibitor, 
demonstrated the essential role of EGFR-dependent signalling in growth of Tspan6 
KO organoids. This data strongly suggested that survival of Tspan6 KO organoids in 
EGF-free media is dependent on the autocrine secretion of an EGFR-ligand, a 
notion, which was further supported by the rescue of WT organoid growth in EGF-
free conditions in co-culture with Tspan6 KO organoids. Interestingly, a similar 
mechanism has been previously proposed in studies using mouse intestinal 
organoids deficient of negative EGFR regulators Lrig-1 and TRPV1 (Wong, Stange et 
al. 2012, de Jong, Takahashi et al. 2014).  
In this study Tspan6 KO organoids were demonstrated to secrete TGF-α 
regardless of EGF presence in the culturing media, indicating that TGF-α release is 
not mediated by limiting exogenous EGFR ligand. TGF-α is ubiquitously expressed 
and binds to EGFR with a high affinity (Singh, Carpenter et al. 2016). In addition, 
TGF-α has been shown to play a role in intestinal homeostasis (Troyer, Luetteke et 
al. 2001). It has also been demonstrated that TGF-α expression is increased in 
HCT116 human colorectal cancer cell line in response to growth factor deficiency in 
culture, providing a mechanism of escape from growth factor dependency (Awwad, 
Sergina et al. 2003). The analysis of media conditioned by the wild-type and Tspan6 
KO organoids revealed increased production of extracellular vesicles by Tspan6 KO 
organoids, specifically the significant increase in exosomes was observed in both 
control and EGF-free conditions. These data suggest that autocrine-dependent 
growth of Tspan6 KO organoids in EGF-depleted media is linked to EV-dependent 
increased production of TGF-α  
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Extracellular vesicles are a class of cell-derived membrane coated particles 
that are secreted by various types of cells and implicated in mediating cell-cell 
communication (Abak, Abhari et al. 2018, Rashed, Bayraktar et al. 2017). 
Extracellular vesicles comprise of micro-vesicles, exosomes, exosome-like particles 
and apoptotic bodies (van Niel, Guillaume, D'Angelo et al. 2018, Mathivanan, Ji et al. 
2010). Interestingly, a recent study demonstrated secretion of exosomes from 
organoid-like 3D cultures of 67 human cancer cell lines (Eguchi, Sogawa et al. 2017). 
Exosomes have been reported to contain lipids, membrane receptors, mRNA, 
microRNA, transcriptional factors, splicing factors, infectious particles, and growth 
factors, including EGFR-ligands HB-EGF, AREG and TGF-α (Quesenberry, Aliotta et 
al. 2015, Mathivanan, Fahner et al. 2012, Tauro, Greening et al. 2012, Balaj, Lessard 
et al. 2011, Bobrie, Colombo et al. 2011, Thery 2011, Al-Nedawi, Meehan et al. 2009, 
Simpson, Lim et al. 2009). Various studies demonstrated the ability of EVs and 
exosomes to mediate EGFR-mediated signalling. As such, expression of epidermal 
growth factor seven-transmembrane subfamily CD97 on exosomes was shown to 
affect proliferation and invasion of gastric cancer cells via exosome-mediated MAPK 
signalling pathway (Li, Liu et al. 2015). Another study demonstrated the capability of 
cancer-derived exosomes expressing a mutant epidermal growth factor receptor 
(EGFRvIII) to promote anti-apoptotic cellular responses and promote cell growth (Al-
Nedawi, Meehan et al. 2008). Furthermore, the EGFR ligand amphiregulin (AREG) 
was shown to be expressed on exosomes derived from KRAS mutant DLD-1 colon 
cancer cells and induce cell invasiveness (Higginbotham, Demory Beckler et al. 
2011). Interestingly, authors demonstrated that exosomal AREG is more potent in 
EGFR activation and augmenting invasiveness of recipient cells than its soluble 
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counterpart. Although the EVs in this experiment were not molecularly characterised, 
the inability of wild-type mouse intestinal organoids to grow in co-culture experiments 
with Tspan6 KO organoids suggests that TGF-α is present on EVs and serves as a 
strong mitogenic activator of EGFR in the intestinal epithelium.  
What could the mechanisms underlying the role of Tspan6 in vesicle-
associated production of TGF-α be? Tspan6 has been previously shown to 
participate in biogenesis of exosomal vesicles in vitro through the interaction with 
syntenin-1 (Guix, Sannerud et al. 2017). Interestingly, pro-TGF-α is able to directly 
bind to the PDZ2 domain of syntein-1 and is expressed on exosomes (Fernandez-
Larrea, Merlos-Suarez et al. 1999). In another study it has been demonstrated that 
the N-terminus of TGF-α is expressed on the surface of exosomes, prompting 
effective binding to EGFR once released (Higginbotham, Demory Beckler et al. 
2011). Unpublished data from Berditchevski’s lab shows the direct interaction of 
syntenin-1 with Tspan6 via PDZ1 and TGF-α via PDZ2 domain in vitro (unpublished). 
These data strongly support the role of the Tspan6-syntenin-1 complex in biogenesis 
of TGF-α containing exosomes. Furthermore, syntenin-1 has been shown to 
associate with Src and such interaction is implicated in syntenin-1 mediated exosome 
biogenesis (Imjeti, Menck et al. 2017). Therefore, one can speculate that Tspan6 
regulates exosomal production via interaction with syntenin-1. 
Production of growth factors essential for stem cell maintenance (EGF, TGF-α, 
Wnt3a and Notch ligands) is executed by Paneth cells (Sasaki, Sachs et al. 2016). 
Paneth cells terminally reside at the bottom of intestinal crypt interspersed between 
stem cells (Date, Sato 2015, Clevers, Bevins 2013). Interestingly, it was found that 
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the number of Paneth cells in crypts of Tspan6 KO organoids is increased. To note, it 
has been shown that Wnt signalling is essential for Paneth cell terminal differentiation 
(Farin, Van Es et al. 2012, van Es, Jay et al. 2005, Andreu, Colnot et al. 2005). As 
such, the increased activation of Wnt signalling in Tspan6 KO organoids was 
demonstrated using TCF/LEF luciferase reporter assay. Importantly, Tspan6 KO 
colonic organoids exhibited Wnt3a and EGF independency in culture (Figure 5-13). 
These data indicate that Tspan6 additionally regulates Wnt signalling in the intestinal 
and colonic epithelium. Paneth cells are absent in colonic epithelium, therefore, there 
is a requirement for exogenous Wnt addition to the culture medium of mouse colonic 
organoids (Date, Sato 2015, Sato, Stange et al. 2011). It has been shown that 
colonic deep secretory cells (DSCs) that are intermingled between colonic stem cells 
are supporting stem cell homeostasis and promote organoid growth in the similar 
fashion to Paneth cells (Sasaki, Sachs et al. 2016). Tspan6 was previously shown to 
be expressed in Lgr5+ and Olfm4+ intestinal stem cells (Dalerba, Kalisky et al. 2011). 
Perhaps, the loss of Tspan6 in stem cells promotes Wnt activation, resulting in 
differentiation to Paneth cells in intestinal crypts and possibly DSCs in colonic crypts 
and regulates their secretory function facilitating bi-directional Wnt activation in 
mouse colonic organoids. The enhanced Wnt signalling in Tspan6 KO organoids can 
occur by one of the following mechanisms: 1) Tspan6 regulates Wnt ligand secretion 
(indeed, Wnt ligands have been previously shown to be expressed on exosomes 
(Zhang, L., Wrana 2014, Gross, Chaudhary et al. 2012, Koles, Budnik 2012)); 2) 
Tspan6 mediated EGFR activation results in robust crosstalk between Wnt and 
EGFR pathways. In this regard, it has been previously reported that KRAS 
synergistically enhances Wnt signalling in intestinal tumour cells (Janssen, Alberici et 
RESULTS CHAPTER III 
167 
  
al. 2006). Furthermore, Akt was shown to be hyperactivated in Tspan6 KO organoids 
and was previously reported to negatively regulate GSK3β, a kinase that mediates β-
catenin proteasomal degradation, resulting in enhanced Wnt signalling as 
demonstrated by increased level of p-β-catenin at Thr41/Ser45 (He, Yin et al. 2007, 
Holmberg, Seidelin et al. 2017). Additionally, it was found that p38 MAPK is 
hyperactivated in Tspan6 KO organoids cultured in EGF-free conditions, which may 
negatively regulate GSK3β (Thornton, Pedraza-Alva et al. 2008), thus providing 
Tspan6 KO cells with an alternative mechanism for Wnt signalling upregulation in 
organoid cultures. EGFR has also been shown to directly interact with β-catenin: 
EGFR phosphorylates β-catenin at Tyr654, destabilising E-cadherin-β-catenin 
complex and releasing β-catenin for nuclear translocation (Georgopoulos, Kirkwood 
et al. 2014). Finally, in organoids lacking Tspan6 enhanced activation of Src family 
kinases was observed. Src may represent another point of Wnt and EGFR signalling 
convergence, as in study by Piedra and colleagues Src was shown to phosphorylate 
β-catenin at Tyr654, whereas Fer or Fyn phosphorylate β-catenin at Tyr142, resulting 
in disruption of β-catenin-α-catenin interaction at the adherent junctions and 
subsequent release of β-catenin into the cytoplasm (Piedra, Miravet et al. 2003).  
In summary, the results described in this chapter demonstrate that Tspan6 
negatively regulates Wnt and EGFR-mediated signalling via production of 
extracellular vesicles, which are likely to contain EGFR-ligand TGF-α. Furthermore, 
one can hypothesise that Tspan6 negatively regulates EVs production via 
association with syntenin-1.
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6 RESULTS CHAPTER IV: TSPAN6 EXPRESSION 
REGULATES LUMENOGENESIS IN CACO-2 3D CYSTS 
6.1 Introduction 
The expression of Tspan6 was shown to regulate the EGFR-dependent 
signalling in mouse intestinal organoids, and Tspan6 knockout resulted in acquired 
EGF-independency in culture. To extend these observations the role of Tspan6 
EGFR-dependent signalling using Caco-2 human colon epithelial cells was 
examined. Specifically, it was investigated whether expression of Tspan6 changes 
growth characteristics of Caco-2 in 2D and 3D cultures, and whether Tspan6 
expression affects EGFR signalling and cellular response to the inhibitory effect of 
cetuximab, an EGFR inhibitor used in CRC treatment.  
6.2 Caco-2 as a colorectal cancer model 
To investigate the role of Tspan6 in CRC further Caco-2 cells were employed. 
These cells express relatively low levels of endogenous Tspan6 protein (Figure 
6-1.C) and harbour only a small number of cancer-driving mutations including stop-
gain mutation in APC (Q1367*) (Table 6-1). Importantly, Caco-2 cells are 
KRAS/BRAF wild-type and express EGFR protein (Figure 6-7). Therefore, the Caco-
2 cell line is a good model for the study of Tspan6 role in EGFR-mediated signalling.  
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Table 6-1. Mutation profile of Caco-2 cell line.  (Catalogue of Somatic Mutations in Cancer 
(COSMIC), accessed in May 2016). 
Caco-2 Mutation Profile 
Gene (name) CDS syntax AA syntax Mutation type 
CTNNB1 c. 734G>C p. G245A Substitution - Missense 
(pathogenic) 
SMAD4 c. 1051G>C p. D351H Substitution - Missense 
APC c. 4099C>T p. Q1367* Substitution - Missense 
 
 
6.3 Tspan6 expression facilitates lumen formation in Caco-2 
cultured in 3D ECM 
Stable expression of FLAG-tagged Tspan6 in Caco-2 cells was established by 
lentiviral transduction to generate Caco-2-Tspan6 cell line (Figure 6-1.A-B). A control 
cell line Caco-2-pLVx was also established by transducing Caco-2 cells with viral 
particles carrying an empty pLVx-puro (puromycin resistant) plasmid. As indicated in 
Figure 6-1.C the level of expression of Flag-tagged Tspan6 protein in a pool of 
transfected Caco-2-Tspan6 cells was 14-fold higher than in Caco-2-pLVx cells. 
Subsequently, the effect of Tspan6 expression on cellular behaviour of Caco-2 cells 
was analysed. The expression of Tspan6 did not change the morphology of Caco-2 
cells when cultured under standard 2D conditions (Figure 6-1.D). Furthermore, cell 
proliferation under standard culturing conditions on plastic in the complete growth 
medium was not affected either (Figure 6-2). Assessing cell characteristics in the 
three-dimensional extracellular matrix (Matrigel™) revealed that Caco-2 cells display 
certain characteristics of differentiating enterocytes and form organised polarised 
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colonies with a central lumen, often referred to as cysts (Ivanov, Hopkins et al. 2008, 
Jaffe, Kaji et al. 2008). It was found that Caco-2-Tspan6 colonies form a well-
developed central lumen at a faster rate than the control Caco-2-pLVx cells 
(p<0.0001) (Figure 6-3.A). Specifically, at day five ~82% of Caco-2-Tspan6 colonies 
and ~ 34% of Caco-2-pLVx colonies have a discernible lumen (Figure 6-3.B). To 
examine if expression of Tspan6 results in higher cell proliferation and, therefore, 
enhanced maturation of Caco-2 3D cysts, the growth rate of colonies was analysed 
using CellTiter Glo-3D (Promega). It was found that proliferation of Caco-2 cells in 3D 
ECM is not affected by expression of Tspan6 (Figure 6-3.C). Therefore, enhanced 
lumen formation of Caco-2-Tspan6 colonies is a result of other cellular processes 
affected by the expression of Tspan6. 
  




Figure 6-1. Expression of human TSPAN6 in Caco-2 colorectal cancer cell line. Caco-2 cells 
were transduced with control (pLVx) or human Tspan6 (T6) packaged lentivirus and stable cell lines 
were established using puromycin (2.5 µg/ml) selection for 7 days. Expression of FLAG-TSPAN6 in 
Caco-2 (expected size 28kDa) detected by (A) anti-Tspan6 antibody and (B) anti-FLAG antibody. (C) 
Expression level of Tspan6 in a stably transfected pool of Caco-2-pLVX and Caco-2-Tspan6 (T6) 
cells. The expression was normalised to β-actin expression. (D) Phase-contrast images of Caco-2 
cells expressing pLVx and Tspan6 vectors. 
 




Figure 6-2. Tspan6 does not affect proliferation of Caco-2 cells. (A) Effect of Tspan6 on cell 
proliferation in high serum (10% FCS) conditions. For high serum conditions no significant difference 
was found between Caco-2 pLVX and Caco-2 Tspan6 cell proliferation, p=0.2146, p=0.4326, 
p=0.8725, p>0.9999 for cells plated at densities 5000, 10000, 20000, and 40000 cells/well 
correspondingly. (B) Cell density standard curve. Caco-2 cells were plated at densities 5000, 10000, 
20000, and 40000 cells/well in 96-well plate and the fluorescence intensity was measured using 
Alamar Blue assay. The high cell density (40000 cells) reaches the saturation of fluorescent intensity 
indicated by the plateauing of the standard curve. All results are expressed as ratio of experimental to 
control (day 0) fluorescent intensities. Vertical bars represent the mean of triplicate assays and error 
bars are plotted as ± SEM. Non-parametric two-tailed unpaired Student T-test was used for statistical 
analyses (n=3). 




Figure 6-3. Tspan6 promotes single lumen formation at a higher rate in colonies of Caco-2 cells 
grown in three-dimensional ECM. (A) Representation of the development of Caco-2 cysts 
throughout five days of culturing in 3D ECM. Caco-2 cells expressing Tspan6 form larger lumen at an 
earlier stage than control cells (day 5) when cultured in 3D ECM. (B) Tspan6 expressing cells formed 
colonies of bigger size (p<0.0001) with median colony size of 79.3 µm and 62.4 µm in control cells; 
Tspan6 expressing colonies develop larger lumens than control cells (p<0.0001) after five days of 
culture in 3D ECM with median lumen diameter of 53.5 µm and 25.9 µm respectively. Images were 
acquired by phase contrast microscopy and images of 25 fields were taken for subsequent analysis. 
Lumen formation was examined by measuring colony and lumen diameter in ImageJ. Error bars 
represent median with range. Mann-Whitney non-parametric t-test was used for statistical analyses. 
(C) Effect of Tspan6 on cell proliferation in 3D ECM. Cell viability was measured using CellTiter Glo-
3D viability assay. Results are shown as growth rate relative to day 0 measurement and expressed as 
the mean of triplicate assays, error bars are plotted as ± SEM (n=3). 
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6.4 Tspan6 does not affect polarisation of Caco-2 cells  
Lumen formation in Caco-2 3D cysts occurs due to cellular polarisation as 
early as the first cell division (Taniguchi, Shao et al. 2015, Rodriguez-Boulan, Macara 
2014, Jaffe, Kaji et al. 2008, Martin-Belmonte, Mostov 2008). First, the localisation of 
Tspan6 in Caco-2 cells was assessed. It was found that Tspan6 is strongly 
expressed at the basal membrane of 3D cysts, and weaker enrichment at lateral and 
apical surfaces (Figure 6-4). Secondly, the markers of cellular polarity were examined 
in confluent 2D and 3D Caco-2 cultures. Caco-2 two-dimensional monolayers are 
intensively used for studies of intestinal polarity due to the ability to spontaneously 
polarise in a tight monolayer (Schneeberger, Roth et al. 2018). The expression of 
Tspan6 did not result in altered polarisation of 2D cell monolayer (Figure 6-5). Both 
cell lines exhibited polarity as early as 10 days of culture, showing formed tight 
junctions at the apical surface (ZO-1), Na+/K+-ATPase at the basolateral surface and 
integrin-α6 at the basal surface of polarised Caco-2 monolayer. In agreement with 
the results of 2D culture experiments, it was found that Tspan6 does not affect 
cellular polarity in Caco-2 3D cysts (Figure 6-6). In both cell lines enhanced F-actin 
accumulation at the apical surface facing a central lumen was observed. Moreover, 
no apparent differences were seen when colonies were stained with antibodies 
recognising tight junctions (ZO-1) or adherens junctions (E-cadherin). A characteristic 
punctate pattern of distribution of ZO-1 at the apical surface and marked localisation 
of E-cadherin at the basolateral surface were seen irrespectively of the expression of 
Tspan6. 
 




Figure 6-4. Localisation of Tspan6 in Caco-2 3D cysts. Single confocal section through the middle 











Figure 6-5. Expression of Tspan6 does not affect polarisation of Caco-2 2D monolayer. The immunofluorescent image of Caco-2 pLVx (A) and 




-ATPase (magenta). (B, D) Z-stack image 
analysis of protein spatial organisation in Caco-2 polarised 2D monolayer expressing pLVx (B) and Tspan6 (D). The red and green lines in the xy plane 
indicates the site from which the xz image was constructed. 




Figure 6-6. Expression of Tspan6 does not affect polarisation of Caco-2 3D cysts. (A) The 
immunofluorescent image of single confocal section shows that cellular polarisation and apical F-actin 
ring (red) formation is preserved in Caco-2 cells expressing Tspan6; Hoechst 33342 marks nuclei 
(blue). (B) Single confocal section through the middle of Caco-2 cysts stained for DNA (blue), ZO-1 
(green), and E-Cadherin (red). 
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6.5 Tspan6 facilitates lumen formation in EGFR-dependent manner 
The RNAseq data analysis of the mouse intestinal polyps derived from 
APCmin/+ and APCmin/+Tspan6-/y double mutant mice, as well as the evidence of 
acquired EGF-independent growth of Tspan6 KO mouse intestinal organoids 
prompted us to investigate if expression of Tspan6 regulates cell signalling via EGFR 
in Caco-2 cells. The expression levels of the receptor and ligand-induced 
phosphorylation at Tyr1068 were examined. The total levels of EGFR was 
consistently higher (by ~1.5-fold) in Caco-2-Tspan6 cells when compared to the 
control Caco-2-pLVx cells. In spite of this, the relative level of activation (i.e. ratio of 
pEGFR to the total EGFR) appeared to be higher in Caco-2-pLVx cells (Figure 6-7.A-
B). Strikingly, these differences were even more pronounced when cells were 
cultured in 3D ECM: here the expression of EGFR was ~9-fold higher in Tspan6–
expressing cells when compared to the control, and conversely, a greater level of 
activation (approximately 4-fold) was seen in the control, Caco-2-pLVx cells (Figure 
6-7.D). In addition, EGFR appeared to localise to lateral and basal surfaces of 3D 
Caco-2 cysts similarly to Tspan6 expression pattern (Figure 6-7.E). 
 





Figure 6-7. The analysis of EGFR expression in Caco-2 cells. (A, C) Western blot representing 
expression and activation of EGFR (by phosphorylation at Tyr1068) in Caco-2 two-dimensional 
monolayer (A) and three-dimensional cysts cultured in Matrigel™ for 5 days (C). (B, D) The level of 
EGFR activation in Caco-2 pLVx and Tspan6-expressing cells cultured in 2D (B) and 3D ECM (D). 
EGFR is hyperactivated in 2D cultures (n=3, p=0.0066) and in 3D cultures (n=2. P=0.0079). The 
resuls are expressed as a ratio of signal intensities to total level of EGFR in cells normalised to β-
actin. Bar chart represents a mean of triplicate (for 2D) and duplicate (for 3D) assays and error bars 
are plotted as SEM. (E) Single confocal section through the middle of Caco-2 cysts stained for DNA 
(blue) and EGFR (green). 
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Further, to examine if attenuation of EGFR activation in the presence of 
Tspan6 correlates with lumen formation in Caco-2 cysts, the effect of EGFR 
stimulation with EGF and inhibition with cetuximab was assessed. Cetuximab is a 
monoclonal antibody against EGFR, which recognises the extracellular portion of the 
receptor and inhibits the receptor-ligand interaction. Firstly, Caco-2 cells were 
cultured in 3D Matrigel™ in the presence of EGF (10 ng/ml) or a vehicle (control). 
The stimulation of Caco-2-pLVx with EGF resulted only in slight changes to the 
number of lumen-forming colonies: 28% of lumen bearing colonies in EGF-treated 
cells versus 34% in control conditions (Figure 6-8.A-D). The lumen formation of 
Caco-2-Tspan6 cells, however, was greatly impaired upon stimulation with EGF, 
resulting in reduction from 82% to 43% of lumen-bearing colonies (Figure 6-8.A-D). 
This observation indicated that EGFR activation is linked to lumen formation and 
suggested EGFR-dependent signalling pathways are negatively regulated by Tspan6 
under normal growth conditions. In the converse experiments, Caco-2 cells were 
cultured in 3D Matrigel™ in the presence or absence of cetuximab at different 
concentrations (10 µg/ml, 25 µg/ml and 100 µg/ml). Little if any difference in cell 
growth and lumen formation was observed when 10 µg/ml of cetuximab was 
administered on cells when compared to control conditions (data not shown). 
Culturing cells with 100 µg/ml cetuximab resulted in near complete growth inhibition 
of Caco-2 cells. By contrast, inhibition of EGFR with 25 µg/ml cetuximab led to 
enhanced lumen formation in control cell line (Caco-2-pLVx) and did not affect 
lumen-formation in Caco-2-Tspan6: 62% and 70% of analysed colonies in the control 
cell line and cells expressing Tspan6, respectively, were presented with the lumen 
(Figure 6-8.E-F). Taken together, these data demonstrate that the expression of 
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Tspan6 negatively regulates EGFR activation that in turn facilitates lumen formation 
in Caco-2 3D cysts and this process is likely to be mediated by ligand binding to 
EGFR.  
  




Figure 6-8. Tspan6 regulates EGFR-dependent growth of Caco-2 cells in 3D ECM.  (A) Caco-2 
cells expressing Tspan6 form a well-developed central lumen at a faster rate than control cells in 3D 
ECM colonies. (B) Tspan6 expression results in more colonies forming central lumen after five days of 
culture (p=0.00090). Number of colonies with and without lumen formed by pLVx and Tspan6 
expressing Caco-2 cell line and expressed as percentage of total colonies counted. Quantification was 
carried out after 5 days of culturing. (C) Activation of EGFR with EGF results in slower development of 
central lumen in Caco-2 Tspan6 3D cysts. (D) EGFR hyperactivation by EGF results in reduction of 
Caco-2-Tspan6 lumen-bearing colonies; Tspan6 expressing cells formed more colonies with lumens 
than control cells (p=0.0239). (E) Inhibition of autocrine activation of EGFR with cetuximab (25µg/ml) 
led to enhanced lumen formation in control cell line and did not affect lumen-formation in Caco-2-
Tspan6. (F) The lumen formation has increased in Caco-2-pLVx 3D cysts upon EGFR inhibition with 
cetuximab and no difference in lumen formation between pLVx and Tspan6 cells was detected 
(p=0.0633). Bar charts represent mean of triplicate assays and error bars are plotted as ± SEM. 
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6.6 Tspan6 regulates EGFR-dependent signalling in Caco-2 cells 
To investigate the role of Tspan6 in EGFR-mediated cell responses, the 
signalling profile of Caco-2 cells in response to EGFR activation by EGF was 
evaluated in more detail. Control and Tspan6 expressing Caco-2 cells were 
stimulated with 10 ng/ml EGF for 10 min, 20 min, 40 min and 60 min and the 
phosphorylation of EGFR, ERK 1/2, Akt, and p38 was analysed by Western blot 
(Figure 6-9). In addition, β-catenin-mediated signalling was also examined. Upon 
EGF administration a rapid activation of EGFR (as indicated by phosphorylation at 
Tyr1068) is taking place in both Caco-2-pLVx and Caco-2-Tspan6 cells. During the 
time course of EGF stimulation, a trend in low levels of phosphorylation of EGFR in 
Caco-2-Tspan6 cells was observed at all time points when compared to Caco-2-
pLVx. A similar trend was noticed when phosphorylation of ERK 1/2 and Akt, well-
established downstream effectors of EGFR, was examined.  
Upon ligand-binding, EGFR is phosphorylated at multiple residues that in turn 
recruit cytoplasmic molecules to regulate EGFR-mediated cellular responses (Wee, 
Wang 2017). Phosphorylation at Tyr1045 results in the recruitment of cCbl to EGFR 
(via Grb2) and subsequent ubiquitin-mediated receptor degradation (Sigismund, 
Algisi et al. 2013). In this regard, the phosphorylation of EGFR at Tyr1045 and cCbl 
at Tyr774 were higher in Tspan6 expressing cells following EGF stimulation. 
Interestingly, a significantly higher increase in cCbl phosphorylation (p=0.0092) in 
Caco-2-pLVx cells in control conditions was also observed. It can be speculated that 
Tspan6 negatively regulates secretion of EGFR ligands, therefore, the increase in 
receptor activation and subsequent degradation by cCbl-mediated ubiquitination in 
Caco-2-pLVx cells under basal growth conditions are expected. An additional 
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mechanism of EGFR-mediated signalling regulation is phosphorylation of Thr654 by 
protein kinase C (PKC) that blocks EGF-induced internalisation and downregulation 
of the receptor (Lund, Lazar et al. 1990). Accordingly, our data indicated that in the 
presence of Tspan6 phosphorylated EGFR at Thr654 was lower than in control cells 
during EGF stimulation, indicating a more effective negative feedback loop of EGFR-
mediated signalling takes place in cells expressing functional Tspan6.  
In agreement with results seen with organoids, it was found that low 
expression of Tspan6 in Caco-2-pLVx cells correlated with the increased activation of 
p38 MAPK. Although the implications of p38 activation and Tspan6 expression are 
currently unknown, it is possible that p38 activation has an inhibitory effect on 
GSK3β, and subsequently affects β-catenin dependent pathways. As such, it was 
found that β-catenin phosphorylation (regulated by GSK3β) at Ser552 is increased by 
~2-fold in Caco-2-pLVx cells upon stimulation with EGF but remains unaffected in 
Caco-2-Tspan6 cells. Furthermore, these changes were accompanied by relatively 
low phosphorylation levels of β-catenin Thr41 and Ser45 in Caco-2-pLVx cells when 
compared to Tspan6-expressing cells.  
In summary, these data presented here further indicate that Tspan6 
expression modifies the EGFR-mediated signalling in vitro. 
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Figure 6-9. Tspan6 regulates EGFR-dependent signalling in Caco-2 cells.  (A) Western blot 
analysis of p-EGFR, p-ERK, p-β-catenin, p-Akt, and p-p38 in pLVx and Tspan6 expressing Caco-2 cells in 
response to timecourse of EGF stimulation (10 ng/ml). (B-J) Quantification analysis of phosphorylation 
level of signalling molecules relative to the total expression of the unphosphorylated molecule expressed as 
mean signal ±SEM of triplicate experiments. Data was normalised to β-actin expression.  
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6.7 Expression of Tspan6 correlates with better response to EGFR 
inhibitor cetuximab 
The emerged role of Tspan6 in regulation of EGFR-mediated signalling 
instigated the rationale to determine whether Tspan6 affects cell proliferation and 
cellular responses to an EGFR inhibitor, namely cetuximab. The effect of cetuximab 
at different concentrations (ranging from 0.1 µg/ml to 50 µg/ml) were assessed using 
Alamar Blue assay. The inhibition of proliferation induced by cetuximab on Caco-2 
cells was determined as percentage viability in comparison with the untreated 
control. Of note, the anti-proliferative effect of cetuximab was observed at 
concentration as low as 0.1 µg/ml (p<0.0001) (Figure 6-10). The level of growth 
inhibition observed in control cells (Caco-2-pLVx) was approximately 10% compared 
to untreated cells at 0.5 µg/ml, reaching 25% of inhibition at 50 µg/ml of cetuximab, 
which is in agreement with previously published studies (Song, Liu et al. 2014, 
Herreros-Villanueva, Muniz et al. 2010, Brandi, Tavolari et al. 2012). However, the 
anti-proliferative effect of cetuximab in cells expressing Tspan6 appeared to be 
significantly more dramatic at concentrations of cetuximab as low as 0.5 µg/ml 
showing 18% of inhibition compared to 12% in Caco-2-pLVx cells (p=0.0128). The 
strongest effect was seen at high concentrations of cetuximab (50 µg/ml), reaching 
approximately 32% of growth inhibition. Thus, these results demonstrate that Tspan6 
expression can potentiate sensitivity to the inhibitory effect of cetuximab. This data 
confirms the role of Tspan6 in regulation of EGFR-mediated cellular responses. 
 




Figure 6-10. Tspan6 affect response of Caco-2 cells to cetuximab after 72-hour treatment in 2D. 
Effect of cetuximab on Tspan6 expressing and control Caco-2 cells. Results expressed as percentage 
of control with 100% representing untreated control cells. Vertical bars ± SEM of triplicate assays. P < 
0.05 versus control values of untreated cells (Two-tailed Student t-test). 
 
6.8 Tspan6-Syntenin-1 complex regulates lumen production in 
Caco-2 three-dimensional polarised cysts  
The results presented in this thesis strongly suggest that Tspan6 plays a role 
in EGFR-dependent signalling via autocrine ligand secretion. It was recently reported 
that Tspan6 regulates exosome secretion in vitro via its cytoplasmic partner syntenin-
1, an adaptor protein implicated in biogenesis of exosomes (Guix, Sannerud et al. 
2017). The possibility of direct association of Tspan6 with syntenin-1 and EGFR in 
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Tspan6 in stringent conditions known to disrupt the association of tetraspanins with 
most of their transmembrane partners (0.5% Brij98 - 0.5% Triton-X-100) (Figure 
6-11.B). By contrast, EGFR co-immunoprecipitated with Tspan6 only under low 
stringency conditions (0.8% Brij98 - 0.2% Triton-X-100) suggesting an indirect 
association of the tetraspanin with the receptor (possibly via other proteins in the 
tetraspanin-enriched microdomain (TEM/TERM)) (Figure 6-11.C). Following this 
observation, we investigated if EGFR-mediated lumen formation in Caco-2 cells is 
regulated by syntenin-1 expression. Syntenin-1 was depleted using small interfering 
RNA in the control and Tspan6-expressing cells cultured in 3D-Matrigel™ for 5 days 
after transfection. A reduction in number of spheroids presented with visible lumen 
was noted in both cell lines (Figure 6-12.C-D). Specifically, only 5% and 3% of 
colonies formed central lumen in Caco-2-pLVx and Caco-2-Tspan6 respectively. 
Importantly, the expression of syntenin-1 remained downregulated after 5 days of 
culture (Figure 6-12.A-B). These data indicate that syntenin-1 may play a role in 
lumen formation in Caco-2 cells, thus supporting the hypothesis that Tspan6 
regulated EGFR-mediated cell responses in the complex with syntenin-1.  




Figure 6-11. Tspan6 is associated with syntenin-1 and EGFR in Caco-2 cells. (A) Schematic 
presentation of FLAG-tagged Tspan6 and syntenin-1 in the co-immunoprecipitation assay. FLAG is 
expressed on the N-terminus of Tspan6 and syntenin-1 binds C-terminus of Tspan6. (B-D) Analysis of 
proteins in Tspan6 immunoprecipitates in buffer containing 0.5% Brij-0.5% Triton X-100 (B) or 0.8% 
Brij-0.2% Triton X-100 (C, D). Immunoprecipitation control using anti-FLAG and Tspan6 antibody (D). 




Figure 6-12. Knockdown of syntenin-1 results in significant reduction of lumen formation in 
colonies of Caco-2 cells in three-dimensional ECM.  (A) Western blot showing level of syntenin-1 
expression in Caco-2 cells treated with control siRNA and syntenin-1 siRNA for 5 days. (B) Bar chart 
representing level of syntenin-1 knockdown by siRNA in Caco-2 3D cysts after five days of culture. (C) 
A phase-contrast image of Caco-2 cells transfected with siRNA (control or syntenin-1) and cultured for 
5 days in 3D ECM after 24 hours of transfection. (D) The percentage of Caco-2 colonies that formed 
the lumen (orange) or appeared without lumen (green) when treated with control (left) and syntenin-1 
siRNA (right) (n=1). 
  




When cultured in three-dimensional ECM Caco-2 cells exhibit characteristics 
of enterocytic differentiation and form organised polarised colonies with a central 
lumen, often referred to as cysts (Ivanov, Hopkins et al. 2008, Jaffe, Kaji et al. 2008). 
The expression of Tspan6 was shown to facilitate lumen formation at a faster rate 
than control cells without affecting cellular polarisation. The lumen formation in Caco-
2 cells is linked to polarised spindle orientation during mitosis, and dysregulation of 
Rho GTPase Cdc42-dependent signalling (or changes in the expression or function 
of other proteins, including cancer-promoting phosphatase PRL-3 and PTEN) were 
shown to disrupt lumenogenesis, promoting formation of multiple lumens in culture 
(Bray, Brakebusch et al. 2011, Lujan, Varsano et al. 2016, Jagan, Fatehullah et al. 
2013). 
 The expression of Tspan6 does not seem to affect proliferation and cellular 
polarity nor does this lead to the formation of multiple lumens when Caco-2 cells are 
cultured in 3D ECM. These results suggest that Tspan6 may be involved in pathways 
which control lumen expansion. It has been previously reported that lumen formation 
by Caco-2 cells in 3D ECM is driven by polarised fluid secretion mediated by Na+/K+-
ATPase and the cystic fibrosis transmembrane receptor (CFTR) localised at the 
basolateral and apical surfaces respectively (Jaffe, Kaji et al. 2008). Interestingly, it 
was found that Tspan6 can be co-immunoprecipitated with Na+/K+-ATPase and two 
proteins are co-localised at the basolateral surface of Caco-2 3D cysts by 
immunofluorescence (Supplementary Figure 8-2 and Supplementary Figure 8-3). 
This data points towards a potentially new mechanism of regulation of Na+/K+-
ATPase in the context of lumen formation by Tspan6. However, more work will be 
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required to understand the biological significance of this interaction and whether the 
activity of the Tspan6-Na+/K+-ATPase complex is linked to the modulatory effect of 
Tspan6 on signalling via EGFR. In this regard, it is interesting that inhibition of 
Na+/K+-ATPase using ouabain, resulted in the increased activation of EGFR 
(Rajamanickam, Kastelic et al. 2017), thus suggesting an alternative pathway 
whereby Tspan6 is regulating the activity of EGFR via Na+/K+-ATPase. Conversely, 
one can speculate that Tspan6-dependent regulation of EGFR signalling would 
regulate activity of the Na+/K+-ATPase pump and control the rate of fluid secretion 
into the central lumen during the formation of Caco-2 cysts. Indeed, it has been 
shown that inhibition of MAPK activity in HT29 colorectal cells promoted lumen 
formation (Herr, Kohler et al. 2015). Furthermore, p38 and ERK were found to inhibit 
the Na+/K+-ATPase pump in Caco-2 cells (El Moussawi, Chakkour et al. 2018).  
It was found that Tspan6 is directly associated with syntenin-1 in Caco-2 cells. 
Remarkably, similar to the effect of EGFR hyperactivation by EGF, knockdown of 
syntenin-1 resulted in near complete ablation of lumen formation by Caco-2 in 3D. 
Therefore, it is possible that syntenin-1 is a key factor that mediates the effect of 
Tspan6 on activation of EGFR. In this regard, syntenin-1 is known to interact with 
syndecans, a family of transmembrane proteoglycans, that are able to capture EGFR 
and ErbB2 with their ectodomain and control autophosphorylation of the receptor 
(Ramani, Purushothaman et al. 2013, Baietti, Zhang et al. 2012, Wang, H., Jin et al. 
2015). Therefore, one can speculate that depletion of syntenin-1 (or Tspan6-
dependent re-localisation of the protein in cells) will affect the mode of syndecans-
EGFR and prolong EGFR autophosphorylation leading to the suppression of lumen 
formation. Alternatively, ablation of the lumen formation in Caco-2 cells following 
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syntenin-1 depletion may be a result of impaired growth, resulting in immature cyst 
formation, as silencing of syntenin-1 demonstrated the reduced growth and 
proliferation of the human colon cancer cell line HT29 and the human breast cancer 
cell line MCF7 (Kashyap, Roucourt et al. 2015). 
Tspan6 was found to bind to the first PDZ domain of syntenin-1 (Guix, 
Sannerud et al. 2017). Interestingly, unpublished data from our lab showed that 
syntenin-1 binds to pro-TGF-α via PDZ2 domain and is able to bind Tspan6 and pro-
TGF-α simultaneously. Thus, it is feasible that Tspan6 acting via syntenin-1 affects 
intracellular trafficking of pro-TGF- (for example, by preventing effective recruitment 
of the protein to exosomes) (Figure 6-13). Consequently, suppressed autocrine 
activation of EGFR and its downstream targets (e.g. MAPKs) would leave Na+/K+-
ATPase more active (see above) and, therefore, result in a quicker expansion of the 
lumen. Alternatively, Tspan6 may use syntenin-1 for activation of other pathways that 
are known to regulate Na+/K+-ATPase function. Src kinase may represent one such 
molecule. Na+/K+-ATPase has been shown to inhibit activity of Src in multiple studies 
(Weigand, Swarts et al. 2012, Banerjee, Cui et al. 2018, Zhang, Aalkjaer et al. 2018). 
On the other hand, Src was implicated in exosome biogenesis through interaction 
with syntenin-1 (Imjeti, Menck et al. 2017). Therefore, one cannot exclude a 
possibility of Tspan6 controlling the balance of Src-Na+/K+-ATPase and Src-syntenin-
1 associations, which may have important consequences for Src activation and, 
subsequently, exosomal production. 





Figure 6-13. Schematic representation of Tspan6 interaction in Caco-2 cells. 
 
In summary, results of this chapter further suggest that Tspan6 may be 
considered as a new modulatory molecule that regulates EGFR-mediated responses 
in colon epithelial cells. Moreover, the interaction with syntenin-1 may represent a 
key factor in regulation of the biological activity of Tspan6 (particularly in the context 
of exosome-dependent production of TGF-α). Further studies will be necessary to 
examine whether or not changes in the expression of Tspan6 in CRC tissue and 
associated modulations of EGFR-dependent signalling could be used as a novel 
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7 DISCUSSION AND FUTURE DIRECTIONS  
7.1 Tspan6 as a biomarker in CRC 
The data presented in this thesis demonstrated that Tspan6 protein 
expression is reduced in CRC when compared to adjacent normal tissue in humans, 
specifically in early stages of CRC (stage II and stage III). It remains unclear whether 
decreased Tspan6 expression results from malignant transformation of cells or drives 
tumorigenesis following tumour initiation by aberrant Wnt signalling as was 
demonstrated in APCmin/+ mice. In this regard, in the small cohort of CRC patients 
analysed, there was no correlation found between Tspan6 expression and cancer 
driver gene mutations, suggesting that Tspan6 regulation occurs independently of 
these signalling pathways, possibly as an alternative mechanism of selection 
pressure acquired by tumour cells.  
The analysis of Tspan6 KO revealed that although Tspan6 is not a tumour 
suppressor gene it has a role in APC-driven neoplastic transformation of epithelial 
cells. This suggests that changes in Tspan6 expression may represent an early event 
in tumorigenesis contributing to the development of polyps in the intestine and colon 
and may be indicative of cancer development. Indeed, it has been recently reported 
that the expression of Tspan6 in polyps adjacent to cancer was lower as compared to 
cancer-free polyps (Druliner, Wang et al. 2018). These findings support the important 
role of Tspan6 in colon tumorigenesis and implicate Tspan6 as a possible marker for 
progression of adenomatous polyps to malignant carcinomas. Further analysis of 
Tspan6 expression along with examination of EGFR activation in the cohort of 
adenoma samples, including sporadic cases and polyps from FAP patients should 
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clarify the involvement of Tspan6 in early events of carcinogenesis. It is important to 
note that only 5% of adenomatous polyps give rise to cancer in humans and yet it 
remains unclear why some polyps transform to malignant type and others do not, 
raising the question if Tspan6 dysregulation favours the malignant transformation of 
adenomatous polyps (Druliner, Rashtak et al. 2016, Heitman, Ronksley et al. 2009, 
Saini, Kim et al. 2006, Church 2004). 
The specific reduction of Tspan6 in the stage II localised tumours and stage III 
invasive carcinomas (lymph node metastases present), but not in metastatic stage IV 
CRCs, is a further indication that Tspan6 may play a critical role in early steps of 
carcinogenesis. Importantly, approximately 20-30% of stage II and ~15% of stage III 
CRC patients relapse after treatment (a combination of surgery and chemotherapy) 
(Paspala, Machairas et al. 2018, Labianca, Nordlinger et al. 2013, de Wit, Fijneman 
et al. 2013). Thus, further experiments will be required to examine whether Tspan6 
expression correlates with patients’ resistance to chemotherapy. This will be 
particularly important in the context of the treatment regimens targeting EGFR. 
Indeed, our results indicate that Tspan6 regulates cellular responses to cetuximab. 
To address if Tspan6 expression correlates with response to anti-EGFR treatment, 
the cohort of CRC samples from the COIN clinical trial is currently being investigated. 
Of note, this trial includes patients with no mutation in Kras, who were treated 
intermittently with chemotherapy plus continuous (or intermittent) treatment with 
cetuximab. The analysis of Tspan6 methylation profiles in tumours resistant to 
cetuximab therapy will also be examined. In addition, samples from the FOxTROT 
clinical trial, in which CRC patients underwent neo-adjuvant chemotherapy ± 
panitumumab (anti-EGFR monoclonal antibody) independently of tumour stage, will 
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be analysed for Tspan6 expression to evaluate if its expression is linked to patient 
responses to the treatment. Analysis of this cohort will also allow examining if Tspan6 
expression correlates with disease recurrence. 
7.2 Tspan6-EGFR axis in CRC 
This study strongly suggests that Tspan6 affects neoplastic transformation of 
intestinal and colonic epithelial cells by regulating the EGFR-mediated signalling via 
mechanisms involving autocrine secretion of EGFR ligand TGF-α. Although there is 
no evidence indicating that TGF-α is directly involved in the CRC development and 
progression, previous studies demonstrated that the high levels of TGF-α expression 
in normal colonic mucosa can be considered as a potential biomarker for the 
development adenoma and CRC (Daniel, Bostick et al. 2009). Furthermore, the 
increased levels of TGF-α in the blood of CRC patients and in cancerous tissues may 
be an informative indicator for designing the optimal treatment targeting EGFR 
(Zhao, Wang et al. 2017, Troiani, Martinelli et al. 2013). Therefore, it will be important 
to extend our study further and analyse a possible link between the expression of 
Tspan6 and TGF-α in CRC patients and its relevance to patient’s responses to 
EGFR-targeting therapies (see above). 
Although the data presented in this thesis suggests that Tspan6 acts via 
regulated secretion of TGF-α, other pathways exist which may link EGFR and 
Tspan6 (via TGF-α) that should be considered and explored in the future studies. For 
example, it is possible that Tspan6 regulates the exit of TGF-α from the ER. In this 
regard, it has been demonstrated that syntenin-1, the only known cytoplasmic partner 
of Tspan6, is important for surface delivery of TGF-α (Fernandez-Larrea, Merlos-
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Suarez et al. 1999). Alternatively, Tspan6 may act via syntenin-1 to regulate TGF-α 
shedding by ADAM17 as syntenin-1 is known to directly associate with Src kinase 
that in turn regulates ADAM17 sheddase function in cleaving pro-TGF-α at the cell 
membrane (Imjeti, Menck et al. 2017, Van Schaeybroeck, Kelly et al. 2008). The 
association with syntenin-1 and the formation of the tri-partite Tspan6-syntenin-TGF-
α complex (preliminary data from Berditchevski’s laboratory) on one hand and 
observed co-immunoprecipitation with EGFR on the other (this study), suggest that 
Tspan6 may regulate the dynamics of EGFR-TGF-α binding by controlling spatial 
localisation of the ligand and/or receptor on the cell surface. 
Tetraspanins have been previously implicated in regulation of EGFR/ErbB2 
dependent signalling by affecting various pathways (Berditchevski, Odintsova 2016). 
In cells expressing Tspan6 the increased amount of EGFR seems to indicate that 
pathways that regulate trafficking or/and degradation of the receptor are most 
affected. The receptor internalisation and degradation are dependent on 
ubiquitination of the protein, which is mediated by cCbl ubiquitin ligase and is 
activated by ligand-induced autophosphorylation of EGFR (at Tyr1045) (Sorkin, Goh 
2009, Thien, Langdon 2001, Carraway 2010). Our results demonstrate decreased 
phosphorylation of cCbl in Tspan6 expressing cells under steady state conditions 
which points towards a yet unidentified intracellular pathways that control activation 
of this protein. Further analysis will be necessary to establish whether this change in 
the phosphorylation status of cCbl would have functional consequences for Tspan6-
dependent regulation of EGFR expression. 
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7.3 Tspan6-syntenin-1 complex in EVs biogenesis 
Our data suggest that Tspan6-dependent regulation of EGFR-mediated 
signalling involves production of EVs (Figure 7-1). Intriguingly, whereas there was no 
obvious difference in the total number of EVs produced by organoids derived from 
the WT or Tspan6 KO animals, there was ~9-fold increase in the production of 
smaller vesicles (50-100nm) by organoids established from the knockout animals. 
Although technical challenges (i.e. small quantities of conditioned media) did not 
allow us to establish the identity of these vesicles (i.e. exosomes or small 
ectosomes), these results further support the notion that Tspan6 plays an important 
role in exocytic (or/and ectocytic) release of vesicles by cells. The mechanisms of 
exosome formation and secretion has been extensively investigated over the last few 
years (Juan, Furthauer 2018, Toh, Lai et al. 2018, Colombo, Moita et al. 2013, 
Ramani, Purushothaman et al. 2013) and our recent data indicate that Tspan6 may 
control the production of exosomes by neuronal cells (Guix, Sannerud et al. 2017). 
Thus, finding a direct mechanistic link between Tspan6 and established pathways 
underlying formation of MVBs and production of exosomes is critical. One of the 
potential candidates is syntenin-1. Syntenin-1 is known to be a key molecule in 
biogenesis of exosomes which functions as a part of the complex containing 
syndecans (Baietti, Zhang et al. 2012). 
Thus, it will be important to investigate the relationship between Tspan6-
syntenin-1 and syndecan-syntenin-1 complexes and establish molecular pathways 
that control their assembly. The role of Src kinase may be particularly important. It 
has been recently demonstrated that Src impacts endocytosis of syndecans from the 
plasma membrane, and recruits syntenin-1 to the endocytic compartments, 
DISCUSSION AND FUTURE DIRECTIONS 
201 
  
promoting budding and biogenesis of syntenin-1-syndecan enriched exosomes 
(Imjeti, Menck et al. 2017). Interestingly, it was noticed that Src phosphorylation is 
increased in cells and organoids expressing low levels of Tspan6, supporting a 





Figure 7-1. Schematic model of Tspan6 regulation of autocrine secretion of EGFR ligands. 
Association of syntenin-1 with Tspan6 (via PDZ-1) and proTGF-α (via PDZ-2) can inhibit (1) 
endocytosis, (2) endosome maturation and production of ILVs, (3) skewing late endosome fate from 
(3a) fusion with plasma membrane and exosomal release to (3b) fusion with lysosomes and cargo 
degradation. 
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In the context of Alzheimer’s disease and degradation of amyloid precursor 
protein (APP) high levels of Tspan6 were shown to inhibit fusion of late endocytic 
vesicles with autophagosomes and lysosomes, favouring exosomal release over 
lysosomal degradation (Guix, Sannerud et al. 2017). Our data suggest that the endo-
lysosomal trafficking pathways linking Tspan6 and polarised production/secretion of 
exosomes may be tissue specific, making this a very interesting topic for further 
investigation. Interestingly, Tspan6 was found to be expressed on exosomes derived 
from the apical membrane of polarised LIM1863 colon carcinoma cell line (Tauro, 
Greening et al. 2012). Moreover, syntenin-1 was also detected in apical endocytic 
compartments in polarised Madin-Darby canine kidney (MDCK) cells (Fialka, 
Steinlein et al. 1999). In this study due to three-dimensional organisation of 
organoids, the vesicles/exosomes derived only from the basolateral surface of 
organoids were analysed. This poses an important question for future investigation: 
whether quantitative differences in production of small vesicles (associated with 
Tspan6 deficiency) are due to changes in the formation of MVBs or, in fact, reflective 
of more general alterations in intracellular secretory apparatus. 
In addition to exosomes, loss of Tspan6 influenced the secretion of 
extracellular macrovesicles (up to 1 µm in diameter). The reliable, unequivocal 
method to isolate and characterise different EV subtypes has not been established to 
date. The protein profile of EVs is similar due to enrichment in transmembrane 
proteins and no unique protein marker for each subtype of EVs has been reported 
(Yanez-Mo, Siljander et al. 2015). The best studied EVs are exosomes that are 
typically isolated by size exclusion chromatography, differential centrifugation or 
sucrose/iodixanol density gradient centrifugation. However, there is no evidence that 
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EVs produced by different pathways (e.g. exocytosis or ectocytosis) do greatly differ 
in size. Therefore, it is also important to consider the possible contribution of Tspan6 
to production of ectosomes, 100 nm-1 µm vesicles derived from outward budding of 
the cell membrane. Although the signalling potential of ectosomes has not been 
studied extensively, the elevated number of ectosomes in plasma and tumour 
biopsies is positively correlated with tumour progression in pancreatic cancer patients 
(Kalra, Drummen et al. 2015, Minciacchi, You et al. 2015). Tetraspanins have been 
reported to induce membrane curvature (Bari, Guo et al. 2011, Wrigley, Ahmed et al. 
2000), and, therefore, may be considered as potential regulators of the ectosome 
production as well. For example, Tspan6 in this study and some other tetraspanins in 
previous reports were shown to regulate activation of ERK 1/2, a key component of 
the ARF6-dependent pathway leading to the formation of membrane-derived vesicles 
by a human melanoma cell line (Muralidharan-Chari, Clancy et al. 2009). 
7.4 Tspan6 and CRC: extracellular vesicles, immunity and 
microbiota 
Exosomes are known to transfer genetic material between cells. In total, 764 
miRNAs and 1639 mRNAs have been characterised in extracellular vesicles (Abak, 
Abhari et al. 2018). The mRNA, miRNA, lncRNA profile was not examined in this 
study; however, it is important to note that the exosome-derived RNAs were 
demonstrated to play an important role in tumorigenesis and modulation of the 
EGFR-mediated signalling. For example, miR-221/222 (transcriptional targets of 
EGFR) promotes migration and metastasis of gastric cancer cells (Wang, Zhao et al. 
2014). In addition, miR-24 expression promotes EGFR signalling in breast cancer 
tumours (Du, Fang et al. 2013) and miR-148a enhances EGFR activation in 
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glioblastoma (Kim, Zhang et al. 2014). Conversely, miR-155 and miR-133a suppress 
EGFR in breast cancer and non-small cell lung carcinoma (NSCLC) respectively 
(Neilsen, Noll et al. 2013, Wang, Hsiao et al. 2014). Therefore, it is important to 
investigate the molecular composition of extracellular vesicles derived from Tspan6-
low expressing cells to identify additional onco-drivers that can be secreted by EVs in 
Tspan6 dependent manner.  
Exosomes have been also shown to modify the tumour microenvironment 
(Abak, Abhari et al. 2018). As such, tumour-derived exosomes expressing TGF-β1 
were shown to induce T-regulatory (Treg) lymphocytes and inhibit cytotoxic cells in 
favour of tumour immune response escape (Clayton, Mitchell et al. 2007). In addition, 
tumour-derived exosomes from the mouse colon carcinoma CT26 cells, lymphoma 
EL4, embryo fibroblast NIH/3T3 cells, and human lung adenocarcinoma H23 cells, as 
well as from human extranodal natural killer (NK)/T cell lymphoma (ENKL) primary 
cells were shown to suppress immune response through production of interleukin-6 
(IL-6) (Nagarajah 2016, Zhang, Li et al. 2015, Chalmin, Ladoire et al. 2010). Of note, 
AREG-induced EGFR signalling was shown to affect T-cell suppressive function. The 
unpublished data from our lab suggests the regulatory role of Tspan6 in modulation 
of the immune-microenvironment in colon adenomas and CRC through recruitment of 
T lymphocytes. The regulation of syntenin-1 by Tspan6 may explain this effect, as 
syntenin-1 was shown to negatively regulate immunoglobulin production in vivo 
(Tamura, Ikutani et al. 2015). Furthermore, the increase in Paneth cells observed in 
organoid cultures upon Tspan6 KO raise the question whether Tspan6 expression 
regulates microbiome interaction with the colon epithelium as Paneth cells are the 
main source of antimicrobial peptides and microbial disbalance modulates 
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susceptibility to CRC (Clevers, Bevins 2013, Tilg, Adolph et al. 2018, Chen 2018). 
Tspan6 may simply affect the number of Paneth cells in the colon epithelium, 
regulate the secretion of antimicrobial peptides or affect bacterial adherence to the 
epithelium, which has been demonstrated for CD9 and Staphylococcus aureus 
adherence to keratinocytes; CD9, CD63 and CD151 in adherence of Neisseria 
meningitidis to human pharynx carcinoma cell line (Ventress, Partridge et al. 2016, 
Green, Monk et al. 2011). Altogether, there are numerous possibilities for Tspan6 to 
regulate not only colon epithelium but also stromal component and microbiota, which 
have implications in CRC development and should be investigated further. 
In summary, the work presented in this thesis demonstrates that Tspan6 is an 
effective regulator of CRC development though modulation of the EGFR signalling, 
and it potentially represents an additional link to anti-EGFR therapy resistance. Work 
presented in this thesis unravelled numerous aspects of Tspan6 in CRC 
development that require investigation. Here I propose that Tspan6 may present as a 
new avenue for CRC management and improved therapy regimen for patients with 
KRAS wt CRC. Finally, understanding the molecular functions of Tspan6 in CRCs 






8 SUPPLEMENTARY DATA 
 
Table 8-1. Tspan6 genotyping primer sequences. 
Primers Sequence 
Reverse common WT and KO 
(GS (E, T)) 
5’- CTTACTCACCAGTTTCAGCATCCAG-3’ 
Forward WT-specific (GS (E)) 5’- TGTGATCAAGGACTCAAGCTTGTAC-3’ 






Table 8-2. Concentrations of RNAs extracted from mouse intestinal polyps. 








































Table 8-3. RIN values and concentration of RNA libraries generated. 
Sample Concentration (ng/ul) RIN 
APCmin/+ (1) 4160 8 
APCmin/+ (2) 9300 8.8 
APCmin/+ (3) 1880 8.5 
APCmin/+ Tspan6-/y (1) 4300 9.2 
APCmin/+ Tspan6-/y (2) 4900 8.9 
APCmin/+ Tspan6-/y (3) 8780 9.6 
APCmin/+ Tspan6-/y (4) 3500 9.9 







Table 8-4. Summary of clinicopathological characteristics of SCORT clinical samples used in the study.  
Patient 
No 
Age Gender Tumour site Histology 
TNM Stage 
EMVI Operation Dead 
Tspan6 H-Score 
T N M Tumour Normal  
1 83 Male Caecum Adenocarcinoma 3 1 0 N Right hemicolectomy Yes 90 220 
2 76 Male Sigmoid Adenocarcinoma 4 0 0 N Anterior resection No 230 190 
3 39 Male Sigmoid Adenocarcinoma 4 0 0 N Anterior resection No 120 70 
4 67 Male Sigmoid Adenocarcinoma 3 1 0 N Anterior resection No 80 190 
5   Rectum Adenocarcinoma 4 0 0 Y Anterior resection No 120 70 
6 91 Female Caecum Adenocarcinoma 4 0 0 N Right hemicolectomy No 80 190 
7 66 Male Sigmoid Adenocarcinoma 3 0 0 N Sigmoid colectomy No 45 80 




2 2 0 N Pan-proctocolectomy No 90 140 
9 72 Male Transverse 
colon (right) 
Adenocarcinoma 3 0 0 N Right hemicolectomy No 180 240 
10 67 Male Rectum Adenocarcinoma 3 0 0 N Anterior resection No 80 170 
11 57 Female Rectum Adenocarcinoma 3 0 0 N Anterior resection No 120 120 
12 81 Female Ascending Adenocarcinoma 3 0 0 N Right hemicolectomy No 190 90 
13 77 Male Caecum Adenocarcinoma 4 2 0 Y Right hemicolectomy No 190 180 
14 86 Female Transverse 
colon (right) 




15 84 Female Sigmoid Adenocarcinoma 4 1 0 Y Left hemicolectomy No 220 180 
16 76 Male Rectum Adenocarcinoma 3 1 0 Y Hartman’s procedure No 80 230 
17 56 Male Sigmoid Adenocarcinoma 4 0 0 Y Anterior resection No 200 220 
18 54 Male Sigmoid & 
hepatic 
flexure 
Adenocarcinoma 4 2 0 Y Total colectomy No 285 200 
19 80 Male Sigmoid Adenocarcinoma 4 2 1 Y Sigmoid colectomy No 105 190 
21 34 Male Caecum Adenocarcinoma 4 2 0 Y Right hemicolectomy No 190 165 
22   Caecum Adenocarcinoma 3 2 0 N Right hemicolectomy No 220 170 
23 87 Female Caecum Adenocarcinoma 3 0 0 N Right hemicolectomy No 230 230 
24 72 Female Sigmoid Adenocarcinoma 4 1 0 N Sigmoid colectomy No 210 210 
25 71 Female Transverse Adenocarcinoma 4 0 0 N Right hemicolectomy No 100 160 
26 84 Male Descending Adenocarcinoma 3 0 0 N Left hemicolectomy No 130 250 
27 84 Male Caecum Adenocarcinoma 3 0 0 N Right hemicolectomy No 170 200 
28 63 Male Sigmoid Adenocarcinoma 2 1 0 N Anterior resection No 110 150 
29 73 Male Caecum Adenocarcinoma 3 1 0 Y Right hemicolectomy No 90 190 
30 76 Male Ascending Adenocarcinoma 3 1 0 Y Right hemicolectomy No 60 180 
31 65 Male Rectum Adenocarcinoma 3 1 0 Y Anterior resection No 100 140 
32 88 Female Ascending Adenocarcinoma 3 1 0 N Right hemicolectomy No 30 130 
33 52 Male Rectum Adenocarcinoma 3 0 0 N Anterior resection No 130 100 
34 47 Female Ascending Adenocarcinoma 4 2 0 Y Right hemicolectomy No 150 220 
35 61 Male Descending Adenocarcinoma 3 0 0 N Left hemicolectomy No 130 150 




37 63 Male Sigmoid Adenocarcinoma 4 0 0 N Sigmoid colectomy No 160 193 
44 79 Female Descending Adenocarcinoma 3 1 0 N Left hemicolectomy No 180 190 
45 77 Female Caecum Adenocarcinoma 3 0 0 N Right hemicolectomy No 110 N/A 




Table 8-5. The genotype of analysed mice. 
Animal ID Gender Strain 
1601 Male Tspan6 KO 
1602 Male Tspan6 KO 
1603 Male Tspan6 WT 
1604 Male Tspan6 KO 
1605 Male Tspan6 WT 
1606 Male Tspan6 WT 
1607 Male Tspan6 WT 
1608 Male Tspan6 WT 
1609 Male Tspan6 KO 
1610 Male Tspan6 KO 
1611 Male Tspan6 KO 
1612 Male Tspan6 WT 
1613 Male Tspan6 WT 
1614 Male Tspan6 WT 
1615 Male Tspan6 KO 
1616 Male Tspan6 KO 
1617 Male Tspan6 KO 
1618 Female Tspan6 KO 
1619 Female Tspan6 KO 
1620 Female Tspan6 HET 
1621 Female Tspan6 HET 
1622 Female Tspan6 KO 






Table 8-6. Summary of histological analysis of oedema in Tspan6 WT and Tspan6 KO mice. 
Mouse ID Genotype Histology 
1601 Tspan6 KO Mild interstitial oedema 
1602 Tspan6 KO Mild interstitial oedema 
1604 Tspan6 KO Moderate interstitial oedema 
1609 Tspan6 KO Mild interstitial oedema 
1610 Tspan6 KO Moderate interstitial oedema 
1611 Tspan6 KO Mild interstitial oedema 
1613 Tspan6 WT Mild interstitial oedema 
1614 Tspan6 WT Moderate interstitial oedema 
1616 Tspan6 KO Mild interstitial oedema 
1617 Tspan6 KO Mild interstitial oedema 
1618 Tspan6 KO Mild interstitial oedema 







Table 8-7. Summary of average weight of collected organs from wild-type and Tspan6 KO mice (WT n=8, Tspan6 KO n=12). At large no differences 
were observed in organ weight between the two strains of the animals; lungs and thyroid gland were significantly heavier in Tspan6 KO mice. The organs 
were weighed immediately after removal from cadavers and Student t-test was used for statistical analysis 
  Heart(g) Lungs(g) Liver(g) Spleen(g) Kidneys(g) Pancreas(g) Thyroid(g) 
Tspan6 WT 
(n=8) 0.23 0.22 0.10 0.10 0.66 0.26 0.37 
Tspan6 KO 
(n=12) 0.23 0.29 0.11 0.11 0.66 0.29 0.28 






Figure 8-1. Mouse intestinal organoids express syntenin-1 at the same level independently of 
APC mutation or Tspan6 expression.  (A) Western blot analysis of syntenin-1 in WT or Tspan6 KO 














-ATPase co-localises with Tspan6 in Caco-2 3D cysts. Single confocal section 













-ATPase is associated with tetraspanin-enriched microdomain in Caco-2 
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